Neuroprotective effects of heat shock proteins in experimental ischaemia: an MRI study. by Aron, B.R.
Neuroprotective effects of heat shock proteins in 
experimental ischaemia: an MRI study
Romina Aron Badin
Thesis submitted for the Degree of Doctor in Philosophy
October 2005
Royal College of Surgeons Unit of Biophysics 
Medical Molecular Biology Unit 
Institute of Child Health 
University of London
1
UMI Number: U591807
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591807
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
“We must never cease from  exploration. 
And the end o f  all our exploring 
will be to arrive where we began 
and to know the place  
fo r  the f ir s t time  ”
T.S. Elliot
2
Abstract
Heat shock proteins (HSPs) are molecular chaperones with essential roles in 
cellular function such as modulating the proteolytic machinery and accelerating cell 
repair. HSP overexpression has been observed in vitro and in vivo under stresses 
including heat, nutrient deprivation and ischaemia. Experiments in in vivo models of 
stroke indicate that transgenically overexpressed or virally delivered HSPs can 
enhance cell survival but cannot always reduce lesion size. This study aims to assess 
the protective effects of HSPs in a rat model of reversible focal cerebral ischaemia 
using magnetic resonance imaging (MRI) techniques to measure cerebral blood flow 
and lesion size.
The experiments described used three different herpes simplex virus (HSV) 
constructs: two potentially therapeutic vectors, HSV-HSP27 and HSV-HSP70, and 
an HSV-LacZ control vector. Initially, the localization and duration of expression 
from the viral vector used to deliver the HSP genes into the rat brain was assessed. 
Subsequently, the effect of pre-ischaemic intra-striatal microinjections of HSV- 
HSP27 and HSV-HSP70 was evaluated in a middle cerebral artery occlusion 
(MCAO) model of stroke. Finally, the effect of delivering the same HSPs 30 minutes 
after ischaemia was assessed. Behavioural tests were carried out in the latter study up 
to a month after MCAO in order to determine whether HSP treatment induced 
functional recovery as well as reduction in lesion size.
Results suggest that intracerebral microinjections with HSV-HSP27 have a 
neuroprotective effect pre-and /?a?Mschaemia. Multislice T2 -weighted images show 
that HSP27 treatment results in a significant reduction in lesion size after MCAO, 
whereas HSP70 treatment does not affect lesion size compared to controls. Western 
blots confirm that virally-induced overexpression of both HSP27 and HSP70 is 
achieved in treated animals. For the first time, non-invasive MRI techniques were 
used to demonstrate the neuroprotective effect of HSP27 and not HSP70 in a rat 
model of reversible focal cerebral ischaemia.
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Introduction Overview
The work presented in this thesis investigates the protective effects of 
overexpressing heat shock proteins (HSPs) in vivo in a rat model of cerebral 
ischaemia. Heat shock proteins are overexpressed through recombinant herpes 
simplex vims (HSV) type 1 vector-mediated transgene delivery to the brain prior to 
and after ischaemic insult respectively.
The general introduction of this thesis is divided into sections dealing with 
various aspects of this project. The first section will discuss the biology of heat shock 
proteins and the role of heat shock proteins in stress. The second section deals with 
pathological changes occurring during ischaemia and the use of magnetic resonance 
imaging (MRI) as a predictive, diagnostic and follow-up tool. The final part deals 
with the choice of vector and issues about gene delivery to the brain.
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Chapter 1 The biology o f Heat Shock Proteins
1.1 Introduction
Heat shock proteins were discovered in 1962 as part of an endogenous 
protective mechanism by which cells respond to environmental stress (Ritossa, 
1962). Their name was initially derived from the observation that their expression 
was enhanced upon exposure to high temperatures that led to protein denaturation. In 
fact, “puffing” in the chromosomes of Drosophila salivary gland cells was noticed 
shortly after elevating the temperature to 37°C. Such changes in the DNA were due 
to increased expression of HSP70 and HSP26 (Tissieres et al., 1974). It was later 
shown that HSPs were upregulated in many organisms, from yeast and bacteria to 
mammalian cells. Interestingly, the temperatures that triggered such induction varied 
according to the organisms’ natural environment: from 28°C in trout and salmon, to 
38°C in mammals and 60°C in thermophilic bacteria (for review see Lindquist, 1986; 
Lindquist and Craig, 1988; Feder & Hofmann, 1999). This phenomenon was 
observed not only after heat shock but also after a series of different insults such as 
ischaemia, nutrient deprivation and hypoxia, in keeping with the idea that raising 
HSP levels can protect cells from stress. This is why the term “stress proteins” was 
believed to be more appropriate than “heat shock proteins” when referring to this 
group. Without any specific knowledge of their function in the cell, their importance 
is highlighted by the fact that their expression is an immediate emergency response 
to stress and that the HSP protein coding domains have been conserved across 
prokaryotic and eukaryotic species throughout evolution (Latchman, 2001).
HSPs are in fact cellular chaperones that assist in protein folding of nascent 
polypeptides or proteins that have been denatured due to environmental stress. The 
generic mechanism by which they act involves binding to the exposed hydrophobic 
domains of nascent or misfolded polypeptides, thus avoiding undesired and/or 
potentially damaging interactions with other proteins or with themselves. Under
17
normal conditions many HSPs are constitutively expressed to ensure proteins achieve 
their correct 3D structure and functional conformation. They are also responsible for 
the localization of nascent polypeptides, by aiding protein targeting and translocation 
within different cellular compartments. They are sometimes involved in antigen 
presentation, steroid receptor function, intracellular trafficking of proteins to 
different organelles, multiprotein complex assembly, nuclear receptor binding and 
apoptosis amongst other housekeeping functions (Jakob et al., 1993; Ehmsperger et 
al., 2000; Richter-Landsberg & Goldbaum, 2003; Latchman, 2004; Katschinski,
2004). Accelerating cell repair after stress is related not only to the abovementioned 
chaperoning activities but also to their ability to present denatured proteins to the 
proteasome for degradation and to their anti-apoptotic functions, which will be 
discussed later (see section 1.5).
The large HSP family consists of proteins with different sub-cellular 
anatomical and temporal distributions and functions and is divided into subfamilies 
named according to their molecular weight in kilo-Daltons (kDa) (Latchman, 1998). 
Some of the most studied HSPs include ubiquitin, HSP27, HSP56, HSP70 and 
HSP90 (Table 1.1). Certain HSPs, like HSP70, have been found to bind to co­
chaperones in order to enhance their activity in the cell. Although these proteins have 
variable roles, it is clear that they are essential for the maintenance of cell viability. 
The following sections will only review the roles of HSP27 and HSP70 in detail 
because these are the only HSPs used in this study and the main ones investigated in 
neuroprotective experiments.
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Heat shock protein Known functions
HSP100/104 ATPase activity, to leran ce  to severe  stress (yeasts), 
protein refolding
HSP90/94 Protein refolding, d egrad ation  & transport, steroid 
recep tor binding, horm one signalling, cell c y c le  
control, co o p e r a te s  with HSP70
HSP70/72
GRP78/Bip
Oligom er dissociation, clathrin u n coatin g , protein  
trafficking & refolding, ATPase activity, n a scen t  
protein folding, prevents a g g reg a tio n , anti- and  
pro-apoptotic, neuroprotective.
HSP60 Mitochondrial chaperon in , protein folding & 
unfolding (m ycob acteria), organ elle  translocation
HSP40 Protein refolding, interacts with HSP70
HSP27 C ytoskeleton stabilization, protein solubilization, 
refolding an d  targeting for degrad ation , anti- 
ap o p to tic , redox control, neuroprotective
HSP10 C o-ch a p ero n e , m itochondrial
Table 1.1. HSP families and main known functions.
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1.2 The heat shock protein 70 family
HSP70 is one of the largest and probably most studied families of 
chaperones. They are highly conserved proteins among eukaryotes and prokaryotes, 
the human HSP70 sharing more than 70% of its amino acid sequence with 
Drosophila and 50% with E.coli (Lindquist, 1986). As mentioned before, the degree 
of conservation throughout evolution reflects the importance of the biological 
functions performed by these groups of proteins. Moreover, the functional 
differentiation of this HSP family suggests that it has amplified and diversified 
throughout evolution (Feder & Hoffman, 1999; Taylor & Benjamin, 2005). 
Understanding their structure has provided some clues towards their mechanism of 
action in cells. They all work in an ATP-dependent fashion in that they require ATP 
hydrolysis in order to release bound proteins. In fact, ATP binding to HSP70 
promotes conformational rearrangements in the molecule that increase its affinity to 
the substrate and stabilize their interaction (reviewed in Wegele et al., 2004). These 
chaperones therefore carry a characteristic 44 kDa ATPase domain at their N- 
terminus and an 18 kDa domain which works as a protein binding site (Mallouk et 
al., 1999). In fact, ATP binding to the N-terminus of HSP70 induces a 
conformational change in the chaperone that allows it to bind to other proteins 
(Giffard & Yenari, 2004). The C-terminus contains a 10 kDa domain with a 
characteristic terminal sequence that allows binding to specific co-factors in all 
eukaryotic cells. There is also some evidence that the carboxy-terminal domain is 
able to inhibit the ATPase activity of HSP70 in the absence of substrate (Wegele et 
al., 2004). These structural characteristics ensure that all HSP70 members function 
as molecular chaperones regardless of their intracellular location, which ranges from 
the cytoplasm to the mitochondria and the endoplasmic reticulum.
Recent findings have shown that human HSP70 has a ribosomal docking site 
equivalent to the ones previously characterized in yeast and eubacteria (Huang et al., 
2005). HSP70 is recruited to the ribosome via Mppl 1 and can interact optimally with 
nascent polypeptide chains as they are being formed, thus ensuring they do not 
aggregate and they are kept in the correct conformation for folding (Hundley et al.,
20
2005). Thus, chaperones provide a link between protein translation and folding, 
acting at a co-translational level.
An interesting hypothesis on the mechanisms of action of HSP70 suggests 
that it can exert its role passively or actively. In the latter case, the binding and 
releasing of substrates without refolding simply reduces the amount of free soluble 
proteins and thus prevents their aggregation. Alternatively, this chaperone can bind 
the substrate to correct its conformation in an energy-dependent fashion by unfolding 
a stretch of protein and refolding it (Mayer & Bukau, 2005). Because misfolded 
proteins have a tendency to aggregate, it is important that HSP70 is able to 
“dissolve” such aggregates in order to refold the proteins. Experiments in E.coli have 
confirmed that HSP70 can solubilize small protein aggregates of heat denatured 
G6PDH enzyme (dimers or trimers), whereas it relies on its cooperation with HSP40 
and HSP 104 for larger aggregates. Based on this evidence, the authors propose two 
mechanisms of action. Several HSP70 molecules acting simultaneously could locally 
unfold parts of the aggregates in repeated cycles of binding and dissociation to allow 
for disaggregation and correct refolding of the proteins to their native state. The 
unfolding of the substrate would occur by Brownian motion in random directions of 
many HSP70s acting synergistically to pull the misfolded protein open. 
Alternatively, less HSP70 molecules could be needed if disaggregation was 
facilitated by the misfolded substrate being held in a multichaperone complex (Ben- 
Zvi et al., 2004).
The presence of co-chaperones is important for HSP70 function. From an 
evolutionary perspective it also implies that more functional differentiation is 
achieved if the chaperone can interact with and be modulated by a range of co­
factors. It has been shown that certain co-chaperones can increase HSP70’s affinity 
in binding substrates, enhancing its ATPase activity and thus accelerating the rate of 
protein binding, refolding and release. An example of this is HSP40 which was 
hsown to aid protein release from HSP70 in E.coli (Liberek et al., 1991; Freeman et 
al., 1995). Co-chaperones can also be involved in recruiting chaperones in specific 
cellular compartments or in large protein complexes. For example, the interaction of 
several chaperones and co-factors including HSP56, Hop, HSP70 and HSP90, has 
been shown to enhance steroid receptor function by inhibiting its translocation to the
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nucleus (Edwards et a l , 1992). HSP70 collaborates with HSP90 in a well described 
cycle (figure 1.1): the substrate bound to HSP70 and HSP40 is presented to HSP90, 
in turn bound to a Hop co-factor to form an intermediate complex. Then, HSP70 and 
HSP40 dissociate to allow p23 binding and the substrate is appropriately processed 
(Wegele et a l, 2004). Moreover, HSP70 and HSP90 chaperone families also 
collaborate in targeting proteins for degradation in the proteasome (Young et al., 
2004). It is important to understand that co-chaperones can modify the function of a 
chaperone, determining whether proteins will be folded or degraded. This will be 
mentioned later in relation to overexpression of chaperones in vivo upon stress and 
possible competition for binding of co-chaperones modulating cellular response.
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ofinal
complexHsp70 Hsp90 PathwayHsp70 Pathway
early
complex
intermediate
complex
Figure 1.1. HSP70 and HSP90 protein folding cycle. HSP40 delivers the newly 
synthesized or denatured protein (x) to the HSP70 complex. HSP70 can then process 
the substrate (x) on its own through an ATP/ADP hydrolysis cycle involving the 
nucleotide exchange factor (NEF). Alternatively, the HSP40-HSP70-X protein 
complex binds to the scaffold protein Hop and enters the HSP90 pathway. This 
intermediate complex in turn binds to p23 and prolylisomerases as the HSP70 
complex dissociates. The folded substrate is then released from this final complex. 
After binding to Hop, HSP90 is able to reenter the cycle. T, ATP-bound form; D, 
ADP-bound form. (Adapted from Wegele et al., 2004).
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1.3 The heat shock protein 27 family
HSP27 belongs to the small heat shock protein group which includes other low 
molecular weight proteins such as aA-crystallin and oB-crystallin, HSP22 and 
HSPB10. This family of chaperones has not been studied in as much detail as others 
but some of their structural features reflect their importance. The N-terminus of 
HSP27 is rather variable across species but contains motifs that are essential in 
regulating its oligomerization (Bova et al., 2000; Theriault et al., 2004). Its C- 
terminus contains an a-crystallin domain highly conserved in prokaryotes and 
eukaryotes, followed by a more flexible extension which is responsible for its 
chaperone activity (Muchowski et al., 1997). All HSPs in this family share this C- 
terminal conformation and the flexibility of it probably explains why these 
chaperones are not substrate-specific. They are thus able to recognize and very 
efficiently bind to a wide range of unfolded proteins in vitro to prevent their 
aggregation (Ehmsperger et al., 1998).
Oligomerization and phosphorylation state are two key features when considering 
HSP27 function. Under normal conditions, HSP27 is found in large multimeric 
aggregates of high molecular weight (600-800 kDa). Phosphorylation upon stress 
causes dissociation of this chaperone into monomers and dimers (Lambert et al., 
1999; Rogalla et al., 1999). Recent studies have shown that mutations in the 141 
cysteine residue of HSP27 prevent dimerization of this chaperone and significantly 
reduce its ability to protect cells from stress-induced apoptosis. Thus, dimerization of 
HSP27 heavily relies on its only cysteine residue (C141) and is essential for 
chaperone activity in vivo (Diaz-Latoud et al., 2005). The same laboratory has shown 
that the C terminus of HSP27 is crucial for its protective activity. Other studies have 
determined that protein kinase D is responsible for phosphorylation of a serine 
residue in HSP27 that also modulates oligomerization and therefore chaperone 
activity (Doppler et al., 2005). The role of oligomerized HSP27 appears to be 
biologically important too. Early studies suggest that large HSP27 aggregates can 
bind denatured proteins and by keeping them soluble, prevent their aggregation and 
misfolding (Ehmsperger et al., 1997). Thus, dimers bind to proteins damaged after
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stress and then oligomerize to generate larger molecules in an ATP-independent 
fashion (Ehmsperger et al., 1997; Arrigo et al., 2005).
1.4 The role of HSPs in stress and apoptosis
A series of experiments on thermotolerance followed the discovery of HSPs 
in 1962. Subsequent experiments in vitro and in vivo have established that these 
proteins are naturally upregulated during a variety of stresses and that artificial 
overexpression confers protection (Lindquist & Craig, 1988; Higashi et al., 1994; 
Wagstaff et al., 1996; Ehmsperger et al., 1997; Feder & Hofmann, 1999). Such 
evidence will be discussed in detail for HSP27 and HSP70 in sections 1.5 and 1.6 
respectively. Table 1.2 summarizes all known up-to-date neuronal studies.
All these experiments assess either the role of HSPs during stress, the effect 
of overexpressing HSPs before and after stress or the effect of the absence of HSPs 
during stress. This section aims to highlight the two main consequences of stress for 
the cell, necrosis or apoptosis, since it is these pathways that HSPs will interfere with 
in order to promote cell stability.
Depending on the nature and length of the insult, the cell will experience 
different degrees of energetic and metabolic impairment that could eventually lead to 
apoptosis or necrosis. Denaturing stresses such as ischaemia cause proteins to unfold 
or misfold. Such proteins have a tendency to aggregate due to their exposed 
hydrophobic segments and it is these aggregates that damage cells (Taylor et al., 
2002). Inducible HSPs can enhance cell survival by binding to and keeping 
denatured proteins soluble, thus preventing their misfolding or aggregation with 
other proteins. Their other main role is refolding aberrant proteins or targeting them 
for degradation in the proteasome (Kiang & Tsokos, 1998; Hershko & Ciechanover, 
1998; Sharp et al., 1999; Latchman, 2004).
A different but equally important mechanism of protection of HSPs is their 
role in preventing programmed cell death. Because ischaemia causes necrosis and,
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more importantly, apoptosis, it is useful to briefly review the pathways that lead to 
the latter form of cell death. This will provide a framework for understanding the 
anti-apoptotic functions of HSPs discussed in the following section (see section 1.5). 
There are several pathways leading to apoptosis. In the intrinsic pathway, stressed 
mitochondria release cytochrome c that binds to Apaf-1 (Apoptotic protease- 
activating factor 1) and this complex recruits pro-caspase 9. This leads to the 
formation of the apoptosome where pro-caspase 9 is cleaved and active caspase 9 
activates caspases 3 and 7. This results in proteolysis and cell death. In the extrinsic 
pathway, activation of death domain receptors such as FADD (Fas-associated protein 
with death domain) leads to the recruitment of pro-caspase 8. Activated caspase 8 
can then trigger other downstream effector caspases. Caspase-independent pathways 
can lead to apoptosis via release of AIF (apoptosis inducing factor) from 
mitochondria. Alternatively, FADD interacts with Daxx protein and this complex 
recruits the apoptosis signal-regulated kinase 1 (Askl). When activated, Askl can 
trigger the stress-activated protein kinase 1/ Jun N-terminal kinase (SAPK1/JNK) 
pathways of cell death. The protective role of HSP27 and HSP70 in apoptosis will be 
reviewed for each chaperone individually in the next section. Figure 1.2 illustrates 
some of the interventions of HSP27 in the apoptotic pathway.
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In vitro
Cell type HSP Vector Stress Effect Reference
DRG/Glia 70 plasmid heat s Uney etal., 1993
DRGs/ND7 70 plasmid heat / Mailhos etal., 1994
70 plasmid apoptosis X Mailhos etal., 1994
DRGs 70 plasmid heat/ischaemia s Amin etal., 1996
TNs 70 plasmid heat Y Wyatt etal., 1996
Astrocytes 70 retrovirus 0 2+GIu removal S Papadopoulos etal., 1996
HPs 70 hsv heat S Fink etal., 1997
70 hsv apoptosis S Fink etal., 1997
Astrocytes 70 retrovirus Glucose removal S Xu & Giffard 1997
HPs 70 adenovirus heat s Beaucamp et al., 1998
Neuronal 27 plasmid apoptosis s Rogalla etal., 1999
DRGs/ND7 70 hsv heat/ischaemia s Wagstaff et al., 1999
27 hsv heat/ischaemia s Wagstaff et al., 1999
DRGs 27 hsv serum removal s Wagstaff et al., 1999
70 hsv serum removal X Wagstaff et al., 1999
27 hsv apoptosis s Wagstaff et al., 1999
70 hsv apoptosis X Wagstaff et al., 1999
27 adenovirus serum removal s Lewis etal., 1999
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Astrocytes 70 retrovirus Glucose removal y Lee et al., 2001a
70 Tg Glucose removal S Lee et al., 2001a
70 Tg Glutamate y Lee et al., 2001a
70 Tg 0 2 +GIu removal y Lee et al., 2001a
HPs 70 Tg 0 2 +GIu removal y Lee et al., 2001a
70 Tg Glutamate+Fe2+ y Kelly et al., 2001a
DRGs 27 hsv serum removal y Benn et al., 2002
Astrocytes 70 retrovirus 0 2 +GIu removal y Giffard et al., 2004
70 Tg H20 2 y Giffard et al., 2004
ND7 27 hsv ischaemia y Zourlidou et al., 2004
70 hsv ischaemia X Zourlidou et al., 2004
27 hsv staurosporine y Zourlidou et al., 2004
70 hsv staurosporine X Zourlidou et al., 2004
70 hsv serum removal X Zourlidou et al., 2004
27 hsv serum removal y Zourlidou et al., 2004
DRGS/ND7 70 hsv apoptosis y Patel ef al., 2005
27 hsv apoptosis y Patel et al., 2005
RG 27 plasmid ischaemia y Whitlock et al., 2005
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In vivo rat 70 hsv ischaemia s Yenari etal., 1998
rat 70 hsv ischaemia Hoehn etal., 2001
rat 70 adenovirus ischaemia Kelly et al., 2001b
rat 70 hsv ischaemia ✓ Kelly et al., 2002
rat 27 hsv kainic acid / Kalwy et al., 2003
mouse 70 Tg ischaemia / Plumier etal., 1997
mouse 70 Tg ischaemia s Rajdev et al., 2000
mouse 70 Tg ischaemia X Lee et al., 2001a
mouse 70 Tg ischaemia ✓ Kelly et al., 2001a
mouse 70 Tg ischaemia s Lee et al., 2001b
mouse 27 Tg kainic acid s Akbar et al., 2003
mouse 70 Tg ischaemia ✓ Tsuchiya et al., 2003
mouse 70 Tg kainic acid Tsuchiya et al., 2003
mouse 70 Tg ischaemia ✓ van der Weerd et al., 2005
mouse 27 Tg ischaemia van der Weerd (p.c.)
Table 1.2. Summary of all in vitro and in vivo studies assessing neuroprotection { / )  of HSP27 and HSP70 against different insults. (DRGs, dorsal 
root ganglion neurones; RG, retinal ganglion cells; HPs, hippocampal neurones; TNs, trigeminal nerve neurones; Tg, transgenics; hsv, herpes 
simplex virus; Glu, glucose; p.c., personal communication)
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Figure 1.2. The anti-apoptotic functions of HSP27. Overview of the targets o f HSP27 
in the cell upon stress (adapted from www.biocarta.com). TNFa, tumour necrosis 
factor alpha; IL -la , interleukin-1 alpha; MAPK, mitogen activated kinase; ROS, 
reactive oxygen species; NFkB, nuclear factor kappa B; Apaf, apoptosis inducing 
factor-1.
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1.5 HSPs and the stress response in neurones in vitro
HSP overexpression has been observed in vitro under a range of conditions 
including hypoxia, nutrient deprivation, ischemia, and thermal stress. Briefly, 
upregulation of HSP27, HSP70 and HSP90 mRNA and protein after several insults 
has been detected in numerous neuronal cultures. In vitro evidence of HSP- 
transfected neurons supports the protective role of HSP27 and HSP70 to a different 
extent in different experimental systems. Such evidence will be discussed in detail 
for each HSP separately.
HSP70
The chaperone properties of HSP70 have been briefly reviewed in section 
1.2, in relation to its role in blocking protein aggregation and promoting protein 
folding in the cytosol. In fact, several experiments have confirmed this chaperone’s 
ability to refold denatured enzymes such as ornithine transcarbamoylase or luciferase 
(for review see Mayer & Bukau, 2005). It has been estimated that 10-20% of all 
bacterial protein synthesis relies on HSP70 for correct 3D conformation of new 
peptides and that this percentage should be greater in eukaryotes and even greater 
after stress (Hartl & Hayer-Hartl, 2002). The importance of the ATPase domain of 
HSP70 has also been highlighted since it is responsible for clathrin uncoating and 
binding to and releasing unfolded proteins. Interestingly, recent in vitro experiments 
have shown that the Hdj-2 co-chaperone, a member of the HSP40 family, is also 
needed to mediate protein binding to HSP70. However, Hdj-2 on its own was found 
to protect cells regardless of the levels of HSP70, suggesting that this co-chaperone 
might have a crucial effect (Giffard et al., 2004). The relevance of co-factors 
becomes more obvious when we consider that their binding can change the fate of 
unfolded proteins and promote either their refolding or their degradation.
The neuroprotective role of overexpression of HSP70 has been established by 
numerous in vitro systems. Neuronal cell lines isolated from transgenic 
overexpressing mice or transfected with engineered viruses have shown enhanced 
viability after a range of stresses but protection was not always conferred against 
apoptosis (for reviews see Kiang and Tsokos, 1998; Yenari et al., 1999; Feder & 
Hofmann, 1999; Kelly & Yenari, 2002; Richter-Landsberg & Goldbaum, 2003).
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Early experiments by Uney and colleagues showed that HSP70 transfected 
dorsal root ganglion (DRG) neurones are protected from heat shock (Uney et al., 
1993). ND7 cells and trigeminal ganglion neurones stably transfected with HSP70 
were protected from heat shock but not from serum removal induced apoptosis 
(Mailhos et al., 1994; Wyatt et al., 1996). Similarly, DRG neurones transfected with 
HSP70 were protected against thermal and ischaemic lethal stresses (Amin et al.,
1996). Moreover, addition of antisense oligonucleotides against HSP70 to primary 
hippocampal rat neurones significantly decreased cell survival after heat shock (Sato 
etal., 1996).
Viruses engineered to overexpress HSP70 have been used to infect neuronal 
cell cultures and test the protective effect of this chaperone against a range of 
stresses. Thus, transfection of hippocampal neurones with HSV expressing HSP70 
(HSV-HSP70) has been shown to enhance their resistance to heat shock but not to 
glutamate or 3-nitropropionic acid (NP-3) exposure (Fink et al., 1997). Similarly, 
adenovirus infected primary hippocampal neurones were protected against thermal 
stress (Beaucamp et al., 1998). Survival of astrocytes in culture to either glucose or 
both oxygen and glucose deprivation was significantly enhanced when transfected 
with HSP70 expressing retroviruses (Papadopoulos et al., 1996; Xu & Giffard,
1997). In contrast to these studies, it has been shown that HSV-HSP70 infected ND7 
cells and DRG neurones are protected from thermal and ischaemic stress but not 
from apoptosis induced by serum removal and retinoic acid addition (Wagstaff et al., 
1999).
Kelly and colleagues observed neuroprotection against glutamate and 
oxidative stress in primary hippocampal neurone cultures from Lmo-1 promoter- 
mediated inducible HSP70 transgenic mice (Kelly, et al., 2001 a). Primary astrocytes 
and pure neuronal cell cultures were isolated from transgenic HSP70 mice and 
subjected to a range of insults. Astrocytes and pure hippocampal neuronal cultures 
were more protected from oxidative stress than glucose and oxygen-glucose 
deprivation whereas pure cortical neuronal cultures were not protected from either 
oxygen-glucose deprivation or glutamate exposure (Lee et al., 2001a).
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As far as its role in apoptosis is concerned, HSP70 has been shown to protect 
cells against both necrosis and caspase-dependent as well as caspase-independent 
apoptotic death pathways. There is evidence suggesting that HSP70 regulates both 
upstream events by inhibiting the formation of the apoptosome, and downstream 
events by binding either the apoptosome complex or the effector caspases. In fact, 
HSP70 can bind to different components of this complex, such as Apaf-1 (Beere et 
al., 2000; Saleh et al., 2000), cytochrome c (Tsuchiya et al., 2003; Mosser et al., 
2000; Creagh et al., 2000; Steel et al., 2004) and dATP. If the apoptosome complex 
forms, it then binds to pro-caspase 9 and activates a downstream cascade of effector 
caspases such as caspase 3. Beere and colleagues have shown that HSP70 prevents 
the binding of pro-caspase 9 to the apoptosome complex upon cytochrome c release 
(Beere et al., 2000). Some studies demonstrate that HSP70 is unable to prevent 
cytochrome c release from mitochondria but it can inhibit activation of caspase 3 or 
act downstream of the caspase cascade by downregulating cytosolic phospholipase 
activity (Jaattela et al., 1998; Li et al., 2000a). There is also some evidence that this 
chaperone can bind to the apoptosis inducing factor (AIF) and stop its release from 
mitochondria (Ravagnan et al., 2001), whereas other groups suggest that inhibition 
of apoptosis occurs via the JNK/SAPK pathway (Gabai et al., 1997; Meriin et al., 
1999).
It is widely recognized that HSP70 is a powerful chaperone, with anti- 
apoptotic activity, as well as providing a link between denatured proteins and the 
proteasome degradation machinery. Certain in vitro studies have, however, shown 
the potentially harmful effects of this chaperone. There is evidence that increased 
levels of HSP70 can be detrimental to neurones by binding to survival elements that 
could otherwise block TNF-induced apoptosis (Ran et al., 2004). It is important to 
note that, in contrast, HSP27 can protect cells from TNF-induced apoptosis (see 
below; Mehlen et al., 1997). In vitro evidence of protection with HSP70, however, 
remains extremely dependent on the type and severity of insult and the susceptibility 
to different environmental insults of the cell population affected (Amin et a l, 1996; 
Jaattela et al., 1998; Lee et al., 2001a; Ran et al., 2004; Latchman, 2004).
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HSP27
HSP27 has been shown to protect cells in vitro by interfering with the stress- 
triggered apoptotic cascades. Numerous experiments have confirmed the anti- 
apoptotic effects of this chaperone after exposure to a range of toxic stimuli such as 
staurosporine (Zourlidou et al., 2004; Patel et al., 2005), FAS/Apo-1 (Amgo et al, 
1998; Melhen et al., 1996), etoposide (Samali et al., 1996, 1999), NGF withdrawal 
(Lewis et al., 1999; Zourlidou et a l, 2004; Patel et al., 2005), doxorubicin (Garrido 
et al., 1997; Hansen et al., 1999), cisplatin (Garrido et al., 1997), actinomycin D and 
others (see Paul et al, 2002; Latchman, 2004). Primary sensory and motor neurons 
benefit from the upregulation of HSP27 after nerve injury induced apoptosis 
(Costigan et al., 1998; Tandrup et al., 2000) whereas HSP27 knockdowns show 
increased cell death (Benn et a l, 2002).
It has been suggested that HSP27 can interfere with both caspase-dependent 
and caspase-independent apoptotic pathways. TNF-a induced cell death can be 
prevented by expression of HSP27, decreasing the levels of reactive oxygen species 
(ROS) and reducing the activation of NF-kB, lipid peroxidation and protein 
oxidation. In has been proposed that the chaperone increases glutathione content in 
the cells, which is in charge of scavenging ROS like TNFa in mitochondria (Melhen 
et al., 1997). Virally transfected HSP27-overexpressing ND7 and DRG cell lines are 
more resistant to heat shock, ischaemia and serum withdrawal with retinoic acid 
addition (Wagstaff et al., 1999). Garrido and colleagues have shown that HSP27 
prevents procaspase 9 activation without interfering with cytochrome c release 
(Garrido et al., 1997 & 1999). Other studies have shown that HSP27 overexpression 
can sequester cytochome c after release from the mitochondria and prevent its 
binding to the apoptosome (Bruey et al., 2000). Cytochrome c release can also be 
delayed by HSP27 and in turn delay caspase activation (Paul et al., 2002). Similarly, 
sequestration of cytochrome c and binding to procaspase 9 can inhibit apoptosis 
(Concannon et al., 2001). Several experiments show that this protein is able to block 
caspase-3 activation after ischaemia (Pandey et al., 2000; Whitlock et a l, 2005). 
Interestingly, replacing HSP27 in rat neurons with a caspase blocking agent does not 
prevent cytotoxicity suggesting that in addition to caspase-3 blockage, HSP27 must 
exert chaperoning functions that prevent necrosis and caspase-independent events
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(Whitlock et al., 2005). Moreover, recent findings suggest that HSP27 
overexpression can reduce stress-triggered membrane translocation of PKCdelta, an 
upstream molecule in the activation of the p38 MAP kinase pathway, which leads to 
ROS formation and mitochondrial-induced caspase-dependent apoptosis (Lee et al., 
2005). Overexpression of HSP27 can also decrease the amount of AIF, which is 
released by mitochondria in the caspase-independent pathway of cell death (Rashmi 
et al., 2003). This chaperone can also interact with Daxx to prevent caspase- 
independent apoptosis (Charette et al., 2000).
Other possible mechanisms of protection by this HSP could be related to its 
chaperone functions. Some experiments have linked cytoskeleton stability to 
mitochondria and apoptosis. They suggest that HSP27 acts further upstream and 
prevents cytochrome c release via Bid relocalization which is in turn associated with 
F-actin filaments modulated by this chaperone (Paul et al., 2002). Previous studies 
had shown that HSP27 could stabilize F-actin microfilaments and intermediate 
microfilaments during stress (Lavoie et al., 1993, Guay et al., 1997). It has more 
recently been found that phosphorylated and unphosphorylated HSP27 binds actin 
and tubulin filaments and can promote axonal growth and regeneration after injury 
(Costigan et al., 1998; Williams et al., 2005). Finally, recent studies have shown that 
although HSP27 cannot prevent thermal denaturation of F-actin, it translocates to the 
cytoskeleton upon stress and binds to its denatured form to prevent aggregates. 
Protection is conferred by solubilization of denatured F-actin, in order for it to be 
refolded or degraded (Pivovarova et al., 2005).
In contrast to other HSPs including HSP70, HSP27 has the ability of binding 
partially or completely denatured proteins in an ATP-independent fashion, which 
could be crucial in preserving cellular stability during the metabolic depletion caused 
by ischaemia (Rogalla et al., 1999; Garrido, 2002). Early experiments have 
demonstrated translocation of HSP27 into the nucleus upon stress signals where it 
can stabilize mRNAs and limit denaturation of proteins involved in transcription 
(Carper et al., 1997). Since protein synthesis is impaired by cerebral ischaemia, 
protection may work by enabling accelerated recovery of protein synthesis rate after 
stress.
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Mehlen and colleagues have proposed that large HSP27 aggregates are able to 
regulate production of reactive oxygen species and TNF alpha damage in cells 
(Mehlen et al., 1997). Arrigo and colleagues have proposed a mechanism of 
protection where HSP27 decreases intracellular iron levels thus preventing free 
radical generation and reducing the levels of oxidized proteins within cells. 
Moreover, such proteins are also actively recruited by HSP27 chaperones and 
presented to the proteasome for degradation (Arrigo et al., 2005).
1.6 HSPs and stress response in neurones in vivo
The temporal expression pattern of several HSPs including HSP27, HSP56, 
HSP60, HSP70, and HSP90 after cerebral ischaemia in rodents has been extensively 
studied. Both mRNA and protein levels of HSP27, HSP70 and HSP60 were 
significantly increased at 2, 4, 8 and 24 hours after stroke although mRNA levels 
seemed higher than protein levels (Wagstaff et al., 1996). Higashi and colleagues 
looked at HSP27, HSP47, HSP70 and HSP90 and determined that HSP70 mRNA 
expression increased 4 hours after focal ischaemia adjacent to the lesion core, 
whereas HSP27 expression peaked at 24 and 48 hours and was more widespread 
(Higashi et al., 1994). Other studies used northern blot or in situ hybridization to 
determine a timecourse of HSP70 mRNA expression increase upon stress. Rabbit 
glial cells in the forebrain region were enriched in HSP70 mRNA at 1, 2 and 3 hours 
after hyperthermia. It is interesting to note that in that study it is oligodendrocytes 
and microglial cells and not neurones or astrocytes that strongly upregulate HSP70 
(Foster & Brown, 1997). However, ischaemic insult induced HSP70 expression in 
astrocytes and neurons in the periphery of the infarct whereas only endothelial cells 
were seen to express it near the core of the lesion (Kinouchi et al., 1993). Cortical 
regions seem to upregulate HSP70 mRNA at higher levels than the caudate in rats, 
possibly delineating an area where protein synthesis is recovering (Abe et al., 1992). 
Interestingly, gerbil CA1 neurons minimally induce HSP70 compared to CA3 cells 
and the former die 48 hours after transient ischaemia (Kawagoe et al., 1993). Further 
ischaemia experiments in rats suggest there might be an imbalance in the amount of 
constitutive and stress-induced HSP70 mRNA that renders CA1 neurons more
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susceptible to ischaemia (Kawagoe et al., 1992a, 1992b, 1993). It has however more 
recently been shown that striatum and cortex are highly immunopositive for HSP70 
after transient focal ischaemia in rats (Rebel et al., 2005).
The distribution of HSP70 in the brain after thermal stress was also studied by 
Pavlik and colleagues. Their experiments revealed high levels of this chaperone in 
glial and vascular cells 1.5 hours after heat shock, with expression peaking at 4 
hours. They detected high expression in the cortex and white matter areas whereas 
neuronal staining was more discrete, localizing in amygdala and hypothalamus. They 
were also able to show that nuclear translocation of HSP70 occurred as early as 1.5 
hours after hyperthermia and relocation to the cytoplasm took place 4 to 5 hours later 
(Pavlik et al., 2003).
These and other studies suggest that although there are similarities in expression 
patterns of HSP27 and HSP70 after stress in the brain, the levels and location of such 
expression depends on the severity and length of the insult and can also be specific to 
cell populations.
Overexpression experiments in in vivo models of epilepsy and stroke have 
yielded different results. Transgenically overexpressed or virally delivered HSP70 
was not always able to reduce lesion size but was able to enhance cell survival. 
HSP70 transgenics showed no reduction in lesion size but decreased damage in 
hippocampal neurons after permanent focal cerebral ischaemia (Plumier et al., 1997). 
Similar results were obtained by one other study after permanent middle cerebral 
artery occlusion (Lee et al., 2001a). In contrast to these findings, transgenic mouse 
models of transient global and focal ischaemia and kainic-acid induced seizures 
showed reduced lesion volume and decreased neuronal damage and apoptosis in the 
hippocampus respectively (Tsuchiya et a l, 2003). Reduction in lesion size was also 
found by two further studies in permanent focal ischaemia models in mice (Rajdev et 
al., 2000; van der Weerd et al., 2005). A slightly different approach involved 
knockout mice carrying deletions in HSP70. Permanent focal cerebral ischaemia 
induced a much larger infarct size in these animals than in wild type mice, supporting 
the idea that HSP70 is neuroprotective (Lee et al., 2001 b). Giffard and colleagues 
have examined the protective role of HSP70, where its overexpression was able to
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reduce protein aggregation in CA-1 neurons in an in vivo model of global ischaemia 
(Giffard et al., 2004). Kelly and colleagues created an inducible HSP70 transgenic 
mouse line where expression was not pan-neural but more discrete and driven to 
specific hippocampal populations. These animals showed reduced neuronal damage 
after 25 minutes of bilateral carotid artery occlusion, although the HSP70 protein 
levels were no different in transgenics and wild type controls subjected to ischaemia 
(Kelly, et al., 2001a).
Viral overexpression of HSP70 has been attempted in four studies, three of 
which used stereotaxic intracerebral microinjections of herpes simplex virus as a 
vector in rats whilst the fourth one used adenovirus in mice. None of these 
experiments provide any evidence of reduction in lesion size due to treatment with 
HSP70. All of them, however, report that the morphology of stressed neurones is 
improved in the presence of this chaperone reflecting its neuroprotective effect. It is 
interesting to note that improving the cell’s appearance is apparently not directly 
related to an enhancement of the cell’s viability and therefore has no consequences in 
the final lesion area. Yenari and colleagues showed that pre-ischaemic delivery of 
HSP70-expressing virus improved neuronal survival in the striatum and in the 
hippocampus after focal ischaemia and kainic acid induced seizures respectively 
(Yenari et al., 1998). Post-ischaemic injection of the viral transgene improved 
neuronal survival in the striatum when delivered at 0.5 and 2 hours but not at 5 hours 
after stroke (Hoehn et al., 2001). Similarly, CA1 hippocampal neurones were 
protected from global ischaemia when the vector was delivered 12 hours before 
insult (Kelly et al., 2002). Finally, engineered adenovirus microinjected two weeks 
before the insult protected mice from 20 minutes of global ischaemia. It is interesting 
to mention that the control vector, an adenovirus carrying enhanced green fluorescent 
protein, also protected striatal neurones so no differences were found between treated 
and controls (Kelly et al., 2001 b).
The great majority of these studies have involved HSP70 whilst the protective 
effect of HSP27 in vivo has been less investigated. Transgenic mice overexpressing 
HSP27 presented a significant decrease in hippocampal neuron death in a kainic-acid 
model of epilepsy (Akbar et al., 2003). This study showed a significant 50% 
reduction in mortality of the animals, less toxicity and less caspase 3 induction,
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which correlates with an anti-apoptotic effect of HSP27. In agreement with these 
findings, a reduction in lesion size was seen in transgenic mice 24 hours after 
permanent focal ischaemia (van der Weerd, personal communication). Only one 
study to date has attempted viral delivery of HSP27 and shown enhancement of cell 
survival in a model of kainate-induced cell death in the hippocampus (Kalwy et al., 
2003).
1.7 Summary
This first chapter has addressed several aspects of the biology of heat shock 
proteins, focussing on the main chaperones induced in the brain, HSP27 and HSP70. 
A brief account of their structure was also given in an attempt to understand the way 
these chaperones bind to other proteins in the cell. Subsequently, an overview of in 
vitro and in vivo studies reporting known functions of HSP27 and HSP70 was 
presented. Although the exact mechanisms of protection are still under investigation, 
the overall importance of HSPs as molecular chaperones under normal and stress 
conditions is clear. The cell’s proteolytic machinery relies on chaperones for its 
correct functioning. A newly formed protein has several fates: it can remain 
unfolded, fold to the appropriate conformation or misfold and either be refolded or 
degraded. The interaction of HSPs and other co-factors is thus crucial in modulating 
cell survival.
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Chapter 2 Cerebral ischaemia
2.1 Introduction
Stroke continues to be a major cause of death and disability in the western 
world and industrialized nations. It has been estimated that on average, one person 
suffers a stroke every 45 seconds in the United States alone (Nudo & Nelson, 2003). 
Incidence figures indicate that 5.5 million people died from stroke around the world 
in 1999, leaving stroke as the third most common cause of death after heart infarction 
and cancer (Lo et al., 2003). Approximately 25% of all strokes lead to death, but 
about 80% of those surviving experience motor weakness and 30% result in long 
term chronic disability (in Dijkhuizen et al., 2001). The term encompasses a range of 
conditions of vascular origin, including total or partial obstruction of a vessel, 
haemorrhage and less often a total lack of blood supply to the brain due to cardiac 
arrest. Excluding this last example, the pathology can manifest itself in two main 
forms: as the thrombotic occlusion of a cerebral artery or as a vessel rupture leading 
to haemorrhage. Symptoms are usually abrupt, reflecting the sudden interruption of 
blood supply to a region of the brain, and persist for at least 24 hours after onset. Of 
the two existing types of stroke, haemorrhagic and ischaemic, the latter accounts for 
approximately 85% of all clinical cases. The patient’s outcome is strongly dependent 
on the type and duration of the stroke. The spectrum ranges from transient ischaemic 
attacks (TIAs), in which small neurological deficit resolves completely in a relatively 
short period of time, to longer periods of ischaemia that might leave permanent 
damage, or even death. Ultimately, the common feature is that brain cells will die 
and some will remain dysfunctional, leading to variable neurological deficit 
depending on the location of the specific brain regions affected by the ischaemic 
event and extent of the damage.
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2.2 Animal models of cerebral ischaemia
The use and development of experimental brain ischaemia models is justified 
by the need to expand treatment options. In fact, thrombolytic therapy has been the 
only available option for stroke patients for over 10 years, and even if  it is 
moderately effective, it is limited by the need for intervention within a very narrow 
therapeutic window (~3 hours post-treatment). Different animal models of stroke 
have been developed over the years in order to study the evolving pathophysiology 
and assess the effect of different treatments. In these models, the duration of the 
ischaemic event determines whether the stroke is transient (where the flow is 
eventually restored), or permanent (where no tissue reperfusion takes place). It is 
also important to distinguish whether the stroke is global, affecting the brain overall, 
or focal, affecting a specific region. Some examples of different animal stroke 
models will be briefly reviewed in the next two sections.
2.2.1 Global cerebral ischaemia
Rodent global models have been used to mimic cardiac arrest in humans but 
can be even more useful in studying the death of certain neuronal populations. 
Decapitation has been used to reproduce this global reduction in blood flow without 
reperfusion (Hossmann, 1998). Other examples are the four-vessel occlusion model 
in rats and the bilateral forebrain ischaemia in gerbils (Small & Buchan, 2000; 
Lythgoe & Gadian, 2000; Lythgoe et al., 2003). In the former, permanent bilateral 
occlusion of the vertebral arteries is obtained by cauterization and both common 
carotid arteries (CCAs) are ligated for at least 10 and up to 30 minutes before 
reperfusion (Pulsinelli & Brierley, 1979). Transient bilateral occlusion of the CCAs 
on its own can induce global ischaemia in gerbils. This is due to an abnormality in 
their circle of Willis, namely a lack of communicating arteries connecting the 
posterior and anterior circulations (Levine & Payan, 1966). The type of cell death 
produced by this model of forebrain ischaemia is delayed and selective: 10 minutes 
of occlusion can damage CA1 hippocampal neurones, whereas longer periods can 
affect or striatal and cortical neurones. It has recently been reported, however, that
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this type of cell death is not strictly “delayed” but the result of a gradual process that 
can be monitored through the reduction in water diffusion in the affected tissue after 
reperfusion (Lythgoe et al., 2005).
2.2.2 Focal cerebral ischaemia
Focal models are thought to more closely correlate with clinical situations 
than global models. This type of stroke causes a gradient of reduction in cerebral 
blood flow (CBF) across the tissue, so that the focal lesion typically has an 
unsalvageable core and is surrounded by tissue at risk that is partially perfused by 
collaterals and is therefore potentially salvageable. Commonly, focal models involve 
occlusion of the middle cerebral artery (MCA) in a transient or permanent fashion. 
Some of the techniques used for the latter are cauterisation, photochemical 
thrombolysis after injection of rose bengal dye, injection of blood clots into the 
common carotid artery or intraluminal occlusion of the MCA (Small & Buchan, 
2000; Lythgoe et al., 2003). Some groups have attempted to increase the 
reproducibility of the lesion size by combining the MCA occlusion with permanent 
occlusion of the CCA or by subjecting the animal to hypotension for a short period of 
time (Brint et al., 1988; Chen et al., 1986; van Bruggen et al., 1992; Lythgoe & 
Gadian, 2000). Occlusion of the MCA by electrocoagulation usually generates a 
large lesion in the cortex and caudate putamen (Tamura et al., 1981). Some of these 
methods have the advantage of avoiding craniotomy but not all of them can be 
specific about the location of the infarct.
Transient models may sometimes be less reproducible than models involving 
permanent occlusion but they allow investigation of the fate of the tissue after 
reperfusion (Longa et al., 1989). MCA occlusion is normally performed via clips, 
ligature or intraluminal thread. In the original method described by Shigeno and 
colleagues, a ligature was loosely placed around the MCA and the blood flow was 
interrupted by pulling and releasing the thread around the artery (Shiegno et al., 
1985). In other models, clips are used to distally obstruct the artery, giving rise to a 
cortical lesion only (Kaplan et al., 1991). Embolic models are thought to better
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resemble clinical stroke (Busch et al., 1997; Mayzel-Oreg et al., 2004). The 
intraluminal method is the least invasive but can yield variable sized infarcts; some 
groups have attempted to reduce the variability by perfecting the suture. In the first 
model proposed by Koizumi and colleagues, a rubber cylinder attached to a thread 
was used to block the MCA via the internal carotid (Koizumi et al., 1986). Nylon 
monofilaments with a blunted tip were later used (Longa et al., 1989). It was then 
noticed that the size, the length, the material and the degree of coating of the suture 
affected lesion size and reproducibility (Garcia et al., 1993). This limitation is 
intrinsic to the method because the thread needs to be positioned correctly to 
completely block the origin of the MCA as it branches from the internal carotid 
artery. Otherwise, partial reduction of flow will lead to smaller lesion size. However, 
unlike some of the listed models, this method is specific about the location of the 
lesion and the size of the lesion can be varied according to the duration of the 
occlusion. Among the other advantages, the surgery does not involve craniotomy and 
is therefore less invasive than abovementioned models. Thus, this method allows the 
study of dynamic changes occurring immediately after occlusion and/or reperfusion 
of the ischaemic area.
2.2.3 Pathophysiology of brain tissue during ischaemia
Cellular damage upon ischaemia involves a range of events including 
exitotoxicity, ionic imbalance, oxidative stress and programmed cell death. The 
degree of damage will depend on the duration and extent of interruption of blood 
flow to the tissue, and this will in turn determine whether the damage is reversible or 
not. After prolonged ischaemia, the centre of the lesion is the most damaged, 
eventually proceeding to pan-necrosis of neurones, glia and endothelial cells 
resulting in infarction. In more peripheral, compromised areas, cells die at a slower 
rate by active cell mechanisms of gene activation that cause apoptosis (Garcia et al., 
1995; Dimagl et al., 1999; Lee et al., 2002; see section 1.4).
One of the first consequences of cerebral ischaemia is energy failure. ATP is 
the main source of energy in the brain and is crucial in maintaining ion pump
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activity. The conversion of ADP to ATP is an oxidative process, and therefore 
heavily relies on constant oxygen and glucose supply and is therefore compromised 
during ischaemia. As a consequence, ion pumps including the Na+/ K+ pump fail, 
causing the disruption of ion gradients across the cellular membrane leading to their 
depolarization. There is a rapid intracellular accumulation of Na+, Ca++ and Cl" ions 
and an efflux of K+ ions, which osmotically obliges an influx of water from the 
extracellular to the intracellular compartment. This results in the phenomenon known 
as cytotoxic oedema or cell swelling (Hansen, 1985).
An inflammatory response is triggered as a result of cytotoxic oedema which 
is mediated by signalling molecules including cytokines, chemokines and immediate 
early genes (c-fos, c-jun). Release of neurotransmitters such as glutamate promotes 
Ca++ influx and triggers a cascade of events that result in release and activation of 
reactive oxygen species (ROS), endonucleases and proteases such as matrix 
metalloproteinases and plasminogen activators from astrocytes and microglia. These 
proteins are able to disrupt tight junctions in endothelial cells of the blood vessels, 
thus degrading the matrix and disrupting the blood brain barrier (BBB). The excess 
of serum/fluid leaking from the blood into the tissue results in vasogenic oedema 
(Klatzo, 1987). This phenomenon involves an increase in interstitial water content 
and overall tissue swelling and is a direct consequence of blood vessel proteolysis. 
As the pathology progresses, cells in this area die by necrosis, are reabsorbed by glial 
tissue and a fluid filled cavity remains.
2.3 MRI and its applications to animal models of stroke
In order to understand how MRI can provide useful information about the 
healthy and diseased brain, it is necessary to describe some of its fundamental 
biophysical properties. This technique is concerned with imaging the hydrogen 
nuclei present in water molecules, which constitute 70-80 % by weight of neuronal 
tissue. A variety of parameters that will be detailed in the following sections can 
describe macroscopic and microscopic motions of water and how its distribution is 
altered by diseases such as stroke. Thus, MRI can report not only on alterations in 
blood flow (perfusion) due to an ischaemic event, but also on metabolic changes
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associated with the distribution of water between intracellular and extracellular 
compartments (diffusion) and in tissue structure due to cytotoxic and vasogenic 
oedema.
2.3.1 Basic theory
Nuclear magnetic resonance is widely used as a diagnostic and research tool. 
Two distinct fields of NMR are concerned with either the detection of metabolites by 
magnetic resonance spectroscopy (MRS), or the characterization of tissue structures 
using magnetic resonance imaging (MRI). For the purpose of this study, only the 
latter will be reviewed. The technique is based on the concept that each nucleus 
possesses a nuclear spin and an associated magnetic moment. The most widespread 
analogy used to describe this phenomenon is thinking of each atom as a small bar 
magnet. The “behaviour” of this small magnet will be affected by the magnetic field 
it experiences: in the absence of a field, the spins will be randomly distributed; in the 
presence of an external field, the spins will align with or against the main magnetic 
field (Bo), although slightly more will be aligned with the field than against it. The 
resulting net magnetization can be represented by a vector aligned with Bo, and its 
magnitude is directly proportional to the spin density (figure 2.1). Moreover, the 
individual spins will precess around Bo at a specific frequency, the Larmor frequency 
(coo), which is directly proportional to the strength of the main magnetic field. This 
relationship is described by the equation: C00 = 7  Bo, where y  is the gyromagnetic 
ratio of the nucleus.
In order to detect this net magnetization (M z), it is necessary to disturb its 
longitudinal alignment and flip the magnetization towards the perpendicular (x-y) 
plane. A radiofrequency pulse at the resonant (Larmor) frequency of the protons can 
be applied for this purpose. A 90° pulse can be used to tilt the magnetization vector 
into the x-y plane. This transverse magnetization gradually decays and returns to its 
original position at equilibrium, longitudinally aligned with the main magnetic field 
Bo (figure 2.2).
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Figure 2.1. Spins align with or against the Bo field. The thick arrow represents the net 
magnetization vector along the direction of the field (z axis).
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Figure 2.2. Schematic representation of the effect of a radiofrequency (RF) pulse on 
the net magnetization vector. Prior to the application of the 90° pulse, the vector is 
aligned to the z axis. After the application of the pulse, the vector is tilted onto the x- 
y plane.
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2.3.2 Ti and T2 relaxation in cerebral ischaemia
The loss of transverse magnetization in the x-y plane over time is 
characterized by the transverse relaxation time T2 . Ti on the other hand is a time 
constant that describes the recovery of net magnetization in the longitudinal direction 
along Bo- The relaxation rate is affected by a number of factors including molecular 
mobility. Ti or spin-lattice relaxation describes an energy exchange between the 
excited protons and their molecular environment, which is facilitated by the presence 
of macromolecules and tissue structures in the immediate surroundings. T2 relaxation 
is also called spin-spin relaxation, reflecting the interactions between neighbouring 
nuclear spins rather than with the lattice.
Free water, such as CSF, has long Ti and T2 relaxation times compared to 
water in brain tissue due to its high mobility. In contrast, water molecules bound to 
macromolecules in the tissue will tumble at slower rates and this causes shortening of 
Ti and more obviously T2 . Thus, variations rates of relaxation will occur between 
different tissues. Ti and T2 can therefore yield information not only about different 
structures in the brain but more importantly for this study, about pathological states 
associated with differences in tissue water properties. As mentioned before, 
ischaemia causes shifts of water from the extracellular to the intracellular 
compartment. Diffusion-weighted imaging (DWI) is sensitive to such microscopic 
alterations and has been extensively used in stroke to detect acute changes in cellular 
energetics that can predict final lesion size and identify areas of salvageable tissue 
(Calamante et al., 1999a; Shen et al., 2004). Pioneering experiments by Moseley and 
colleagues established that changes in the apparent diffusion coefficient (ADC) of 
water occur minutes after ischaemia onset due to the formation of cytotoxic oedema 
and consequent relocation of water from the extracellular to the intracellular 
compartment (Moseley et al., 1990). Electrophysiology and spectroscopy studies 
later confirmed that the timecourse of events following cell swelling is directly 
related to the decrease in the ADC of water (Hossmann et al., 1994; van der Toom et 
al., 1996). Moreover, the relationship between energy failure, ADC and cerebral 
blood flow thresholds after ischaemia was also studied in gerbil models and embolic 
rat models, indicating that all these parameters are interdependent (Busza et al.,
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1992; Busch et al., 1998). Although DWI is a very powerful technique, this study is 
not concerned with acute phase of ischaemia and other MRI sequences were used 
instead.
Vasogenic oedema, leads to an increase in overall water content in the lesion 
area due to BBB breakdown, which causes an increase in the Ti and T2 relaxation 
rates of the affected tissue. Changes in the relaxation times are important in 
determining contrast in the acquired image. In practice, Ti and T2 changes have been 
accurately correlated to histological areas of tissue damage (Pierpaoli et al., 1993). 
However, T2 -weighted images are most frequently used to delineate lesion areas 
because of more apparent changes in T2 relaxivity (Van Bruggen et al., 1994). Early 
studies have used T2 -weighted images to evaluate lesion size at 24 hours after 
permanent MCA occlusion in rats and found strong correlations with histology 
(Allegrini & Sauer, 1992). Another study followed changes in the ischaemic lesion 
after 7 hours of permanent middle cerebral artery occlusion in rats. ADC reduction 
was highest in the core of the lesion (60% of control) and was larger in area than the 
areas of increased relaxation times during the first 2 hours of occlusion. Later 
measurements showed a 29% change in T 1 within the lesion and a much higher 51 % 
increase in T2 (Hoehn-Berlage et al., 1995).
Changes in ADC, CBF and T2 have been measured in embolic MCA 
occlusion models in rats subjected to recombinant tissue plasminogen activator (rt- 
PA) intervention and untreated controls. Immediately after occlusion, changes were 
seen in CBF and ADC values as expected, while a small increase in T2 was detected 
only 4 hours after stroke induction (Jiang et al., 1998). T2 signal enhancement was 
maximal at 24 and 48 hours in untreated controls and rt-PA treated rats respectively. 
These values declined at 1 week but remained higher than baseline in both groups. In 
fact, the reduction in lesion size in treated animals due to thrombolysis is reflected by 
the increase in CBF and ADC and by the lower T2 values at 24 hours compared to 
untreated controls. Similarly, Ti, T2 , perfusion and diffusion measurements have 
been made in reversible MCA occlusion models in rats. Van Lookeren and 
colleagues used diffusion and T2 weighted imaging to establish the degree of damage 
following different occlusion times, ranging from 20 to 90 minutes. Moreover, the 
changes in T2 and ADC were correlated with histology. Short periods of ischaemia
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(< 20mins) resulted in no changes in either ADC, T2 or tissue morphology. After 90 
minutes of occlusion on the other hand, a significant decrease in ADC and increase 
in T2 relaxation time were observed 6 hours after reperfusion (van Lookeren et al.,
1999). More importantly, these changes were accompanied by major signs of 
necrosis on histological sections indicating that the tissue was irreversibly damaged. 
That study also demonstrated that the volume of tissue with increased T2 relaxation 
time was maximal at 3 days in animals occluded for 30-45 minutes and at 24 hours in 
rats occluded for 90 minutes. This suggests that the expansion of cerebral oedema is 
related to the duration of the initial insult and can be measured in T2-weighted 
images. Further support for this hypothesis comes from a focal transient stroke model 
in rats, where a 2.5 hour occlusion caused the maximum amount of signal change at 
48 hours compared to 30 minutes and 1 hour occlusion times. Moreover, this 
increase in T2 relaxation was correlated with an increase in lesion volume in 
histological sections as well as an increase in the duration of the ischaemic event 
(Neumann-Haefelin et al., 2000).
Another study used MRI and histology to investigate the effect of 10 and 30 
minutes of middle cerebral artery occlusion in rats (Li et al., 2000b). A temporal 
profile of T2 changes showed that values remained equal pre- and post-occlusion in 
animals subjected to 10 minutes of ischaemia and there were no differences between 
ipsilateral (ischaemic) and contralateral (non-ischaemic) hemispheres up to 72 hours 
after stroke induction. The 30 minute group, on the other hand, showed significant 
hyperintensity in the lesion area at 12 hours, with T2 values peaking at 48 hours after 
tissue reperfusion. In agreement with the MRI data, histology on brain sections 
revealed 17% of neurones were necrotic in the infarct core of the 10 minute transient 
ischaemia group compared to 95% pannecrosis in the 30 minute group (Li et al., 
2000b). Similarly, a comparison between the 60 and 90 minutes duration of MCA 
occlusion in rats shows that the increase in T2 is highest for the longer occlusion time 
and continues rising after reperfusion as measured at 4.5 hours. The initial changes 
found upon ischaemic onset followed the timecourse described for permanent 
occlusion, with a rapid reduction in diffusion of water and a more progressive 
increase in Ti and T2 relaxation times (van Dorsten et al., 2002). As for models of 
permanent occlusion, T2 increase was more pronounced and correlated with areas of 
decreased ADC, suggesting the evolution of vasogenic oedema.
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Interestingly, some experiments have indicated that changes in the relaxation 
properties of the tissue can be influenced by factors other than vasogenic oedema, 
such as changes in the oxygenation state of haemoglobin or the exchange of 
magnetization between free and bound water (Ogawa et al., 1990; Ordidge et al., 
1991). Changes in Ti and T2 have been observed at early stages of ischaemia in rats 
at high magnetic field (8.5 T). Remote occlusion of the MCA allowed for immediate 
simultaneous acquisition of diffusion, perfusion, Ti and T2 and allowed for 
comparison between pre- and post-occlusion values. These experiments showed that 
alongside the expected decrease in ADC, a decrease in T2  and an increase in Ti were 
also observed (Calamante et al., 1999a).
2.3.3 Cerebral blood flow (CBF)
Blood is the constant source of nutrients for the brain. The exchange of 
oxygen, nutrients and waste between blood circulating at the capillary level and 
tissue is reflected by the extent of perfusion, i.e. the rate at which blood is delivered 
to the capillaries in the tissue (figure 2.3). This parameter is therefore conventionally 
measured as the amount of blood in millilitres per mass of tissue in grams per time 
i.e. ml/lOOg/min. A distinction has to be made between measuring blood at the 
capillary level that exchanges with the tissue, and blood flowing in main arteries and 
vessels that is simply being transported to and out of the brain. Capillaries are narrow 
and have semi-permeable vessel walls that facilitate nutrient exchange. Also, blood 
velocity is much slower than in arteries. Thus, one aim of perfusion techniques is to 
identify alterations in the rate of such exchange in haemodynamically compromised 
tissue.
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Figure 2.3. Schematic representation o f tissue perfusion.
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The two main MRI perfusion techniques used to measure CBF are bolus 
tracking and arterial spin labelling (ASL). The former is widely used in the clinical 
setting and involves the intravenous injection of an exogenous tracer, a gadolinium 
based contrast agent. ASL techniques, on the other hand, are based on the use of 
water protons as an endogenous diffusible tracer. The most obvious advantage of this 
technique is its truly non-invasive nature since no exogenous contrast agent is 
needed. This eliminates potential intolerance of the subjects to the contrast agent and 
the cost of the bolus. From a clinical and research perspective, it offers an 
unrestrictedly repeatable measurement of blood flow.
In 1992, Detre and colleagues introduced an ASL technique, continuous 
arterial spin labelling (CASL). Two images are acquired in CASL: the first image is 
the ‘tagged’ image, where the blood entering the imaging slice is magnetically 
labelled with respect to the tissue in that slice. An RF pulse is continuously applied 
for a few seconds to invert the magnetisation of the blood flowing through a major 
vessel supplying the brain. The inversion slice is commonly placed in the neck so 
that the water in the blood inflowing to the brain becomes magnetically tagged. Thus, 
the labelled spins in blood travel into the brain and exchange with tissue water at the 
capillary bed, altering the magnetization of the perfused tissue in the imaging slice 
(figure 2.4). In the second image, the control image, inflowing blood is not labelled 
and thus can be subtracted from the labelled image to reflect the level of perfusion of 
the tissue (Detre, 1992). Quantification of CBF is, however, not straightforward and 
several parameters, including the blood-brain partition coefficient of water (A,), the 
rate of longitudinal relaxation Ti, the efficiency of spin inversion (a) and the steady 
state vs fully relaxed magnetization per unit mass of brain tissue, need to be 
considered in order to obtain flow values (Herscovitch & Raichle, 1985; Roberts et 
al., 1996; Zhang et al., 1995; Alsop & Detre, 1996; Calamante et al., 1999b).
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Figure 2.4. Representation o f the continuous arterial spin labelling (CASL) 
technique. Axial scan of the rat brain showing the position o f the imaging, control 
and labelling planes. Blood inflowing from the neck is magnetically labelled when 
passing though the inversion plane. The site o f the inversion slice was chosen in each 
animal by locating the coordinates for end o f the cerebellum. The control plane was 
chosen by default to be equidistant to the imaging slice in the opposite direction.
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2.3.4 CBF thresholds and pathology
The term cerebral ischaemia broadly refers to the interruption of blood flow to 
the brain. However, the reduction in blood flow needs to reach a certain threshold for 
the tissue to become infarcted. In the latter case, blood flow levels are extremely low, 
affecting tissue structure and metabolic rates and impairing normal cerebral function. 
If the reduction in flow is milder, the tissue is certainly compromised, but is defined 
as oligaemic rather than ischaemic (Lythgoe et al., 2000). The reduction in blood 
flow can be heterogeneous after ischaemia and CBF estimation can be useful in 
classifying the metabolic state of the tissue and therefore its fate (Shen et al., 2004).
Immediately after occlusion of an artery, both blood flow and pressure 
decrease. Blood flow will then be determined by the extent to which collateral flow 
and alternative arterial routes compensate for the occluded artery. Autoregulation via 
vasoconstriction or vasodilation is the main mechanism by which the body 
compensates for fluctuations in blood pressure. Vasodilation increases the 
availability of oxygen and can maintain normal neuronal function for some time after 
a drop in flow. Once these mechanisms are exhausted, the tissue becomes severely 
compromised and can become infarcted via processes already detailed in section
2.2.3 (Powers et al., 1991).
Several groups have determined cerebral blood flow thresholds in different 
animal species and through different methods. Experiments in rats and gerbils have 
determined that protein synthesis starts to be compromised when CBF levels drop to 
55 ml/lOOg/min, which corresponds to oligaemic perfusion (Astrup et al., 1981; Xie 
et al., 1989; Mies et al., 1991; Hossmann et al., 1994). Lactate accumulation, tissue 
acidosis and excitatory amino acid release occur at values of about 35 ml/lOOg/min 
(Obrenovitch et al., 1988; Allen et al., 1993). A 25-20 ml/lOOg/min threshold exists, 
below which metabolic dysfunction is severe, causing ATP and glucose decrease 
(Mies et al., 1991; Allen et al., 1993). Because brain tissue has no oxygen stores, it is 
unable to sustain brain activity. In fact, it has been shown that below 15 ml/lOOg/min 
electrical activity in neurones disappears: failure of the ion pumps on cell membranes
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leads to disturbances of ionic gradients and cell depolarization (Astrup et al., 1981; 
Hossmann et al., 1994).
Moreover, early experiments by Busza and colleagues established a 
relationship between CBF thresholds and ADC decrease in a gerbil model of 
forebrain ischaemia (Busza et al., 1992). Only when flow values were lower than 20 
ml/lOOg/min did the decrease in ADC become significant. This threshold was found 
to be higher in rat models of focal ischaemia where flows of 30-35 ml/lOOg/min 
were sufficient to correlate with ADC changes (Kohno et al., 1995). In fact, these 
experiments found a further relationship with the duration of the insult whereby the 
CBF threshold increases in a time dependent manner (reviewed in Thomas et al.,
2000). Combined analysis of ADC changes, CBF values and ATP levels has been 
useful in classifying different territories within the ischaemic lesion: normal tissue is 
defined as a region of normal perfusion and diffusion, whereas hypoperfused regions 
can present normal diffusion but decreased CBF values and severely compromised 
tissue at the core of the lesion tends to exhibit abnormal perfusion and diffusion 
values (Hoehn-Berlage et al., 1995; Kohno et al., 1995; Calamante et al., 1999a; 
Shen et al., 2004). These studies have helped in the investigation of the penumbra, 
the hypoperfused border region of the lesion that can potentially lead on to 
infarction.
2.4 Summary
This chapter has aimed to briefly review the pathophysiological changes 
occurring in cerebral ischaemia. The brain has high energetic demands and needs a 
continuous supply of oxygen and nutrients from blood. A reduction or suppression in 
flow can severely and irreversibly damage neurones. This is, however, a complex 
phenomenon encompassing a series of gradual events that lead to cell death and 
infarct formation. Even if the pathophysiology of the lesion evolution has been 
characterized over a number of years, there is still a need for further therapeutic 
study. Animal models of stroke are therefore essential for the development of 
neuroprotective strategies that can reduce the brain’s vulnerability to an ischaemic
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event. The application of MRI techniques has been crucial in studying stroke because 
it allows non-invasive and repeatable image acquisition on the same animals over 
time. This enables the design of longitudinal studies while significantly reducing the 
number of animals required. Moreover, it is possible to simultaneously obtain 
multiparametric data reflecting the consequences of ischaemia at a cellular level, 
reporting on changes in energy status, metabolism, function and morphology along 
with perfusion alterations that underlie the pathology. Furthermore, the longitudinal, 
multiparametric data sets acquired can then be integrated with end point histological 
analysis.
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Chapter 3 Gene delivery to the brain
3.1 Introduction
Gene therapy was initially conceived as the replacement of defective genes 
causing a particular disease with functional ones. However, this concept has now 
been extended to other pathologies in which symptoms can be relieved by expressing 
or overexpressing certain genes even if the disease has no genetic aetiology. Several 
systems have therefore been developed to incorporate foreign genes and deliver them 
into specific cell types, often to determine whether overexpression of a particular 
protein has any impact on an ongoing biological process. This is of great value for 
both research and medical applications. This chapter will discuss the desirable 
features of a viral vector, concentrating on the herpes simplex virus vector used in 
this study, its applications to gene delivery to the central nervous system and the 
relevance of gene therapy for cerebral ischaemia.
3.2 Gene delivery methods
Gene therapy relies on the efficient delivery of genes in vivo. Numerous 
laboratories have attempted this via two main approaches: ex vivo and in vivo gene 
introduction using either DNA plasmids or engineered viral vectors. Ex vivo gene 
therapy involves transfection of cells with the gene of interest via plasmids or viruses 
in vitro, followed by grafting of the cultured cells into the tissue. For example, 
fibroblasts and myoblasts have been used for the treatment of Parkinson’s disease in 
animal models: the grafted cells were engineered to express tyrosine hydroxylase and 
their transplantation reduced rotational behaviour in a 6-hydroxydopamine rat model 
of the disease (Fisher et al., 1991). Some of the limitations of this method are the 
finite duration of expression of the transgene and the potential tumorigenic effects of 
transplanting tumour derived cell lines.
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Direct injection of DNA in a plasmid vector has proved rather unsuccessful in 
the brain, probably due to the rapid degradation of the foreign nucleic acid upon 
entry into the host. In an attempt to refine this simple method, the nucleic acid was 
coated with a cationic liposome that facilitated entry to the cell (Tsuda & Imaoka, 
1996). In vivo injections to the mouse brain have yielded low numbers of transfected 
cells and astrocytes were more often transfected than neurones (Imaoka et al., 1995). 
These and other studies suggest that gene delivery efficiency and specificity are still 
too low to envisage its applications to therapeutics.
Viruses, on the other hand, are natural and highly efficient nucleic acid 
delivery systems. A straightforward strategy is to use such viruses to directly and 
efficiently deliver therapeutic genes to the nervous system. The main concern, 
however, is the potential toxicity of the vector to the host. Several laboratories have 
attempted to engineer disabled or attenuated viruses that are safe whilst retaining 
their efficiency of transfer. The range of viruses now available for research purposes 
makes choosing the right vector for the study more difficult, although adenoviruses, 
herpesviruses and retroviruses such as lentiviruses are the most commonly used. 
Hence, the advantages of the herpes virus chosen for this study will be briefly 
reviewed in the next section.
3.3 Choice of vector
Several issues need to be considered when using viruses for gene therapy. 
Firstly, the vector should have no cytopathic effects in order to cause minimum or no 
toxicity to the host. Secondly, it should be efficient in delivering the transgene, 
which implies it should have high infectivity. Moreover, it should be able if possible 
to selectively infect the target cells. These properties will in turn determine how 
many cells need to be infected to achieve the desired result. The insert capacity of the 
vector should also be taken in to account since it will determine the allowed size of 
the transgene. Lastly, viral expression should be sustained for a considerable period 
of time depending on the aim of the study. Most of the vectors available for gene 
therapy are derived from common human pathogens and tend to be able to infect
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more than one cell type. This is important when considering that the brain contains a 
variety of cells, and targeting a specific sub-group can be difficult.
The method of delivery of the transgene should be as safe as possible. In the 
case of viruses this is a key factor because of their pathogenicity. They enter the 
nucleus and use the cell’s own machinery to replicate their nucleic acid and form 
new virion particles. This cycle results in lysis and death of the cell as the new 
viruses accumulate in the cytoplasm to be released. There are several mechanisms 
that the virus interferes with in order to survive in the cell, like avoiding an immune 
reaction from the host or entering the nucleus and shutting down the cell’s protein 
synthesis to establish its own. It is therefore important to know the entry routes for 
each specific virus and how they replicate in the specific cell type. This is the only 
way of introducing disabling mutations in the viral vector that will impede its 
replication, thus rendering it non-toxic but allowing it to stably infect the cell and 
express the inserted transgene.
A generic division is helpful in understanding the mechanisms of entry to the 
cell. Capsid virions like adenovirus and adeno-associated virus (AAV) have their 
nucleic acid surrounded by a protein structure, whereas enveloped virions like herpes 
simplex virus and retroviruses have a lipid bilayer surrounding the capsid. 
Adenoviruses, for example, enter the cell by binding to specific receptors and 
integrins on the plasma membrane and become temporarily enclosed in an 
endosome. This process is known as receptor mediated endocytosis. Enveloped 
viruses, on the other hand, use their glycoproteins to attach to the cell’s membrane 
and diffuse along it until they encounter receptors that enable penetration (Frampton 
et al., 2005). After the envelope fuses with the cell surface, the viral capsid is 
released directly into the cytosol where it binds to dynein proteins associated to 
microtubules and is transported to the nucleus (Davidson & Breakefied, 2003).
Similarly, the mechanism of entry to the nucleus can vary. Small viruses, like 
parvoviruses, are able to enter the nucleus directly through the nuclear pore without 
being modified. Adenoviruses induce rupture of the endosomal membrane and 
release the viral DNA for nuclear entry. Retroviruses wait until the cell undergoes 
division and take advantage of the nuclear membrane reorganization during mitosis
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to associate with chromatin and integrate to a newly assembled nucleus. This implies 
that the infectivity of retroviruses depends largely on the rate of division of the 
specific cell type in question and that they are unable to infect non-dividing neurones 
(Whittacker et al., 2000). On the other hand, certain retroviruses like lentiviruses are 
able to infect non-dividing cells and have the advantage of being non-immunogenic 
and not very toxic to the host. However, the main disadvantage of retroviruses is the 
fact that their DNA is incorporated into the host genome and genes can be mutated in 
this process. Similarly, adenoviruses carrying deletions in essential early genes that 
control replication have been found to sometimes express late viral genes leading to 
cytotoxicity. Such “leaky” gene expression results in the stimulation of an immune 
response by the host in vivo (Yang et al., 1994). Several mutations have been 
introduced to the herpesvirus genome and this will be reviewed in the next section.
The size of the genome is also very important in determining the choice of 
vector. Table 3.1 lists some of the most commonly used viruses and their size in base 
pairs (bp). Adenoviruses and adeno-associated viruses are often used but have small 
genomes and therefore very limited cloning capacity of 8 and 4.5 kb respectively 
(Bett et al., 1994). Attempts to overcome such limitations resulted in the generation 
of “gutless” adenoviruses in which the viral genome is provided in trans by a cell 
line or helper virus, thus potentially extending the cloning capacity to 37 kb (Mitani 
et al., 1995). Similarly, the disadvantage of adeno-associated virus is that it needs co­
transfection with a helper virus in order to replicate. Herpesviruses in contrast have a 
large genome size and the fact that many non-essential genes can be deleted without 
impairing viral replication processes allows it to accommodate a large amount (~30- 
40 kb) of foreign DNA (Latchman, 2002). This is important for therapeutic purposes, 
since it is feasible that more than one gene may need to be delivered, possibly 
therapeutic genes acting together or even in combination with a marker gene. An 
example of the benefits of large transgene capacity is an experiment by Haase and 
colleagues where two separate adenoviral vectors carrying neurotrophin-3 and ciliary 
neurotrophic actor respectively were delivered simultaneously to alleviate motor 
neurone disease in mice (Haase et al., 1997).
The duration of transgene expression is determined by more than one factor. 
Retroviruses ensure long term expression because they integrate to the cell’s
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genome. Some experiments have in fact demonstrated p-galactosidase transgene 
expression six months after inoculation using an HIV-based lentiviral vector in 
neurons in vivo (Blomer et al., 1997). However, as stated before, this also represents 
an inherent mutation or inactivation risk for the host. Herpesviruses are the only 
pathogens that naturally establish a latent asymptomatic infection in human 
neurones. The reasons for this will be discussed in detail in the next section but 
suffice to say it possesses latency associated transcripts (LAT) that can potentially be 
engineered for long term expression.
This study uses herpes simplex virus type-1 (HSV-1) because it meets many 
of the abovementioned demands. The vector has a large transgene capacity and is 
able to infect neurones in vivo thus ensuring high infectivity and efficiency of gene 
delivery into the brain. Other advantages that make this virus very suitable for gene 
therapy are that it can be manipulated to enter long-term stable asymptomatic latency 
in the infected cells and its genome remains episomal, thus reducing the risk of 
insertional inactivation or mutation of host genes (Fink et al., 1996; Wolfe et al., 
1999; Latchman, 2001). Overall, this viral vector appears to be more suitable for 
investigating the effect of heat shock protein expression before and after ischaemia 
than others reviewed. The next sections will describe the way HSV enters the cell, 
the genetic controls of its replication cycle and the mutations that have been 
introduced in order to maximize its safety as a vector.
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Virus Type Genome size (kb)
Adenovirus 35
Adeno-associated virus 8.5
Lentivirus 10
Herpesvirus 152
Table 3.1. Genome sizes of the viruses most commonly used for gene therapy.
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3.4 The biology of HSV type 1
HSV is a double stranded DNA virus consisting of two unique DNA 
segments, the unique long ( U l )  and unique short (Us), each flanked by a pair of 
inverted repeats (Ir) (figure 3.1). The nucleic acid is surrounded by an icosahedral 
capsid composed of four different proteins. Between this capsid and the external 
glycoprotein lipid envelope lies the tegument, a layer attached to the capsid that 
contains a range of proteins with diverse functions. The genome’s size is 152 kb and 
it encodes for more than 80 different genes with characteristic temporal expression 
patterns upon infection: immediately early genes (IE) are followed by early (E) and 
late (L) genes respectively (Wagner et al., 1995; Stingley et al., 2000).
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Figure 3.1. Schematic representation of the herpes simplex virus structure and 
genome (adapted from Fink et al., 1996).
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The infection cycle begins with fusion of the viral envelope to the plasma 
membrane of the host cell. Because HSV is such a large virus, it cannot enter the 
nucleus directly. Instead, it contains a nuclear localization sequence on the surface of 
the capsid that helps it bind to the nuclear pore complex, a channel that controls 
traffic between the cytosol and the nucleoplasm. Here, the virus uncoats and leaves 
its capsid behind so that its DNA can enter the nucleus (Whittaker et al., 2000). 
Some tegument proteins detach from the capsid and enter the cell’s nucleus in order 
to mediate viral genome entry and IE gene activation (Morrison et al., 1998). The 
virion trans-activator protein VP 16 in particular forms a complex Oct-1 and host cell 
factor (HCF), which binds to the promoter region of each of the IE gene promoters 
(O’Hare, 1993). Another protein, the virion host shut-off (vhs) protein is also 
essential at early stages of infection and is in charge of interrupting the cell’s protein 
production. Vhs triggers endoribonuclease activity leading to the degradation of host 
mRNA and the rapid replacement with viral mRNA (Lu et al., 2001). Similarly, 
gamma 34.5 is involved in preventing shut-down of protein synthesis by the host at 
late stages in the infection cycle (He et al., 1997).
There are five IE genes in HSV-1 that are expressed in the absence of de novo 
protein synthesis: infected cell polypeptide 0 (ICP0), ICP4, ICP22, ICP27 and 
ICP47. Overall, IE genes are responsible for orchestrating viral replication. ICP4 and 
ICP27 regulate E and L gene expression at the transcriptional and post- 
transcriptional level and have been shown to be crucial for lytic viral replication in 
vitro and in vivo (reviewed in Weir, 2001). E genes encode for important enzymes 
that produce nucleotide pools and initiate viral DNA synthesis, such as thymidine 
kinase and DNA polymerase. L gene products include structural proteins of the 
capsid, tegument and envelope and do not become activated until the newly 
synthesized DNA is cleaved to the right length and ready to package. The “a” 
sequence within the short IR is used as a packaging signal. The envelope is acquired 
as the particle exits the cell through a modified patch of the nuclear membrane that 
expresses viral glycoproteins (for reviews see Roizman & Sears, 1996; Fink et al., 
1996; Whittaker et al., 2000; Weir, 2001).
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HSV has the ability to infect a range of cell types but is naturally neurotropic 
(Roizman & Sears, 1987; Latchman, 1990). After infecting and replicating in 
epithelial cells, it migrates up nerve processes to cell bodies via retrograde axonal 
transport. Once in the neurone, HSV can undergo lytic replication or remain latent. If 
the virus establishes such silent infection, it remains in the sensory neurones that 
innervate the peripheral skin cells originally infected without expressing most genes 
or disrupting the host cell. This dormant state can be disrupted by stress and the virus 
can reactivate to enter the lytic cycle. The fact that the virus can transport away from 
nerve termini, remain latent in neurones, reactivate and transport again to the 
peripheral epithelial cells explains the patterns seen in the pathology it causes. The 
initial skin infection gives rise to cold sores or genital sores that tend to disappear but 
are characteristically recurrent. It is important to note that the infection does not 
cause damage to the neurone or its processes and is entirely asymptomatic. These 
characteristics already address some of the issues raised by gene therapy: 
permanence in the neurone with minimal toxicity. It should, however, be noted that 
direct injection of the virus to the brain could potentially lead to encephalitis if the 
attenuated virus reverted to wild type. The virus can potentially be engineered for 
long term gene expression but during its latency period, viral gene expression almost 
completely shuts down and the virus remains silent (Roizman & Sears, 1987). Hence, 
transfected genes will also be silenced and the therapeutic effect is lost. Latency 
associated transcripts (LATs), however, are the few genes still active during latency. 
Many laboratories have attempted to use the promoters for such genes to drive long 
term expression of exogenous genes, by either inserting the transgene close to the 
LAT region or linking the LAT promoter to a different part of the genome where the 
foreign gene lies (for review see Latchman, 2002). Some of these experiments have 
been successful in producing long term expression both in vitro and in vivo, 
indicating that, in this respect, HSV is more advantageous than other viruses for gene 
therapy (Ho & Mocarski, 1989; Goins et al., 1994; Coffin et al., 1998; Palmer et al., 
2000).
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3.5 Disabled HSV-1 vectors
Two different HSV-1 types of vector are currently available for central 
nervous system gene delivery, amplicon vectors and recombinant viruses. Amplicon 
systems involve introducing the transgene into a plasmid containing an HSV origin 
of replication and packaging signal (“a”). This is grown in bacterial cells and 
transfected into cell lines together with a deficient HSV helper virus. The plasmid 
replicates into concatamers with the aid of the helper virus and is packaged into viral 
particles (reviewed in Fink et al., 1996). The alternative system still involves the 
insertion of the gene of interest in a plasmid but this time flanked by specific HSV 
sequences. Cells are then co-transfected with plasmid and HSV and homologous 
recombination leads to insertion of the transgene directly into the viral genome 
(Coffin et al., 1996; Freese et al., 1996). Reporter genes such as green fluorescent 
protein (GFP) or LacZ can then be used to select recombinant versus non­
recombinant viruses. This in turn renders quantification by titration and plaque assay 
easier. Although both amplicon and recombinant viral systems are currently in use, 
this study used the latter and it will therefore be the only one discussed.
A lot of effort has been focused on improving the efficiency of gene transfer 
and, more importantly, the degree of disability of the vector without compromising 
its ability to grow in culture. The simplest way of making viral vectors safe to their 
host is to render them avirulent by deleting some of the key immediately early genes 
involved in the lytic growth cycle. Viruses lacking ICP4 and or ICP27 have in fact 
been constructed to impair lytic replication in all cell types and eliminate the risk of 
encephalitis after injection to the brain (Chiocca et al., 1990; Dobson et al., 1990; 
Howard et al., 1998). Deletion of ICPO or ICP22, on the other hand, does not impair 
replication completely but reduces titre and therefore some of its toxicity (Post & 
Roizman, 1981; Sacks & Schaffer, 1987). Some of these mutations, like deletion of 
ICP4 or ICP27, require that the defective virus is grown in complementing cell lines 
engineered to express the missing gene in order to allow replication to occur. Special 
care should be taken so that the gene sequence in the cell line and the ones remaining 
in the virus do not overlap so that no recombination can take place that could revert 
the virus to wild type. Losing avirulence of the vector could obviously have
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disastrous consequences to the host in terms of toxicity and could lead to encephalitis 
in vivo.
Reversion to virulence by homologous recombination with genes added to the 
cell line can be avoided through different strategies. Some have attempted the 
deletion of ICP34.5, a viral gene needed for replication in non-dividing cell types 
only. This mutation does not affect growing of the virus in dividing cells in vitro and 
therefore does not require a complementing cell line, but it prevents lytic growth 
after brain delivery in vivo (Maclean et al., 1991; Robertson et al., 1992; Coffin et 
al., 1996). Another target protein is vmw65 or VP16 which is involved in 
transactivating IE gene promoters at early stages of infection. Mutations in it vastly 
reduce IE gene expression and such vectors have been used for in vivo delivery of p- 
galactosidase to dorsal root ganglion neurones (Ecob-Prince et al., 1995; Thomas et 
a l, 1999).
Alternatively, deletion of more than one gene for viral attenuation is a more 
efficient strategy since it reduces the chances that all deleted genes required for viral 
replication will be recombined at once. Even if this approach is technically more 
laborious, it has been widely applied when developing new viral vectors in order to 
increase safety. The ICP34.5 disabled virus has been used as a platform for 
developing other vectors. Howard and colleagues combined deletions in this gene 
and ICP27 to guarantee no lytic replication in either dividing or non-dividing cell 
types in the rodent brain in vivo. The double mutant was less damaging to cells and 
more efficient in delivering the LacZ transgene than a vector with a single ICP34.5 
mutation (Howard et al., 1998). Similarly, a virus deleted for ICP4, ICP22 and 
ICP27 stops synthesizing DNA transiently and safely expresses the transgene in 
primary neurones in vivo for over three weeks (Krisky et al., 1998). Other vectors 
used have combined mutations in vmw65 and ICP4 or ICP27, which are unable to 
undergo lytic growth and efficiently express the desired transgene but require further 
modifications to grow in culture even when using complementing cell lines (Thomas 
et al., 1999; Lilley et al., 2001). Moreover, viruses carrying deletions in ICP34.5 and 
inactivating mutations in vmw65 are successful in delivering the LacZ transgene to 
dorsal root ganglion (DRG) neurones in mice (Coffin et al., 1996). Such constructs 
have been further engineered by inserting the transgene under the control of LAT
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promoter in order to improve long term (3-galactosidase gene expression in DRG 
neurones after footpad inoculation (reviewed in Palmer et al., 2000).
Overall, there is sufficient evidence to suggest that different alterations to the 
HSV genome can be made in order to optimize efficient and safe gene delivery to the 
brain. This encouraging work has been essential in the development of the vector 
used in this study, a recombinant HSV-1 vector disabled for lytic replication by 
deletions in ICP25, ICP34.5 and vmw65.
3.6 Applications to the CNS
Gene therapy for neurological diseases has yielded some promising results 
but is still in its infancy. The use of viruses for gene delivery provides an important 
tool to address key issues about the aetiology and molecular biology of such 
disorders. Viral vectors have been developed to efficiently introduce therapeutic 
proteins in vivo and assess their effects (see Wolfe et al., 1999; Burton et al., 2002; 
Verma & Weitzman, 2005). HSV in particular has been used in several models of 
neurodegenerative disease since its latency state can be exploited for long term gene 
expression. One of the main concerns with HSV is that being such a common human 
pathogen its incidence in the population is high and the latent virus could revert the 
attenuated one to wild type. However, animal experiments and to some extent human 
clinical trials suggest this is not very likely (reviewed in Latchman, 2002).
HSV vectors have been used to deliver GDNF, a glial derived neurotrophic 
factor, to prevent dopaminergic cells in the substantia nigra from dying in a rodent 
model of Parkison’s disease (Choi-Lundberg et al., 1997). Viruses expressing GDNF 
or tyrosine hydroxylase cause a reduction in rotational behaviour in 6- 
hydroxydopamine rat models of Parkinson’s disease (Latchman & Coffin, 2000). 
Similarly, viral driven overexpression of Bcl-2 was shown to prevent death of 
dopaminergic neurones in vivo (Yamada et al., 1999). HSV has also been used to 
deliver the Bm-3a transcription factor where it promoted neuronal survival after 
sciatic nerve injury (Smith et al., 2001).
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Applications of gene therapy to stroke are fewer but promising. Many studies 
have preferentially used HSV-based vectors for reasons stated before. 
Overexpression of Bcl-2 before or after a 1 hour ischaemic insult is able to 
significantly protect striatal neurones (Lawrence et al., 1996; Lawrence et al., 1997). 
This protein is able to block cytochrome c release and therefore interrupt the 
downstream cascade of events leading to apoptosis. Pre-ischaemic delivery of the 
glucose transporter gene Glut-1 was found to protect neurones against ischaemia in 
rats (Lawrence et al., 1996). It is thought that glutamate overexpression can improve 
energy availability to compromised cells in the penumbra and increase the ATP 
levels needed for cellular functions. A different strategy is to reduce the amount of 
intracellular Ca++ in order to prevent cytotoxic oedema and consequent cell death 
following ischaemia. HSV-driven calbindin D28K expression in the striatum has 
improved neuronal survival after MCA occlusion in rats by acting as a calcium 
buffer (Yenari et al., 2001). Other experiments have shown that pre- and post- 
ischaemic delivery of HSP70 can protect the brain from stroke, possibly through its 
chaperone properties and by reducing the effect of reactive oxygen species (Yenari et 
al., 1998; Hoehn et al., 2001).
Although the feasibility of such experimental evidence directly correlating to 
successful clinical trials is low, investigating gene and cell therapy in animal models 
can yield important information. Because stroke, like any other pathology, involves a 
complex series of events, it might be necessary to address each of these events 
individually or through combined therapies. An excellent review by Szentirmai and 
Carter highlights the fact that delivery of a single gene or pharmacological agent at 
an acute stage is unlikely to prevent or ameliorate the damaging consequences of 
stroke. The authors suggest that cell and gene therapy might in fact be more useful in 
enhancing the recovery of the tissue by restoring cellular architecture and helping 
cells to regain their functionality (Szentirmai & Carter, 2004). This, in combination 
with neuroprotective strategies and targeting of the ongoing pathology in penumbral 
areas, might prove a more effective strategy.
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3.7 Summary
This chapter has concentrated on how viruses can be exploited for gene 
delivery if appropriate modifications are engineered into them in order to avoid lytic 
growth and toxicity. The application of viral vectors, and in particular herpes simplex 
virus, to animal models of disease has also been reviewed, paying particular attention 
to the relevance of gene therapy for cerebral ischaemia. Such issues are crucial in the 
context of this study since the effect of pre- and post-ischaemic viral delivery of 
therapeutic genes is assessed.
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Project Aims
The overall aim of this project is to use MRI techniques to assess the 
neuroprotective effect of heat shock protein (HSP) overexpression in a rat model of 
stroke. Three different experiments have been designed in order to investigate such 
effect:
a) intracerebral microinjections with herpes simples virus vector carrying LacZ 
(HSV-LacZ) control protein in order to determine viral expression levels and 
regional distribution in the rat brain (Chapter 4);
b) pre-ischaemic delivery of HSV engineered to express HSP27 (HSV-HSP27), 
HSP70 (HSV-HSP70) and control protein (HSV-LacZ) into the rat striatum, 
using MRI to determine changes in the ischaemic lesion size (Chapter 5);
c) post-ischaemic intrastriatal microinjection of HSV-HSP27, HSV-HSP70 and 
HSV-LacZ virus, using MRI to measure the effect of therapy on lesion size 
and behavioural tests to assess functional recovery up to 1 month after stroke 
(Chapter 6).
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Chapter 4 Viral microinjections
4.1 Aims
The purpose of this study was to assess viral expression in vitro and in vivo. 
Although this construct has been previously used, it was necessary to verify that the 
vector was effective in expressing the transgene. Viral stocks were grown on a large 
scale and the infectivity of the HSV-LacZ virus was tested initially in vitro. Once p- 
galactosidase expression was verified, the efficiency of the construct was 
investigated in vivo by intracerebral microinjection in 18 rats. These were divided 
into 5 sub-groups which were sacrificed at 6 different time points following 
microinjection: 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks (see schematic 
representation below). Spatial distribution and expression levels of the LacZ 
transgene in the brain were assessed by X-gal staining.
Micro inject ion Histology
0 3d 5d 1w 2w 3w 4w
Figure 4.1. Schematic representation of the experimental design. Animals were 
microinjected with HSV-LacZ and sacrificed at different timepoints to confirm viral 
transgene expression in vivo.
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4.2 Methods
4.2.1 Tissue culture
4.2.1.1 Reagents and solutions
All solid chemicals were dissolved in either ddKhO or autoclaved phosphate 
buffered solution (xl PBS). General laboratory chemicals were of analytical grade 
and purchased from either: Sigma Chemical Company Ltd, U.K; Life Technologies, 
U.K., or Amersham Biotechnologies, UK. General disposable plasticware was 
supplied by Sterilin unless otherwise stated. General solutions were prepared as 
follows:
Phosphate buffered saline (PBS), stock concentration (xlO): 104mM sodium, 1.8mM 
potassium chloride, 5.4mM disodium orthophosphate dihydrate, 1.25mM potassium 
dihydrogen orthophosphate (pH7) in ddlUO.
Paraformaldehyde (PFA): 4% w/v in sterile PBS.
Full growth medium (FGM): 10% Foetal Calf Serum (FCS) in Dulbecco’s modified 
Eager s medium (DMEM).
Selection medium: 10% FCS-DMEM, G418 (Geneticin) as 64mg x 100ml medium, 
Zeocin as 700pl x 100ml medium.
Virus medium: 20% FCS-DMEM + 2 x HMBA (2.8ml of HMBA x lOOmls of 
medium).
HMBA: 2% w/v solution = lg in 50mls of DMEM (filter sterilized).
CMC solution: 1.6% w/v carboxymethyl cellulose (CMC) in water.
Freezing medium: 30% FCS-DMEM and 8% DMSO.
Cresvl violet stain: 0.1% w/v cresyl violet in 20% ethanol.
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4.2.1.2 Growth conditions for mammalian cell lines
A laminar flow safety cabinet was used to perform all tissue culture and viral 
preparations in order to ensure sterility and safety conditions. A baby hamster kidney 
(BHK) cell line, B 130/2, was modified to stably express the zeocin resistance gene 
and the ICP27 gene from HSV-1 strain 17+ under the control of an ICP27 promoter. 
The cells were grown in Dulbecco’s modified Eagel’s medium (DMEM), containing 
10% foetal calf serum (FCS). B130/2 cells were selected by adding 500ju.g of 
Geneticin or G418 sulphate per ml to the growth media. Cells were grown from 
frozen stocks at 37°C/ 5% CO2 , seeded, allowed to reach confluence (48-72 hours 
approximately) and passaged as many times as required for infection. Stocks of cells 
were frozen down for repeated use.
4.2.1.3 Thawing BHK B130/2 cells
Cells were removed from -80°C and quickly placed at 37°C. Once thawed, 
the cells were rapidly pipetted onto 1 Omls of pre-warmed DMEM and spun down at 
lOOOrpm for 5 minutes. The supernatant was discarded and the pellet resuspended in 
0.5mls of medium. The cells were then plated onto a medium or large flask and 
incubated at 37°C/ 5%C02 for at least three days or until confluent.
4.2.1.4 Freezing BHK B130/2 cells
Once cells reached 80-90% confluence, they were passaged by washing with 
lOmls of Hank’s Balanced Salt Solution (HBSS) and trypsinizing. This was achieved 
by incubating the monolayer for 1 or 2 minutes with 4mls of a detergent solution 
containing 10% trypsin in versene. Once the monolayer was disrupted, 6mls of 10% 
FCS-DMEM were added and mixed thoroughly. The cells were then centrifuged in 
15ml tubes at lOOOrpm for 5 minutes. Most of the supernatant was then very 
carefully removed and discarded. The pellets were resuspended in 4mls of freezing
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medium, consisting of 30% FCS-DMEM and 8% DMSO. Cells needed to be counted 
in a hemocytometer and freezing medium was added in order to adjust the final 
concentration, until 1-2 million cells per vial was achieved. Vials were wrapped in 
paper roll and placed in a polystyrene cup, covered with aluminium foil at -80°C for 
at least 24 hours. The vials were transferred into liquid nitrogen for long term 
storage.
4.2.2 Infection of mammalian cell lines with recombinant virus
4.2.2.1 Creating a virus stock
A 6 well plate of B130/2 cells was grown by splitting a large flask (175cm2) 
of confluent cells as detailed before (i.e., wash with lOmls of Hank’s Buffer; 
trypsinize with 4mls of trypsin-versene, add 6mls of full growth medium and mix). 
An aliquot of 1.25mls out of the resulting lOmls of cells and medium was used for 
each plate, i.e. 200pl of cells per well. Each well was topped up with selection 
medium for a total final volume of 2mls per well. The solution was thoroughly mixed 
and incubated at 37°C/ 5% CO2  for 24 hours or until confluent. All the medium was 
carefully discarded and replaced with 500pil of DMEM + 5pi of virus. The plates 
were gently rocked sideways in order to completely cover the cells with the viral 
suspension. After incubating at 37°C/ 5% CO2 for 1 hour, the wells were overlaid 
with 500pl of viral medium (20% FCS-DMEM + 2 x HMBA) and incubated at 37°C 
for 48 hours. Once most cells had lysed, the edges of the plate were sealed with 
parafilm very carefully and placed at -80°C at least overnight before using.
4.2.2.2 Large scale viral culture
A 6 well plate was initially grown and each of the wells was harvested and 
used to seed a 175cm tissue culture flask as detailed in the previous sections. Once
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the flasks were fully confluent, all supernatant was removed and enough serum free 
DMEM was added in order to cover the cells (6mls approximately). The 6 well plate 
of viral stock was thawed and one well of solution was added to each flask. The cells 
and virus were mixed gently and incubated at 37°C/ 5% CO2 for 1 hour. Then, each 
flask was overlaid with lOmls of virus medium and incubated at 37°C/ 5% CO2 for 
48 hours. Once most cells had lysed, the large flasks were frozen at -80°C before 
further use.
Once again, 10 large flasks of cells were grown until fully confluent and split 
so that each flask contained lOmls of cells and medium. Each of these lOmls was 
placed in an 850cm2 disposable roller bottle (Corning Glass Works, Corning, New 
York, U.S.A.) and 40mls of FGM were added for a total volume of 50mls per bottle. 
The bottles were supplemented with 5% CO2 in 95% air through a double filtered gas 
line in a laminar flow cabinet thoroughly sprayed with 70 % ethanol for sterility. The 
lids were then closed tightly and the bottles incubated for approximately three days 
until fully confluent at 37°C in a roller bottle incubator rotating at 0.5rpm. Once the 
cells were fully confluent, the bottles were infected by removing all medium and 
replacing it with 25mls of a mixture of virus and medium prepared as: 12.5mls of 
thawed virus stock (i.e., the large flasks infected and stored at -80°C) and 12.5mls of 
fresh serum free DMEM. The bottles were incubated at 37°C for 1 hour and a further 
25mls of virus solution was added to each bottle for a total volume of 50mls. CO2  
gas was added to each bottle before incubating at 37°C for a further 48 hours.
As infection progressed, the medium started acidifying and changing colour, 
and most cells appeared dead under the microscope (i.e. rounded and floating instead 
of in a monolayer). The virus was harvested by shaking and collecting all the media 
from the bottles into 50ml falcon tubes. This solution was frozen at -80°C at least 
overnight and then thawed at room temperature in order to lyse any remaining intact 
cells and maximize the amount of virus available.
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4.2.2.3 Large scale viral concentration and filtration
The falcon tubes containing virus were thawed slowly at room temperature or 
in a 37°C water bath for 1.5 to 2 hours approximately. Once completely defrosted, 
the falcons were centrifuged at 3500rpm at 4°C for 45 minutes in order to eliminate 
cell debris. All pellets were discarded and the supernatants filtered through a 0.22pm 
filter on ice. The filtered viral solution was transferred to 250mls autoclaved 
centrifuge vials on ice. The tubes were weighed in order to distribute the volumes 
evenly before centrifuging in a Beckman J2-21 at 12000rpm at 4°C for 2 hours.
All supernatant was carefully discarded and the tubes placed upside down, 
resting on their lids to further drain supernatant. The pellets were resuspended in 
350pl of either DMEM or autoclaved PBS. Although these pellets are extremely hard 
to resuspend, a small volume was chosen in order to obtain a more concentrated final 
viral solution. Once all pellets had been resuspended, they can be transferred to an 
eppendorf and sonicated in a sonicating water bath for 10 seconds at a time, placing 
the sample on ice for 30-40 seconds in between each sonication to avoid overheating 
the viral solution. The virus was then aliquoted and stored at -80°C before using.
4.2.3 Titration of virus on complementing cells
A confluent 6 well plate of BHK B 130/2 complementing HSV-ICP27 cells
was obtained as described before. The wells were infected with 1:10 serial dilutions 
2 11of virus from 1x10' to 1x10' . The initial solution was made up as lOpl of virus 
with lOOpl of DMEM mixed thoroughly for a final 10'2 dilution factor. lOpl of this 
mix was added to lOOpl of DMEM for 10'3, mixing thoroughly every time and 
changing tip for every lOpl that were mixed into the following well. Before 
infection, the medium was removed from the 6 well plates and replace with 500pl of 
fresh DMEM. The prepared serial dilutions of virus are added to each well, from 
lowest to highest concentration. Special care was taken not to squirt the liquid onto 
the fragile monolayers of cells. The plates are carefully mixed and placed in the 
incubator at 37°C/ 5% CO2 for 1 hour. After this incubation period, the medium was
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discarded and replaced with 2mls of 1:2 CMC:FGM with 1 x HMBA and placed in 
the incubator for 48 hours. The wells were washed twice in 1ml PBS and fixed for 10 
minutes in 4% paraformaldehyde (PFA). After rinsing the PFA off with PBS, the 
wells were covered with cresyl violet stain for a few minutes. Plaques can be 
visualized and counted under a light microscope. The infection titre of the virus was 
defined by multiplicity of infection (MOI), as the number of plaque forming units per 
cell.
4.2.4 Intracerebral microinjections
Adult male Sprague-Dawley rats (250-300g, n=18) were anaesthetized with 
2% isoflurane in 100% oxygen and secured by a bite bar and ear bars in a stereotaxic 
frame (Korf, Germany). A midline incision was made on the head and the skin and 
dura were retracted to locate bregma. This reference point was used to calculate the 
coordinates for the striatum defined as anterior-posterior = +0.10cm; lateral =- 
0.35cm; ventral = -0.50cm. A burr hole was made on the right side of the skull at 
these coordinates. The virus was delivered using a 33’ gauge stainless steel cannula 
attached to a 25 pi Hamilton syringe under the control of a microsyringe pump 
(UltraMicroPump II, WPI, UK) at a rate of 0.25pl/min. The syringe was left in place 
for 10 minutes after the microinjection was completed to minimize dispersion of the 
virus through the needle tract. A total of 2.5pi of lx l0 6 pfu/pl of HSV-LacZ viral 
suspension was injected. The needle was retracted and the wound closed with a 
mersilk braided non-absorbable suture (Ethicon, Ethylon, UK).
4.2.5 Detection of transgene expression
LacZ expression patterns following HSV delivery were investigated using X- 
Gal staining to detect p-galactosidase enzymatic activity.
81
In vitro assays were carried out on 6 well plates in duplicate. BHK B 130/2 
cells were grown until 80% confluent as described in section 4.2.2.1. The cells were 
infected with HSV-LacZ recombinant virus as previously detailed. The virus medium 
was washed twice with PBS and the cells were incubated with 1ml of fixing solution 
(0.05% glutaraldehyde in PBS) for 10 minutes at room temperature. The plates were 
rinsed with PBS twice again and overlaid with 3mls of X-gal solution consisting of:
xl PBS 
ImM MgCl2 
150mM NaCl
5mM potassium ferricyanide (K3 Fe(CN)6 )
5mM potassium ferrocyanide (K4 Fe(CN)6 )
0.1% NP40 or Igepal
150 pg/ml 5'bromo-4chloro-3indolyl-B-Dgalactopyranoside (X-gal) in di- 
methyl-sulfonamide (DMSO)
The plate was incubated at 37°C/ 5% C 02 in the dark for at least 2 hours or 
more depending on the intensity of the staining. The wells were then examined under 
a light microscope and blue viral plaques were identified as sites of (3-galactosidase 
activity and therefore LacZ expression. The buffer was then discarded and the wells 
rinsed with water and overlaid with 2mls of 70% glycerol for long term storage.
For in vivo detection, 3 rats were killed at each timepoint investigated. 
Animals were deeply anaesthetized with 3-5% halothane in 0 2 and transcardially 
exanguinated with 0.9% saline followed by ice cold 4% paraformaldehyde (PFA). 
Brains were extracted, kept in PFA overnight at 4°C and embedded in 3% agarose. A 
vibrotome was used to slice the brains into 250pm thick coronal slices which were 
collected in PBS. Sections were rinsed in PBS twice and stained free floating with 
the following X-gal solution:
xl PBS 
ImM MgCl2 
0.2% Igepal in PBS
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lOOmM potassium ferricyanide 
lOOmM potassium ferrocyanide 
40 mg/ml X-gal in DMSO
The slices were incubated at 37°C for at least 6 hours in the dark or 
overnight, depending on the desired staining intensity. The plates were rinsed twice 
in PBS to dilute the solution and stop the enzymatic reaction in order to inspect the 
slices under the microscope. Pictures were captured and slices discarded.
4.3 Results
4.3.1 LacZ expression in vitro
The aim of this experiment was to verify that the disabled HSV virus was 
able to express the transgene in culture. To this purpose, the BHK B130/2 
complementing cell line was infected with a recombinant disabled HSV-1 vector 
lacking ICP27 and engineered to carry LacZ. The assay was prepared by titration of 
the virus in serial dilutions of 1:10 on 6 well plates seeded with B 130/2 cells. After 
48 hours of infection the cells were stained with X-gal solution to detect p- 
galactosidase enzymatic activity as described in section 4.2.5. Consistent with other 
in vitro work from this laboratory, blue stained plaques were seen under light 
microscopy and this staining suggested that the virus was efficiently expressing the 
transgene (data not shown). Thus, this simple assay re-confirmed that the construct 
was suitable for applications in vivo.
4.3.2 LacZ expression in vivo
The ability of the virus to express the LacZ gene in adult rat brain was tested 
by intracerebral microinjection followed by X-gal staining of 250pm fixed brain 
slices. The purpose of this study was not to characterize the vector’s ability to infect
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different neuronal populations in vivo or its expression levels. This work has already 
been published and established HSV-1 and this recombinant vector in particular as a 
suitable for gene delivery to the brain (see sections 3.5 and 3.6 for references). 
However, determination of the regional distribution of the virus was necessary 
ground work for the subsequent gene therapy study that will be described in chapter 
5. This allowed a direct comparison between the area of viral expression and the area 
affected by middle cerebral artery occlusion.
LacZ expression was observed in all 18 rats at 6 different timepoints (n=3), 
ranging from 3 days to 1 month after infection. Figure 4.2 clearly reveals blue 
staining in the striatum of a rat 3 days after microinjection. An overall view of the 
stained region in slices from front to back of the brain is presented in figure 4.2a. The 
same distribution and signal intensity was observed throughout all timepoints tested. 
In fact, all animals presented strong blue signal in the striatum but none showed 
staining in the cortex with the exception of some traces of expression along the 
needle tract (figure 4.2c). Protein expression was strongest at 3 days but was 
sustained below peak levels for at least 1 month after injection although no later 
timepoints were tested (figure 4.3). Some blood traces and mild p-galactosidase 
expression was detected along the needle tract in the cortex at early timepoints, but 
this disappeared within a maximum of 10 days (figure 4.2b).
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Figure 4.2. LacZ expression in the basal ganglia peaks 3 days after HSV 
microinjection, a) X-gal assay showing HSV-LacZ spatial distribution and 
expression levels at 72 hours after intracerebral microinjection in 250pm slices from 
front to back of the rat basal ganglia, b) Detail o f traces o f blood seen 3 days after 
microinjection, c) Detail o f LacZ expression in the basal ganglia.
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Figure 4.3 Sagittal section o f a rat brain 1 month after intracerebral microinjection 
with HSV-LacZ. /3-galactosidase expression was detected in the basal ganglia.
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4.4 Conclusions
The p-galactosidase enzyme is the product of the LacZ gene and is often used 
as a reporter gene to verify gene expression in vitro and in vivo. This transgene has 
been recombined into several HSV vectors to assess their efficiency in delivering a 
foreign gene. The vector used in this study has been tested in vitro and in vivo 
following delivery to ND7 and DRG neurones (Wagstaff et al., 1998, 1999; Kalwy et 
al., 2003).
Injection of this virus into the rat motor cortex and the marmoset striatum 
shows high levels of LacZ expression and no signs of tissue damage as seen on light 
and electron microscopy at 14 and 28 days respectively (Howard et al., 1998). 
Similarly, striatal inoculation in rats was efficient in delivering the transgene for 1 
week and the virus exhibited retrograde transport to the substantia niagra, but 
expression dramatically declined 1 month after injection (Lilley et al., 2001). 
Following footpad inoculation or direct inoculation into the nerve, animals were 
sacrificed at different timepoints and DRG neurones fixed and stained. Virally-driven 
expression of p-galactosidase was detected up to 1 month after injection (Palmer et 
a l , 2000).
Since the infectivity, efficiency of transgene expression and safety of the 
disabled virus has already been established, this study was concerned with the 
distribution of the virus after intrastriatal microinjection. The reasons for this will 
become more apparent in the next two chapters, where this vector is used to deliver 
therapeutic proteins and the LacZ protein to the brain following middle cerebral 
artery occlusion. In views of these studies it was important to:
• verify the vector was able to efficiently and safely deliver the gene in 
vivo as suggested by previous experiments;
• asses the regional distribution of the gene following intrastriatal 
microinjection;
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• asses the timecourse of expression.
The experiments described confirm previous findings about the recombinant 
HSV-1 vector used, and establish that its expression coincides with the areas affected 
by focal ischaemia. Moreover, although LacZ expression was not quantified, intense 
blue signal was still detected up to one month after inoculation. Since the same viral 
backbone and promoter are used, the studies detailed in chapters 5 and 6 assume that 
the expression profile of the virus carrying heat shock protein 27 (HSP27) and 
HSP70 is the same as that of the HSV-LacZ vector. However, HSP27 and HSP70 
protein expression levels were later quantified via end point histology in 
microinjected rats in vivo (chapter 5).
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Chapter 5 Pre-ischaemic viral delivery o f  heat shock proteins in vivo
5.1 Aims
The experiments reported in this chapter examine the neuroprotective effect 
of pre-ischaemic gene therapy with two heat shock proteins (HSPs) in an 
experimental model of stroke.
Aims were therefore:
• to deliver HSPs into the central nervous system using engineered herpes 
simplex virus type-1 (HSV-1) as a vector;
• to use MRI to assess the neuroprotective effects of pre-ischaemic viral 
delivery of HSPs on lesion size in a rat model of reversible focal cerebral 
ischaemia.
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5.2 Introduction
Heat shock proteins are part of a natural mechanism of cell defence to 
environmental stress in all living organisms. Following the initial thermotolerance 
study in Drosophila, many in vitro and in vivo experiments have established that 
these proteins are upregulated during a variety of stresses in different species 
(Lindquist & Craig, 1988; Higashi et al., 1994; Wagstaff et al., 1996; Ehmsperger et 
al., 1997; Feder & Hofmann, 1999). HSPs can enhance cell survival by binding to 
denatured proteins to prevent their misfolding or aggregation with other proteins. 
They are also responsible for refolding aberrant proteins or targeting them for 
disposal into proteasomes (Kiang & Tsokos, 1998; Sharp et al., 1999; Latchman,
2004). HSP27 and HSP70 have been specifically, although not exclusively, linked to 
protection in the CNS and extensive in vitro and in vivo evidence has been detailed in 
chapter 1.
Endogenous HSP27 and HSP70 have been shown to be upregulated upon 
transient focal ischaemia in rats (Wagstaff et al., 1996). Moreover, the in vitro and in 
vivo evidence suggests that overexpression of these chaperones has a neuroprotective 
effect (chapter 1). The hypothesis here tested is that viral overexpression of heat 
shock proteins can enhance protection upon stroke. An intraluminal middle cerebral 
artery (MCA) occlusion model of transient focal cerebral ischaemia was used 
because it is currently retained to be the least invasive and most relevant to clinical 
stroke cases (chapter 2). The lesion induced typically has an unsalvageable core that 
is surrounded by hypoperfused, compromised but potentially salvageable tissue.
The choice of delivery method was based on a rich literature supporting 
viruses as efficient vectors (chapter 3). A disabled herpes virus engineered to carry 
HSP27, HSP70 or LacZ was used. The viruses were delivered three days prior to 
induction of ischaemia because viral expression of the LacZ transgene was 
previously established to peak at this timepoint (chapter 4). The method of assessing 
the consequences of therapy was non-invasive magnetic resonance imaging 
combined with end point histology. As described in chapter 2, MRI techniques 
enable the measurement of lesion size and cerebral blood flow and have been
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extensively used in experimental stroke models to describe the evolution of the 
lesion after occlusion and/or reperfusion. Gene therapy studies with HSPs to date 
have exclusively used histological techniques to evaluate the effects of therapy. The 
novelty of the study presented here is the use of non-invasive MRI to determine 
changes in lesion size due to pre-ischaemic delivery of HSP27 and HSP70 to the 
brain. Moreover, it is the first time that therapeutic intervention with HSP27 has been 
assessed in a rat model of stroke.
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5.2 Materials and Methods
5.2.1 Experimental design
All animal care and procedures were carried out in accordance with the UK 
Animals (Scientific Procedures) 1986 Act. This experiment involved 3 different 
studies, A, B and C, all using adult male Sprague-Dawley rats (220-250 g, Charles 
Rivers):
Study A: 18 rats were divided into 3 sub-groups microinjected with HSV-HSP27 
(n=6), HSV-HSP70 (n=6), or HSV-LacZ as a control (n=6). All rats underwent 
occlusion of the middle cerebral artery (MCA) 3 days after microinjection and 
MRI scanning 24 hours later was used to assess CBF and lesion size.
Studies B and C: 2 different groups of rats were divided into sub-groups 
microinjected with HSV-HSP27 (n=4), HSV-HSP70 (n=4), or HSV-LacZ as a 
control (n=4). All rats underwent middle cerebral artery occlusion (MCAO) 3 
days after microinjection. T2 -weighted multislice scans were run 24 hours later 
not to determine lesion volume but to confirm the presence of a lesion. 48 hours 
after MRI, brains were extracted for immunohistochemistry (study B, n=12) or 
Western blotting (study C, n=12) respectively. A schematic representation of the 
experimental design is included below (figure 5.1).
93
Microinjection
Stroke MRI Histology
i i
0 3d 4d 6d
Figure 5.1. Schematic representation of the experimental design. Animals were 
subjected to viral microinjection three days prior to stroke induction. Rats were 
scanned 24 hours later and sacrificed 48 hours later for end point histology.
5.2.2 Virus growth
This procedure has been described in detail in chapter 4. Herpes simplex 
virus strains 4+/27-/pR19-HSP27, 4+/27-/pR19-HSP70, 4+/27-/pR19-LacZ have 
been previously described (Coffin et al., 1996; Wagstaff et al., 1999; Wolfe et al., 
1999; Latchman, 2001; Lilley et al., 2001). Briefly, the HSV-1 backbone 
1764/4+/27-/RL1 was attenuated by a disabling mutation in Vmw65 and deletion of 
ICP34.5. An expression cassette containing cDNA inserts from either Chinese 
hamster HSP27, inducible human HSP70 or (3-galactosidase under the control of a 
cytomegalovirus immediate early promoter was inserted into the backbone via the 
pl9/20.5/UL43 vector by homologous recombination. Replication of such 
incompetent viruses was obtained in the complementing B130/2 BHK cell line 
(stably over-expressing ICP27 gene of HSV-1). Viruses were extensively grown; the 
cell lysates were initially centrifuged at 3500rpm for 45 minutes and the supernatant 
further clarified by filtration through a 0.22pm filter. The resultant medium was 
centrifuged (2 hours at 12500rpm in a Beckman J2-21 centrifuge) and the virus pellet 
resuspended in sterile phosphate buffered solution (PBS). Concentrated virus was 
titrated by counting plaque formation on B 130/2 BHK cells. Titres of l-2 x l0 10 
plaque forming units (pfu) were routinely obtained.
5.2.3 Intracerebral micro injections
Rats were anaesthetized with 2% isoflurane in 100% oxygen. All rats in 
studies A, B and C were stereotaxically microinjected with 2.5pl of lx l0 6 pfu/pl of 
HSV-LacZ, HSV-HSP70 and HSV-HSP27 respectively. The virus suspensions were 
introduced into the right rat striatum (Bregma coordinates: AP= +0.10; L =-0.35; V= 
-0.50) using a 33’ gauge stainless steel cannula attached to a 25pi Hamilton syringe 
under the control of a microsyringe pump (UltraMicroPump II, WPI, UK) at a rate of 
0.25pl/min. Animals were allowed to recover for three days before being subjected 
to focal reversible MCAO.
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5.2.4 Middle cerebral artery occlusion
All rats in studies A, B and C were anaesthetized with 2% isoflurane in a 
70:30 N20:C>2 delivered by a nose cone. The origin of the right MCA was occluded 
with an intravascular suture as described elsewhere (Longa et al., 1989). Briefly, the 
common, internal and external carotid arteries were exposed by a cervical midline 
incision. A 3/0 monofilament suture (Monocryl, Ethicon, UK) with an araldite (Sil- 
Mid, UK) coated rounded tip was used. This 290pm suture was introduced into the 
lumen of the right common carotid artery up to the carotid bifurcation and advanced 
approximately 17mm into the internal branch of the carotid artery to block the origin 
of the MCA. The embolus was secured by sutures at two points: first, to the common 
carotid artery at the base of the neck and then further up on the same artery and 
before its branching. An arterial clip was also placed further up from the second 
suture just before the carotid bifurcation into internal and external carotid arteries. 
The artery was carefully nicked and the intraluminal suture pushed through, until the 
clip; then the second upper suture was tightened and the clip removed. The animals 
remained occluded for a total of 30 minutes after which they were carefully 
reperfused by retracting the embolus and securing both sutures at either side of the 
nick. The cutaneous wound was then sutured and cleaned. Rectal temperature was 
maintained at 37±1°C via a heating blanket controlled by a thermocouple. The whole 
procedure took 1.5 hours and the animals were left to recover for 24 hours before 
scanning with free access to food and water.
5.2.5 Magnetic Resonance Imaging
Animals in studies A, B and C were anaesthetized with 2% halothane in a 
70:30 N20 :0 2 mix delivered via nose cone and placed on a probe with bite and ear 
bars securing the head to minimize movement artefacts (figure 5.2). The change in 
anaesthetics for the scanning sessions was based on the fact that halothane has 
vasodilating properties that were convenient when acquiring perfusion data. All 
scans were performed on a 2.35 Tesla horizontal bore magnet (Oxford Instruments, 
UK) interfaced to a SMIS console (Guilford, UK). Physiological monitoring
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included electrocardiography (ECG) recordings and rectal temperature, which was 
maintained at 37±1°C using an air warming system.
Figure 5.2. Animal in preparation for an MRI experiment. The head is secured by 
ear and bite bars and anaesthetics are delivered via the nose cone.
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Images were acquired using a volume transmitter coil and a separate 
decoupled surface receiver coil. All sequences were run on a single 2-mm-thick 
coronal slice located in the MCA territory (0.5mm from bregma). The matrix size 
was 128x64 and the field of view was 40x20mm. The imaging protocol included two 
echo planar imaging (EPI) sequences, Ti measurement and continuous arterial spin 
labelling (CASL), and a T2 -weighted spin echo (SE) sequence. The Tj and CASL 
scans were used to determine CBF whereas the T2-weighted SE was run to determine 
the lesion volume. The Tj sequence parameters were 2000ms repetition time (TR), 
18ms echo time (TE), an inversion time (TI) array of 284ms, 434ms, 634ms, 834ms, 
1234ms, 1734ms, 2734ms, 3734ms and the number of averages was 16. For CASL, 
the TR was 1000ms, the TE was 18ms, and the number of averages was 44. The 
inversion slice was positioned approximately 13mm from the back of the cerebellum 
and labelling and reference scans were obtained with a 500ms delay time (Alsop & 
Detre, 1996). The multislice T2-weighted SE sequence consisted of 9 slices with a 1- 
mm thickness. The parameters used were TR = 1500ms, TE = 120ms, and the 
number of averages was 8. The centre slice was determined by visual inspection of 
anatomical landmarks. In the chosen image, the ventricles appeared y-shaped and 
bright due to the presence of CSF. Total scan time was 35 minutes.
5.2.6 Image processing and data analysis
All images were reconstructed with IDL Software Version 5.2 (Research 
Systems Inc., USA) in order to obtain quantitative maps. Labelled and reference 
CASL images were subtracted and Tj values used to calculate CBF maps. Lesions 
and regions of interest were delineated on all processed images and analyzed with 
SMIS Image Display Version 3.7 and Scion Image software. Lesion size was then 
expressed as a percentage of total pixel number in the brain slice. It is important to 
clarify that the term “lesion” will be used throughout the thesis in reference to the 
lesion seen on T2-weighted images. Data analysis was performed by an observer 
blinded to the groups and resulting lesion areas per slice were used to determine 
lesion volume across the whole brain. An analysis of the group differences in lesion 
spread from front to back of the brain was performed using a random coefficients
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model, as required to deal with the expected spatial correlation in the data. A 
comparison based on Akaike’s Information Criterion indicated that a parallel 
response model provided an adequate description of the lesion data over slices 3 to 9 
inclusive, covering the MCA territory. These calculations were performed using SAS 
PROC MIXED (SAS Institute, 1999). Student’s t-test assuming unequal variances 
and Mann-Whitney tests were used to compare all other measurements. Data were 
presented as mean ± standard error and considered significant at p < 0.05.
5.2.7 Western blots
5.2.7.1 General reagents and solutions
Phosphate buffered saline (PBS), stock concentration (xlO): 104mM sodium, 1.8mM 
potassium chloride, 5.4mM disodium orthophosphate dihydrate, 1.25mM potassium 
dihydrogen orthophosphate (pH7) in ddH20.
Protein extraction buffer: 50 mM Tris HC1, 150 mM NaCl, 1 mM EDTA 
(ethylenediaminetetraacetic acid), 0.1% Tween 20 (polyoxyethylene sorbitan 
monolaurate), 10% glycerol, containing protease inhibitors (complete, mini protease 
inhibitor cocktail, Roche, Germany).
Resolving Gel (10%): 20ml of mix prepared as: 7.9ml dH20 ; 6.7ml 30% acrylamide 
mix (30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide); 5ml 1.5M Tris (pH 8.8); 
0.2ml 10% sodium dodecyl sulfate (SDS); 0.2ml 10% APS (ammonium persulfate, 
prepared fresh and added last); 0.008ml TEMED (NNNN-tetraethylethalinediamine).
Stacking gel (5%): 10ml of gel mix as: 6.8ml H2 O; 1.7ml 30% acrylamide mix; 
1.25ml 1.0M Tris (pH 6.8); 0.1ml 10% SDS; 0.1ml 10% ammonium persulfate; 
0.01ml TEMED.
Electrophoresis running buffer: 25mM Tris HC1; 250mM Glycine (pH 8.3); 0.1% 
SDS in ddH20.
99
Transfer buffer: lx running buffer; 20% methanol.
Blocking buffer: 5% Marvel skimmed milk powder dissolved in 0.1% PBST (PBS- 
Tween 20).
Wash buffer: lx PBS; 0.01% Tween 20.
Protein loading buffer (6 x): 300 mM TrisHCl (pH 6.8), 600 mM DTT, 10% SDS, 
30% glycerol, 0.1% bromophenol blue.
5.2.7.2 Protein extraction and analysis
Fresh brain tissue of all animals in study C was quickly isolated and flash- 
frozen in liquid nitrogen. Basal ganglia and cortical regions were dissected and 
placed in sterile culture tubes. Vials were then flash frozen in liquid nitrogen and 
either used immediately or stored at -80°C. Total tissue weight was calculated by 
individually weighing the tubes and subtracting their weight from the weight of an 
empty vial. Protein extraction buffer was added as 3 volumes of buffer to 1 volume 
of tissue. The tissues were then homogenized with a Polytron PT 1600 E 
homogenizer (Kinematica AG, UK) on ice as 3 pulses at 30000rpm for 10 seconds 
cooling on ice in between. Samples were allowed to rest for at least 30 minutes on 
ice before being aliquoted into eppendorf tubes. The vials were then centrifuged at 
1300g for 30 minutes at 4°C and the resulting supernatant was collected and frozen 
at -80°C.
5.2.13 Protein quantification
The Bradford Assay (Perbio Science, UK) was used to quantify total protein 
levels from homogenised samples. Briefly, bovine serum albumin (BSA) standards
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were diluted to 1 mg/ml in water. Solutions A and B were mixed as 50 to 1, loading 
200pl per well (e.g. 10 samples, 2mls A + B = 1960pl A + 40pl B). Standards were 
then loaded onto the first row of a 96 well plate on an increasing protein 
concentration gradient as follows:
1st well: 195pi of A+B solution + 5 pi of water 
2nd well: 195pi of A+B + 5pi BSA standard 
3rd well: 190pl of A+B + lOpl BSA standard 
4th well: 185pi of A+B + 15pi BSA standard 
 etc
One of the wells was loaded with a tween extraction buffer (5 pi tween buffer 
+ 195pi A+B solution) as a control. All tissue samples were loaded as 5pi of sample 
+ 195pl A+B solution. The plate was then incubated at 37°C for 30 minutes in an 
incubator in the dark, and then placed into a spectrophotometer in order to measure 
optical densities (ODs) with a 560nm filter (GS-800 calibrated densitometer, BIO­
RAD, UK). The ODs obtained for the standards were used to plot a standard protein 
concentration curve, which in turn allowed the determination of the appropriate 
pg/pl protein values of the samples. Moreover, the standard curve was constructed 
by subtracting the first OD value (water+A+B) to all other ODs. As the values were 
given for pg protein/ 5 pi sample volume, all final values were divided by 5 to obtain 
their concentration as pg/pl. All sample ODs were inserted into the formula for 
standard curve regression [eg y = (25.723xOD-1.0226)/5pl of sample]. Once all 
protein concentration values were obtained for all samples, the volume of sample 
required for 30pg of protein per well was calculated for Western blotting (see section 
52.1.5).
5.2.1 A  Polyacrylamide gel electrophoresis
The mini-gel casting apparatus consisted of 0.1mm space glass plates and a 
10 well comb. The resolving gel was prepared as detailed in Section 5.2.7.1 and 
poured in between the plates. Approximately 1cm space was calculated when
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pouring the resolving gel to allow for the stacking gel and the comb. This space was 
covered with isopropanol in order to avoid air bubbles and seal the gel off from air to 
accelerate polymerization. The gel was then allowed to set for 30 minutes at room 
temperature (RT), isopropanol was poured out and rinsed with ddfhO. Meanwhile, 
the stacking gel was prepared as stated in section 5.2.7.1. and generously poured over 
the resolving gel. The comb was immediately inserted and the gel was allowed to set 
atRT.
5.2.7.5 Protein loading
Values obtained with the Bradford assay were used to determine the amount 
of sample required for a final protein concentration of 30jLig/pil. Protein samples were 
prepared as equal amounts of loading SDS buffer and cell lysate aliquots and a 
maximum total volume of 15pl per well was loaded. After mixing, all samples were 
placed in a hot plate for 1 minute, then on ice immediately and spun down at 
14000rpm for 5 minutes. A rainbow ladder (Amersham Biotechnologies, UK) was 
used as a molecular weight marker and was prepared as 6pi of marker mixed with 
6pi of SDS loading buffer. The comb was removed and the wells were flushed with 
running buffer. All samples were loaded in duplicate and run at 120 V for 1.5-2 
hours.
5.2.7.6 Protein transfer to nitrocellulose membranes
Blotting paper, sponges, and hybond C membranes (Hybond C, Amersham 
Biotechnologies, UK) cut to fit the gel were pre-moistened in a tray with transfer 
buffer (see section 5.2.7.1). Once the run was finished, the plates were separated and 
the sacking gel removed. The gel was gently peeled off the plate and the transfer 
“sandwich” assembled as: sponge 1, blotting paper 1, hybond membrane, gel, 
blotting paper 2 and sponge 2. The “sandwich” was closed and tightened, making 
sure there were no air bubbles by rolling a falcon over it. After placing it in its 
holder, the tank was filled up completely with transfer buffer and run at room
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temperature at 100 V for 1 hour. An ice block was placed in one of the compartments 
of the tank to cool down the buffer during the run.
52.1.1 Immunodetection of proteins on western blot
Once the transfer was over, the membranes were incubated in blocking buffer 
for 30-60 minutes. After rinsing 3 times in PBS, membranes were incubated with 
rabbit polyclonal anti-HSP27 (1:1000, product # SPA-801, Stressgen
Biotechnologies, UK) and monoclonal anti-human HSP70 (1:1000, product # SPA- 
810, Stressgen Biotechnologies, UK) overnight at 4°C or at RT for 1.5 hours. 
Negative controls were incubated with blocking solution only. Membranes were 
washed 3 times for 5 minutes in 0.1% PBST before being incubated with the 
appropriate secondary antibody at RT for 1 hour. A secondary anti-rabbit HRP 
(1:2000, DAKO, Denmark) and anti-mouse HRP (1:2000, DAKO, Denmark) 
antibodies were used against HSP70 and HSP27 respectively. Once again, 
membranes were washed 3 times in 0.1% PBST for 5 minutes before developing 
with the enhanced chemoluminescence kit (ECL, Amersham Biotechnologies, UK). 
The solution was left on the membranes for 1 minute only and immediately exposed 
to X-ray film (Hyperfilm™-MP from Amersham International, UK) in the dark until 
the desired exposure was obtained, typically ranging from 10 seconds to a maximum 
of 1 minute. Band densities were measured in a GS-800 calibrated densitometer 
using QuantityOne Version 4.2.1 software (BIO-RAD, UK).
5.2.7.8 Re-probing membranes
All blots were re-probed with GAPDH antibody at room temperature for 1 
hour (1:3000, Chemicon International, UK) followed by anti-mouse secondary to 
confirm equal protein loading. Membranes were rinsed 3 times for 5 minutes in 
PBST in order to remove any traces of the developing solution. After incubating in 
blocking solution for 30-60 minutes at room temperature, the primary GAPDH 
antibody (1:3000) and secondary anti-mouse HRP (1:2000) antibody were added at
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RT for 1 hour as described the previous in section. If the original antibody could 
interfere with the new antibody, the membrane was stripped by washing 3 times for 5 
minutes in 0.2M NaOH and a further 3 times in PBS before blocking and re-probing.
5.2.8 Immunohistochemistry
5.2.8.1 Tissue embedding for cryosections
Animals in study B were deeply anaesthetized with 5% halothane in 100% 
N2 O for decapitation, their brains extracted and lightly covered with Cryo-embed 
medium (Bright Instruments Co., UK). The tissue was snap frozen in isopentane (2- 
methyl-butane, BDH, UK) cooled in liquid nitrogen. Then, the brains were blot dried 
and quickly retuned to in liquid nitrogen before transfer to -80°C for storage. 
Alternatively, they were placed directly into the cryostat for 1 hour in order to 
equilibrate their temperature to -20°C before slicing. lOpm-thick sections were cut in 
a cryostat (Bright Instruments Ltd., UK), placed on polysine coated slides (BDH, 
UK) and allowed to air dry thoroughly before storing at -20°C.
5.2.8.2 Immunohistochemistry on cryosections
Brain sections taken from HSP treated animals were stained with HSP27 and 
HSP70 antibodies to verify expression levels of microinjected proteins in the brain. 
The slides were thoroughly thawed, fixed in 4% PFA for 10 minutes and rinsed 3 
times for 5 minutes in PBS. Incubation in 0.3% H202-methanol for 10 minutes was 
used to quench endogenous peroxidase activity. Samples were rinsed 3 times for 5 
minutes in PBS and incubated for 10 minutes in 0.1% Triton-X-PBS for membrane 
permeabilization followed by two 5 minute washes in water. Samples were then 
blocked in 3% goat serum-PBS for 30 minutes at room temperature. Rabbit anti- 
HSP27 (1:200, Stressgen Biotechnologies, UK) and mouse anti-HSP70 (1:500, 
Stressgen Biotechnologies, UK) primary antibodies were applied on the sections 
overnight at 4°C. Slides were then rinsed in TBS and incubated with secondary
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antibody (StreptABC Complex/HRP Duet Mouse/Rabbit, DAKO, Denmark) 
according to manufacturer's instructions. Signal was amplified with DAB (3,3- 
Diaminobenzidine tetrahydrochloride, Sigma, UK) in the dark and rinsed in water 
several times. Haematoxylin and acid alcohol were used to counterstain the brain 
sections. Slices were dehydrated through gradient alcohols (50, 70, 100%), washed 
twice for 5 minutes in xylene and coverslips were mounted with DPX mounting 
media (BDH). All slides were viewed under an Axioskop 2 Plus microscope (Carl 
Zeiss Ltd., UK) and pictures captured with an AxioCam HRc camera and viewed 
with Axiovision 3.0.6 SP2 software.
5.2.9 X-gal staining
Three out of six brains extracted from animals in study A injected with the 
control HSV-LacZ vector were processed for X-gal staining to detect enzymatic 
activity as described in section 4.2.5. Briefly, 24 hours after MCAO, rats were deeply 
anaesthetized with 3-5% halothane in O2  and transcardially exanguinated with 0.9% 
saline followed by 4% paraformaldehyde at 4°C. Brains were embedded in 3% 
agarose and sliced into 250pm thick slices. Sections were stained with X-gal solution 
(5mM potassium ferricyanide, 5mM potassium ferrocyanide, ImM MgCU, 0.2% 
Igepal in PBS and 4 mg/ml X-gal, 5'bromo-4chloro-3indolyl-B-Dgalactopyranoside, 
in DMSO, di-methyl-sulfonamide) at 37°C for approximately 6 hours in the dark.
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5.3 Results
5.3.1 MRI measurement of lesion size
Figure 5.3 shows multislice T2 -weighted-spin echo MR images obtained 24 
hours after MCA occlusion. The three groups of six animals had been microinjected 
with HSV-HSP27, HSV-HSP70 or HSV-LacZ as a control, three days prior to 
occlusion (study A). The reason for this delay is that viral expression was shown to 
peak at three days post inoculation in rats that had not undergone MCAO (Chapter 4, 
section 4.3). Averaged total lesion volumes measured from the images were: 223.5 ± 
5.2mm3 for HSV-LacZ controls, 218.3 ± 4.6mm3 for HSV-HSP70 injected rats and
100.1 ± 3.7mm3 for HSV-HSP27 injected rats. A marked lesion volume reduction of
44.9 % [Cl (26.4 %, 76.0 %)] was seen in HSP27 injected animals compared to LacZ 
injected rats (p = 0.019). HSP70 treated animals showed no significant difference in 
lesion size from controls (p = 0.88).
Figure 5.4 shows lesion volume per slice from front to back of the brain in 
HSV-HSP27, HSV-HSP70 and HSV-LacZ injected rats. Results yielded by the 
parallel response statistical model indicated that there was a constant volume 
difference between the HSP27 treated group and the other two groups in slices 3 to 9 
of the multislice dataset [p<0.003, difference = 14.35mm3, Cl (5.08, 23.62)]. No 
lesion volume differences were found between HSP70 treated and control animals.
5.3.2 MRI measurement of CBF
Cerebral blood flow (CBF) was measured 24 hours after occlusion- 
reperfusion. Values in the ischaemic hemisphere were expressed as a percentage of 
flow in the contralateral hemisphere: 82.3% ±5.3 for HSV-HSP27, 77.1% ± 1.4 for 
HSV-HSP70 and 78.2% ± 5.0 for control animals. Complete recovery of CBF was 
not achieved but all values were above the ischaemic threshold (Kohno et al., 1995;
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figure 5.5). Statistical analysis showed there were no significant differences between 
animals in each group (Controls vs. HSV-HSP27 p>0.2; Controls vs. HSV-HSP70 
p>0.7) at 24 hours after reperfusion.
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Figure 5.3. Representative centre slice T2-weighted images of treated and control 
animals obtained 24 hrs after occlusion of the MCA. Intracerebral microinjections 
into the rat striatum with HSV-HSP27, HSV-HSP70 and HSV-LacZ were performed 
three days before ischaemia. Lesion area appears as bright signal on these T2- 
weighted images. The first image was obtained from an un-operated, intact animal 
for anatomical comparison.
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Figure 5.4. Absolute lesion volume per slice from front to back of the brain in 
HSP27, HSP70 and LacZ control groups. Total lesion size was calculated from 
multislice T2-weighted scans at 24 hrs after ischaemia and expressed as volume 
(mm3) ± s.e.m.
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Figure 5.5. Cerebral blood flow (CBF) values and lesion size in HSP treated and 
control rats. CASL maps obtained 24 hours after MCAO were used to determine 
levels o f reperfusion in the ischaemic hemisphere.
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5.3.3 Histological detection of HSP27, HSP70 and LacZ expression
Studies B and C assessed the spatial distribution and levels of HSP 
expression by immunohistochemistry and Western blotting respectively. These 
studies were performed in separate groups of animals due to differences in brain 
extraction and processing for the two histological techniques.
For immunohistochemistry experiments (study B), intracerebral 
microinjections were used to deliver HSV-HSPs into the rat striatum at the same 
concentration and rate as HSV-LacZ. Sections were taken 5 days after injection and 
stained with appropriate antibodies against HSP27 or HSP70 (figure 5.6). 
Comparisons between ipsilateral and contralateral brain hemispheres of HSP27 or 
HSP70 microinjected and MCA occluded rats showed high levels of expression of 
both proteins. On visual inspection, cortex and basal ganglia showed an increased 
number of stained neurons expressing the desired protein compared to the same areas 
in the contralateral uninjected hemisphere. Figure 5.6 shows expression of HSPs in 
representative brain sections of the ipsilateral cortex and basal ganglia of HSP27, 
HSP70 and LacZ injected animals. However, these differences were very difficult to 
quantify. Therefore, the experiments were repeated (study C) and a different 
biochemical technique was used.
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Figure 5.6. HSP27 and HSP70 protein expression in the rat brain. 
Immunohistochemistry on 10-pm cryo-sections taken 3 days after ischaemia 
induction shows both HSPs are overexpressed in the ipsilateral basal ganglia and 
cortex of microinjected and MCA-occluded rats. HSV-HSP27 and HSV-HSP70 
injected rat brain sections were stained for HSP27 or HSP70 respectively. HSV-LacZ 
injected controls shown were stained with HSP27 antibody for comparison. (A) 
Coronal sections of the basal ganglia (magnification 4X); (B) Coronal sections of the 
cortex (4X); (C) High magnification pictures (40X) showing expression of HSP27 or 
HSP70 in HSP injected or LacZ injected rat brains.
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Western blots were carried out for all animals in study C (n=12) in order to 
verify that total HSP levels were elevated due to both ischaemic insult and viral 
overexpression. Four different regions were dissected from each microinjected and 
ischaemic brain: ipsilateral basal ganglia (BGI), ipsilateral cortex (CTXI), 
contralateral basal ganglia (BGC) and contralateral cortex (CTXC). Figure 5.7a 
shows protein extracts from an HSP27 injected animal where HSP27 expression 
levels in BGI and CTXI were higher than both its contralateral counterparts and the 
equivalent brain regions in a LacZ injected control. Similar results were seen in 
HSP70 treated animals. Membranes were rinsed and re-probed with GAPDH 
antibody to control for protein loading and no differences were detected between 
samples (figure5.7b).
Quantification of the bands revealed that both HSV-HSP27 and HSP70 
microinjected rats had an approximate four-fold increase in protein levels of the 
appropriate HSP in ipsilateral brain regions compared to their contralateral 
counterparts. Similarly, a significant four-fold increase was seen when comparing 
ipsilateral basal ganglia and cortex of HSP treated and HSV-LacZ injected animals. 
Ratios of protein increase in basal ganglia and cortex within and between animals are 
summarized in Table 5.1. These results indicated that the injected vectors were 
successfully expressing HSPs and raising the total levels of expression of the 
appropriate HSP after ischaemic insult. Moreover, this is consistent with 
immunohistochemistry findings, indicating that total HSP levels were higher in HSP 
injected hemispheres than in LacZ injected controls.
Finally, an X-gal assay was used to visualize LacZ expression in 3 of the 6 
rats used as controls and the results confirmed that, as for previously described 
experiments, protein expression overlapped with the ischaemic lesion area in the 
basal ganglia but not in the cortex (see chapter 4).
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HSP27 expression levels
HSP27 treated LacZ treated P
BG 5.08 1.24 0.029
CTX 4.31 1.37 0.029
HSP70 expression levels
HSP70 treated LacZ treated P
BG 5.27 1.12 0.029
CTX 9.19 1.92 0.057
Table 5.1. HSP protein levels in basal ganglia (BG) and cortex (CTX), expressed as 
ratios ipsilateral/contralateral. Values represent the average of Westerns run in 
duplicate for each sample (ipsilateral and contralateral basal ganglia and cortex) for 
each of the 12 animals in this study. The p values refer to the comparison between 
HSP treated and LacZ treated animals (Mann-Whitney test).
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Figure 5.7. Western blots showing HSP27, HSP70 protein expression levels in three 
repersentative microinjected and MCA occluded rats. Four brain regions were 
dissected from each rat brain: ipsilateral basal ganglia (BGI), ipsilateral cortex 
(CTXI), contralateral basal ganglia (BGC) and contralateral cortex (CTXC).
(a) Protein levels in the ipsilateral basal ganglia and cortex in HSP injected rats and 
in LacZ injected controls.
(b) GAPDH loading controls for all samples.
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5.4 Discussion
The aim of the study was to investigate neuroprotection in vivo after delivery 
of an HSV-based vector expressing HSP27 or HSP70 in a rat model of cerebral 
ischaemia. MRI enabled the measurement of the effect of HSP27 and HSP70 
treatment on lesion size at 24 hours after stroke. For this in vivo study, a transient 
occlusion of the middle cerebral artery, a well established and reproducible rat model 
of stroke, was chosen. This creates a relatively large area of vasogenic oedema in the 
cortex and basal ganglia that can be detected by multislice T2 -weighted scans (figure 
5.3). These images demonstrated a marked reduction in lesion size in HSV-HSP27 
treated animals compared to HSV-LacZ controls. In contrast, HSV-HSP70 treatment 
had no effect on lesion size. All CBF values obtained 24 hours after occlusion- 
reperfusion were above the ischaemic threshold and similar in the three groups. 
Immunohistochemistry and Western blotting were used to examine the expression 
profile of the HSP27 and HSP70 vectors in brain tissue. It was not possible to 
establish whether the virus was infecting neurons, glial cells or both due to the 
absence of a specific neuronal marker in the sections. Thus, histology revealed 
widespread staining for both proteins in ipsi- and contralateral brain hemispheres of 
injected and MCA occluded rats. Western blots, however, demonstrated a significant 
increase in HSP27 and HSP70 expression in the ipsilateral cortex and basal ganglia 
of treated animals compared to LacZ injected and MCA occluded controls.
5.4.1 HSP expression
Interestingly, T2 -weighted images showed that reduction in lesion size was 
not only localized to the basal ganglia where the virus was injected but extended to 
the cortex. Based on HSV-LacZ profiles of spatial distribution and expression 
timecourse described in chapter 4, HSPs were expected to be present only within the 
basal ganglia. The reason for this increase in the cortex is unclear and needs to be 
further investigated. Several studies have shown that HSPs can either be locally 
produced in axonal compartments away from the neuronal cell body (Willis et al.,
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2005) or transferred from glia to neuronal axons (Tytell et al., 1986; Sheller & 
Bittner, 1992; Guzhova et al., 2001). Moreover, in vitro studies in neurons suggest 
that uptake of exogenous HSPs added to the culture medium can protect these cells 
from stress (Tidwell et al., 2004; Guzhova et al., 2001). In the context of this study, 
increased HSP expression in the cortex could therefore reflect the secretion of 
proteins from virally transfected cells and their recruitment to the injured cortex.
5.4.2 HSP27 effect on lesion size
HSP27 treatment caused a significant 44% reduction in lesion size. This 
protein is naturally expressed in glial cells and not in neurons, and some have 
suggested it could not therefore directly contribute to neuroprotection (Kato et al.,
1994). However, glial cells appear to be crucial for structural and metabolic support 
of neurons, maintaining synapse homeostasis and regulating the rate of neuronal 
repair (Wagstaff et al., 1996; Jessen, 2004). Thus, their ability to secrete HSPs upon 
stress might be a crucial mechanism to protect neurons, although this has not yet 
been investigated for HSP27. Regardless of the function of the endogenous protein, it 
was observed that viral microinjections successfully induce expression of exogenous 
HSP27 across the brain, thus raising total HSP levels and possibly enhancing the 
neuroprotective effect.
A “preconditioning” or “tolerance” effect in the brain has been reported in in 
vitro and in vivo studies showing that exposure to an initial mild stress can render 
cells more resistant by enhancing protection against a second more severe insult 
(Chen & Simon, 1997; Kirino, 2002; Dimagi et al., 2003). In experimental models, 
brief periods of global ischaemia have been shown to reduce lesion size after 
induction of permanent MCA occlusion (Simon et al., 1993). Interestingly, the 
protection conferred was not limited to neurones but extended to glial and 
endothelial cells (Chen et al., 1996). Experiments in global ischaemia in gerbils have 
suggested that tolerance develops 24 to 48 hours after the mild insult and lasts for 
approximately one week (Kitagawa et al., 1990; Kirino et al., 1991; Schaller et al., 
2003).
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Heat shock proteins were originally described in thermotolerance in vitro 
experiments and their overexpression prior to insult was shown to confer protection. 
The protective role of these chaperones in the brain is supported by evidence of their 
expression pattern (Nishi et al., 1993; Chen et al., 1996). HSP70 mRNA increases 2 
hours after ischaemia in affected regions and its temporal profile of expression 
mirrors the degree of vulnerability of the different cell populations, being present 
first in CA1 and then CA3 hippocampal neurones, then cortical and thalamic regions 
and finally in dentate granule cells (Simon et al., 1991; Welsh et al., 1992; Nishino 
& Nowak, 2004). Upregulation of heat shock proteins is therefore likely to be one of 
the mechanisms involved in ischaemic tolerance. The protection observed in this 
study may therefore be due to a pre-ischaemic induced tolerance following 
microinjection combined with the effect of the endogenous HSPs.
This could be relevant in a clinical context, since analogous situations have 
been described for stroke patients presenting multiple transient ischaemic attacks 
(TIAs). TIAs have long been identified as risk factors for subsequent ischaemic 
stroke but more recently they have been thought to improve outcome after stroke by 
triggering neuroprotective mechanisms (Schaller, 2005). In fact these have been 
described as a “naturally occurring analog to experimental ischaemic tolerance 
strategies” (Dirnagl et al., 2003). Several studies now support the hypothesis that 
TIAs before stroke can decrease tissue vulnerability and therefore reduce infarct size 
in the human brain (Weih et al., 1999; Moncayo et al., 2000; Wegener et al., 2004; 
Schaller, 2005).
HSP27 has been shown to protect cells in vitro by interfering with the stress- 
triggered apoptotic caspase-dependent and caspase-independent cascades (Melhen et 
al., 1996; Paul et al., 2002; Benn et al., 2002; Akbar et al., 2003; Latchman, 2004; 
Zourlidou et al., 2004). Several experiments have shown that this protein is able to 
sequester cytochome c after release from the mitochondria, prevent formation of the 
apoptosome, block caspase-3 activation and decrease the amount of AIF (apoptosis 
inducing factor) released by mitochondria after ischaemia (Garrido et al., 1997 & 
1999; Pandey et al., 2000; Bruey et al., 2000; Rashmi et al., 2003; Whitlock et al., 
2005). Chapter 1 has already described these functions in detail together with the
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cytoskeletal involvement of this chaperone in attempting to explain how HSP27 can 
accelerate cell recovery (Carper et al., 1997; Costigan et al., 1998; Paul et al., 2002; 
Williams et al., 2005). Perhaps one of the unique features of this chaperone is its 
ability to bind denatured proteins in an ATP independent fashion, which is 
advantageous in an energetically compromised ischaemic brain (Rogalla et al., 1999; 
Garrido, 2002).
5.4.3 HSP70 effect on lesion size
MRI scans suggest that pre-ischaemic injections with HSP70 had no effect on 
lesion size in this model. Most of the literature concentrates on HSP70 as the major 
constitutive and inducible HSP in the brain (Yenari, 1999; Kelly & Yenari, 2002). It 
is widely accepted that HSP70 protects cells from apoptosis but it is important to 
note that many in vitro experiments use toxic substances to induce apoptosis without 
causing protein denaturation, misfolding and/or aggregation. This might therefore 
mask the chaperone functions of HSP70 and emphasize how it can interfere with the 
apoptotic cascade. In fact, at least one study has shown that neuronal cells virally 
transfected with HSP70 were protected against ischaemic and thermal stress but not 
against apoptosis (Wagstaff et al., 1999). HSP70’s ability to accelerate cell survival 
by repairing the protein machinery is more related to necrotic forms of death. Several 
studies have shown that binding of this chaperone to denatured proteins prevents 
their aberrant aggregation and restores their functional conformation, thus increasing 
stabilization and reactivation of protein machinery after stress (Kabakov et al., 2002; 
Beaucamp et al., 1998).
The evidence of HSP70’s involvement in apoptosis indicates that it might 
regulate both upstream and downstream events, such as inhibiting the formation of 
the apoptosome, binding to cytochrome c or blocking the effector caspases like 
capsase 9 or 3 (Saleh et al., 2000; Mosser et al., 2000; Creagh et al., 2000; Beere et 
al., 2000; Tsuchiya et al., 2003; Steel et al., 2004). However, a different line of 
research suggests that overexpression of HSP70 can have damaging effects on cells. 
It is suggested that in the presence of TNF, the chaperone binds to survival elements
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and prevents them from blocking apoptosis (Ran et al., 2004). This may explain why 
HSP70 treatment fails to reduce lesion size since viral injections might induce 
activation of cytokines such as TNF. It is important to note that HSP27 can protect 
cells from TNF-induced apoptosis, which might account for the differences in 
protection observed in this study (Mehlen et al., 1997).
In vitro and in vivo evidence of protection with HSP70 remains extremely 
dependent on the type and severity of insult and the susceptibility to different 
environmental insults of the cell population affected (Amin et al., 1996; Jaattela et 
al., 1998; Lee et al., 2001a; Ran et al., 2004; Latchman, 2004). Although 
morphological improvement of the cells is observed after viral delivery of HSP70, 
there is no indication of reduction in lesion size (Yenari et al., 1998; Kelly et al., 
2002). It could be argued that, when using viral microinjections as a delivery 
method, the virus itself might render infected cells more or less responsive to HSP 
treatment. Previous studies however, suggest that microinjection of the vector used in 
this study does not cause any obvious damage to hippocampal cells in vivo and other 
neuronal cell types in vitro (Wagstaff et al., 1999; Kalwy et al., 2003; Zourlidou et 
al., 2004). Literature on transgenic animals overexpressing HSP70 should help 
circumvent the problem of unwanted effects of virally delivered proteins. Some 
studies show reduction in lesion size both in stroke and epilepsy mouse models 
(Rajdev et al., 2000; Tsuchiya et al., 2003; van der Weerd et al., 2005), while others 
show improved neuronal survival with no effect on the lesion size (Plumier et al., 
1997; Lee et al., 2001a; Kelly et al., 2001). The variability of protection against 
ischaemia reported in these HSP70 transgenic mice studies has been partially 
attributed to differential levels of expression. In the present experiments, the levels of 
endogenous and virally delivered HSP70 expression could have simply not reached a 
required threshold for lesion size to be reduced. However, histological analysis of the 
HSP70-injected and MCA-occluded animals showed widespread staining across the 
brain suggesting high levels of expression following ischaemia. Moreover, in vitro 
experiments have shown that the viral vector used yields the same levels of 
expression of both HSP27 and HSP70 (Wagstaff et al., 1998), although only the 
former protein has a potent protective effect in this experimental model. It is also 
possible that although HSP70 can be protective, the lack of ATP in the ischaemic
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lesion limits the chaperone’s ability to bind and release denatured proteins and 
therefore the amount of repair this chaperone can exert.
5.4.4 Summary
This study is the first to show that viral delivery of HSP27 has a significant 
effect in reducing lesion volume after focal cerebral ischaemia in rats. The fact that 
HSP70 treatment was unable to decrease lesion size might reflect different protective 
activities of the two chaperones. In this particular model, HSP27 might be more 
efficient due to its links with cytoskeletal stability and its ability to bind proteins in 
an ATP-independent fashion in conjunction with its anti-apoptotic functions. The 
high expression levels of both HSPs detected in the cortex suggested these proteins 
could either be transported to or secreted in lesion areas. There could also be 
signaling events leading to cooperation between endogenous and exogenous HSPs 
that enhanced the brain’s natural response to stress.
In conclusion, these findings provide evidence supporting the role of HSP27 
as a major protective protein in the brain and highlight the need for further 
investigation of the mechanisms underlying its neuroprotective effect. The difficulty 
in elucidating a precise cascade of events might simply be due to the variability of 
experimental systems, cell lines and species employed, or the complexity and 
specificity of the cell repair machinery in response to stress.
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C hapter 6 Post-ischaem ic viral delivery o f  heat shock proteins in vivo
6.1 Introduction
In view of the pre-ischaemic evidence of protection described in Chapter 5, 
the effect of post-ischaemic viral delivery of HSPs on lesion size was investigated in 
the same rat MCAO model of stroke. MRI techniques were once again used to 
measure lesion size and CBF at 6 different timepoints after induction of ischaemia. 
Moreover, behavioural tests were used to assess whether gene therapy could improve 
the functional deficits caused by the stroke in treated animals compared to controls.
6.1.1 Post-ischaemic gene therapy: general considerations
Animal models have made important contributions to elucidate the 
pathophysiology of stroke and this has in turn helped to develop treatment strategies. 
The middle cerebral artery occlusion model of stroke in rats has been extensively 
used because it reproduces the most common type of stroke occurring in humans 
(Hunter et al., 1995). The focal lesion produced has a core with severe decrease in 
blood flow and a peri-infarct or penumbral region with moderate reductions in CBF 
(see chapter 2). The duration of the ischaemic period is an essential factor in 
determining final lesion size. Aronowski and colleagues generated a computerized 
graded bioassay in order to correlate these two variables. No infarct was observed 
after 5 minutes of transient MCA occlusion, whereas small lesions were apparent 
after 10 minutes of ischaemia. Occlusion times of 20 to 50 minutes triggered a 
dramatic increase in brain damage and this was maximal at 1 hour and remained 
constant up to 2.5 hours of ischaemia (Aronowski et al., 1994). Similarly, these 
experiments showed that treatment was most effective if administrated at 50 minutes
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of occlusion time or less. A 30 minute occlusion followed by reperfusion was used in 
the present study because it has been estimated to be the minimum time required to 
produce a reproducible lesion encompassing basal ganglia and cortex (van Lookeren 
Campagne et al., 1999). Thus, the extent of damage caused is expected to be less 
than with longer occlusion times and should provide more potentially salvageable 
tissue to target by gene therapy.
The interval between onset of stroke and therapeutic intervention is another 
crucial factor to consider. While the effect of HSP27 treatment has not been 
previously investigated, the only post-ischaemic HSP neuroprotection study to date 
demonstrated that viral delivery of HSP70 at 0.5 and 2 hours after transient 
ischaemia in rats results in lesion size reduction (Hoehn et al., 2001). Interestingly, 
delivering a virus expressing HSP70 5 hours after reperfusion had no effect on lesion 
size or neuronal morphology as assessed at 48 hours. This suggests a narrow window 
of therapeutic intervention of ~3-6 hours after stroke that is consistent with clinical 
scenarios. In fact, patients show a significant improvement in neurological outcome 
when thrombolytic therapy is applied within 3 hours after the ischaemic event 
(NINDS Stroke Study Group, 1995). In general terms, the outcome of the patient is 
expected to improve the earlier the therapy is applied (Aronowski et al., 1994). 
Neuroprotective drugs delivered within the first few hours after stroke are likely to 
reduce final lesion size by preventing the growth of the lesion at this critical stage 
(see Ward et al., 1997). In the present study, gene therapy was applied at 30 minutes 
after the start of reperfusion, the earlier timepoint of the established therapeutic 
window, to allow for maximal efficacy of the treatment.
The route of administration of the treatment is also important. 
Pharmacological drugs are easier to administrate immediately after stroke. In the 
present study, however, the use of a vector implied a delay between administration 
and active therapeutic intervention, as the virus requires some time to express the 
transgene. An early delivery timepoint was therefore chosen in order to allow enough 
time for the viral vector to infect cells and guarantee expression the HSP genes by 3 
hours after stroke induction (Hoehn et al., 2001). Moreover, since intracerebral 
microinjections were used to deliver the viral vector, the area of infarction was 
directly targeted. The high infectivity and spatio-temporal distribution of the virus in
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the basal ganglia and its overlap with the area affected by MCA occlusion has 
already been discussed (chapter 4) and is assumed to be similar in this study.
It should be noted that experimental evidence of protection with a variety of 
drugs in rats often cannot be directly translated to effective clinical trials in stroke 
patients (reviewed in Hunter et al., 1995, 1998; de Keyser et al., 1999; Modo et al., 
2000). One of the limitations of animal neuroprotective experiments is that long-term 
functional recovery in motor and cognitive tasks is not always assessed. Although 
reduction in the size of the infarct is an important predictor of outcome, equal 
attention should be given to the ability of these treatments to resolve sensorimotor 
deficits. The next section will review the literature on the relevant behavioural 
studies that have been carried out in animal models of stroke.
6.1.2 Behavioural studies
Neurological score scales have been more widely used than sensorimotor 
tests in animal models and give an adequate but crude estimation of functional 
impairment due to stroke. Moreover, many studies have reported spontaneous 
recovery when using these tests at acute or short timepoints after ischaemia (Modo et 
al., 2000). More comprehensive scales include limb placement, beam or grid 
walking, rotarod, sticky label and staircase tests alongside the global neurological 
score tests such as postural/righting reflex, spontaneous exploration, circling 
behaviour, visual placement, inclined platform and horizontal bar (reviewed in 
Hunter et al.y 1998). A more sophisticated analysis of impairment requires a more 
complex battery of tests to probe for spatial memory and cognitive function, such as 
the radial or water maze tests (Yamamoto et al., 1991; Wahl et al., 1992; Markgraf et 
al., 1992; Okada et al., 1995).
In this study, long-lasting behavioural impairment was assessed via the 
bilateral asymmetry or “sticky tape” and the grid walking or foot-fault tests. Animals 
were not tested until 72 hours after ischaemia since it has been shown that 48 hours 
are required for animals to recover from MCA occlusion and this delay could
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therefore minimize the measurement of acute deficits due to the surgical procedure 
(van der Staay et al., 19966). The rational behind the bilateral asymmetry test is that 
animals suffering from unilateral damage will experience sensory neglect of the 
contralateral limbs (Schallert et al., 1982). This task mimics the contralateral neglect 
syndrome caused by damage to the parietal cortex and the tactile extinction observed 
in patients with unilateral stroke (Heilman et al., 1985; Rose et al., 1994). A variety 
of parameters can be measured with this test such as time to contact each paw and 
order of contact, however time to removal has been previously suggested to be the 
most reliable measure (Corbett & Nurse, 1998; Modo et al., 2000). No tests were 
performed in pre-ischaemic animals in this study because no differences have been 
previously found in baseline testing between operated and control animals (Hunter et 
al., 2000).
The foot-fault test measures spontaneous locomotor activity, motor 
coordination, and sensorimotor integration (Hunter et al., 1998). The total number of 
steps taken in 1 minute is counted together with the number of left paw 
misplacements on the grid. No pre-ischaemic testing was performed because 
previous studies have established that the number of foot faults are typically zero or 
near zero in intact animals (Rogers et al., 1997; Modo et al., 2000). This test has 
been shown to give a good indication of motor impairment due to unilateral MCA 
occlusion up to 3 weeks after stroke (Markgraf et al., 1992; Aronowski et al., 1996). 
Interestingly, a study in spontaneously hypertensive rats suggests that the 
behavioural recovery observed in the foot-fault test at 1 month after stroke is related 
to functional plasticity, to the ability of neurones to integrate to other regions in the 
cortex. This was shown by correlating the resolution of the motor deficit of the 
affected forelimb only at 30 days after stroke with elevated GAP-43 and 
synaptophysin expression in the ipsilateral neocortex. These two proteins are 
involved in neurite growth and in the increase in number of synapses and are often 
used as markers of neuroanatomical remodelling and neural development (Stroemer 
et al., 1995).
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6.1.3 Neurological score and experimental stroke
Differences in the evolution of pathology between permanent and transient 
occlusion models used in the literature could explain some of the variability observed 
in the rate of recovery of these animals (Hunter et al., 1998). Many permanent and 
transient stroke models in rats have demonstrated varying degrees of behavioural 
deficit compared to sham operated controls (Benderson et al., 1986; Persson et al., 
1989; Belayev et al., 1995). Early experiments established a direct correlation 
between the extent of neurological deficit and histological determination of lesion 
size at 24 hours after MCAO in rats (Benderson et al., 1986). Similarly, neurological 
tests were used to predict the degree of injury after stroke. A strong correlation was 
found between the number of necrotic neurones due to ischaemia and the mean 
neurological score with increasing times of transient occlusion (30 and 60 minutes 
respectively) and permanent occlusion in rats measured 1 week after stroke (Garcia 
et al., 1995). Subsequent experiments in cats subjected to permanent or 0.5, 4 and 8 
hours of transient MCA occlusion further supported these findings (de Courten 
Myers et al., 1998).
Permanent MCA occlusion in rats caused deficits in postural reflex, visual 
placement, grasping, motor coordination and bilateral asymmetry tests that were 
restored to pre-operative standards only 30 days after stroke induction. This was 
correlated with histology, where severe neuronal loss was observed in the striatum 
and the parietal, temporal and frontolateral cortex (Markgraf et al., 1992, 1994). In 
transient rat models, 90 minutes of MCA occlusion cause a decrease in the number of 
rearing in locomotor tests at 1 and 30 days after stroke (Sakai et al., 1996). Wood 
and colleagues showed that photothrombotic lesions in the cortex cause sensorimotor 
deficits, impairing rats in beam walk tests and grid walk tests (Wood et al., 1996). 
Hunter and colleagues used rotarod and bilateral asymmetry tests to assess functional 
deficit at 24 hours and 1 week in rats subjected to 90 minutes of MCA occlusion. 
Their results indicate that the performance on the rotarod is significantly impaired at 
1 but not at 7 days after stroke, whereas deficits in the bilateral asymmetry test were 
maintained at 1 week. The same laboratory has used MRI to correlate how specific 
pathological changes in different regions of the ischaemic brain contributed to
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functional impairment in the sticky tape task over 1 month after 90 minutes of 
MCAO (Virley et al., 2000).
6.1.4 Neurobehaviour and lesion size
Fewer studies have, however, attempted to correlate functional impairments 
as well as neurological score with lesion size. One study used a pathological scale to 
measure lesion size in combination with a neurological scale to validate the stroke 
model itself. Thus, infarct size could be predicted from the results of the neurological 
evaluation in 83% of the 82 MCA occluded animals tested (Menzies et al., 1992). 
Rogers and colleagues have shown that there is a correlation between motor 
impairment and extent and severity of infarct by varying the duration of the 
ischaemic period from 0 to 120 minutes in transient models and comparing these 
with permanent occlusion. The volume of infarction was seen to increase with 
occlusion time as expected and correlated with severity of neuronal and pancellular 
necrosis on histological sections. Moreover, permanently occluded rats showed more 
foot-fault errors than sham operated or rats occluded for 30 minutes and a linear 
relationship between the duration of ischaemia and number of errors was observed 
(Rogers et al., 1997). Similarly, MCA occlusion by endothelin-1 injection had a 
significant effect on sensorimotor function even if the infarct size was 
heterogeneous. Rats preferentially contacted the ipsilateral paw first and took longer 
to contact the contralateral paw as measured at 2 and 3 weeks after stroke induction 
(Ward et al., 1997).
These findings are further validated by neuroprotection studies that have 
shown reductions in lesion size and improved neurological outcome in focal models 
of ischaemia in rats (Belayev et al., 1995; Mackay et al., 1996; Minematsu & Fisher, 
1993). Infarct volume was significantly reduced in rats undergoing 2 hours of MCA 
occlusion and treated with neutrophil inhibitory factor upon reperfusion and at 4 and 
6 hours after insult. This was in turn correlated with a reduction in brain swelling and 
an improved neurological outcome as measured at 24 hours after stroke (Mackay et 
al., 1996). Post-ischaemic delivery of a different drug, HU-211, caused significant
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reductions in lesion volume, brain swelling, improved neurological score and 
forelimb placing after 90 minutes of occlusion in rats (Belayev et al., 1995).
Some studies, however, suggest that infarct size does not necessarily correlate 
to improvement in behavioural outcome. Experiments in hypertensive rats have 
shown that varying the duration of ischaemia from 45 to 60, 90 and 120 minutes 
correlated directly with an increase in lesion size and in sensorimotor impairment 
measured at 21 days by forearm flex and foot-fault tests (Aronowski et al., 1994, 
1996). Interestingly, post-ischaemic treatment with CNS-1102 caused a significant 
improvement in all behavioural tasks but no reduction in maximal lesion size (at 
maximum occlusion time) compared to untreated MCA occluded controls 
(Aronowski et al., 1996). A similar lack of correlation between infarct size and 
neurological impairment was reported in focal cerebral ischaemia in rats (Wahl et al., 
1992; van der Staay et al., 1996a). Nevertheless, most studies support such 
correlation allowing for variations in the size and location of the lesion, strain of rat 
and sensitivity of the scoring systems used (Benderson et al., 1986; Markgraf et al., 
1992; Grabowski et al., 1993; Belayev et al., 1995; van der Staay et al., 19966).
6.1.5 Summary
As described in chapter 1, HSPs are naturally upregulated after a range of 
stresses both in vitro and in vivo. The experiments presented in this chapter 
investigate the effect of enhancing the levels of HSP overexpression after a transient 
ischaemic insult by delivering an HSV-1 viral vector engineered to express HSP27 or 
HSP70 30 minutes after tissue reperfusion. Although MRI scans indicated that pre- 
ischaemic overexpression of HSP27 caused a significant reduction in lesion size 
(chapter 5), it was necessary to test the efficacy of such treatment after stroke 
induction in order to relate these findings to clinical scenarios. Finally, 
neurobehavioural improvement was assessed by two sensorimotor tests in an attempt 
to correlate changes in lesion size with functional recovery over time.
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6.2 Methods
6.2.1 Experimental design
Three groups (n=6) of adult male Sprague-Dawley rats (220-280gr) were 
subjected to 30 minutes MCA occlusion and microinjected with either HSV-HSP27, 
HSV-HSP70, or HSV-LacZ as a control. Rats were allowed to recover for 24 hours 
before scanning. All animals were then scanned at multiple timepoints and subjected 
to behavioural tests up to 1 month after stroke as schematically shown in the diagram 
below (figure 6.1).
MCAO +  M icroinjection
MRI +  Behavioural Studies
MRI
0 24h 72h 1 wk 2 wk 3 wk 4wk
Figure 6.1. Schematic representation of the experimental design for the post- 
ischaemic gene therapy study. Three groups of animals (n=6) were subjected to 
MCA occlusion and microinjected on day zero and subsequently scanned and tested 
for behavioural recovery up to 1 month after stroke.
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6.2.2 Virus growth
Viral growth methods have been thoroughly described in section 4.2.2 and 
microinjection procedures have been detailed in section 4.2.4. Briefly, a herpes 
simplex virus type 1 strain deleted for ICP27 and engineered to express either 
HSP27, HSP70, or LacZ was grown in B130/2 BHK complementing cells. The viral 
suspensions were harvested, filtered and concentrated and the virus pellets were 
resuspended in sterile PBS. Titration assays confirmed the viruses had a high titre of 
l-2 x l0 10 plaque forming units (pfu).
6.2.3 Intracerebral microinjections and middle cerebral artery occlusion
Rats were anaesthetized with 2% isoflurane in 70:30 N20:02 placed in a 
stereotaxic frame (Korf, Germany). A midline incision was made on the head and the 
skin was carefully retracted. A burr hole was made on the skull at the appropriate 
coordinates for the striatum (Bregma coordinates: AP= +0.10cm; L = -0.35cm; V= - 
0.50cm) on the right hemisphere. The skin was then temporarily closed with masking 
tape and the animals were transferred to the microscope for MCA occlusion. The 
common, internal and external carotid arteries were exposed and a 290pm Monocryl 
suture (Ethicon, UK) with an araldite-coated tip was introduced into the lumen of the 
right common carotid artery up to the origin of the MCA. The animals remained 
occluded for a total of 30 minutes after which they the embolus was carefully 
retracted and the tissue reperfused. The cutaneous wound was then sutured and 
cleaned and the animals were placed in the stereotaxic frame once more. The rats 
were kept under anaesthetics and the intracerebral microinjections were performed 
30 minutes after the start of reperfusion for all three groups. Viral suspensions were 
diluted to lx l0 6 pfu/pl and a microsyringe pump (WPI, UK) was used to deliver 
2.5pl of HSV-LacZ, HSV-HSP70 and HSV-HSP27 to the right striatum at a constant 
rate of 0.25pl/min. Throughout the surgery, rectal temperature was maintained at 
37±1°C via a heating blanket controlled by a thermocouple. The whole procedure
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took 2 hours and the animals were left to recover for 24 hours before scanning with 
free access to food and water.
6.2.4 Magnetic Resonance Imaging
Scans were performed on a 2.35 Tesla horizontal bore magnet (Oxford 
Instruments, UK) interfaced to a SMIS console (Guilford, UK). All animals were 
anaesthetized with 2% halothane in a 70:30 N20 :0 2 mix delivered via nose cone and
placed on a probe with bite and ear bars securing the head to minimize movement
artefacts. Physiological parameters monitored included electrocardiography (ECG) 
recordings and rectal temperature, which was maintained at 37±1°C using an air 
warming system.
The imaging protocol included two echo planar imaging (EPI) sequences, T i 
and continuous arterial spin labelling (CASL), for the determination of CBF and a 
multislice T2 -weighted spin echo (SE) sequence for the determination of lesion size. 
The sequence parameters were identical to the ones described in section 5.2.5 and 
total scan time was 35 minutes. As stated in the previous chapter, the centre slice of 
the multislice dataset was determined via anatomical landmarks on visual inspection 
of pilot coronal scans and not by the maximal lesion area.
6.2.5 Image processing and data analysis
Quantitative maps were obtained by reconstructing all images with IDL 
Software Version 5.2 (Research Systems Inc., USA). Ti values and subtracted 
labelled and reference CASL images were used to calculate CBF maps. Lesion area 
and regions of interest were delineated on all processed images and analyzed with 
SMIS Image Display Version 3.7. The resulting lesion areas per slice were used to 
determine lesion volume across the whole brain. Moreover, a regional analysis was 
performed on the T2 -weighted multislice dataset based on knowledge of the vascular 
territories in the rat brain (Paxinos, 2004). Slices were grouped into three regions: the
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frontal region (slices 1, 2), the mid MCA territory region (slices 3, 4, 5, 6) and the 
posterior region (slices 7, 8, 9). A restricted maximum likelihood (REML) analysis 
of the longitudinal lesion volume data was performed using a full random 
coefficients model, assuming a linear dependence on time. The probability values 
were obtained using the F test and considered significant at p < 0.05. These 
calculations were performed using SAS PROC MIXED (SAS Institute, 1999).
The CBF and behavioural test results were analyzed using repeated measures 
ANOVA (SPSS 12.0.1, SPSS Inc., USA) with groups as the between-subjects factor 
and assessment timepoints as the within-subjects factor. The Bonferroni correction 
was used post hoc to compare groups. Standard t tests were used for end point 
comparisons.All data is presented as mean ± standard error.
6.2.6 Behavioural tests
6.2.6.1 Bilateral asymmetry test
The bilateral asymmetry or sticky label test gives a measure of sensory 
neglect and tactile extinction (Schallert et al., 1982). Two identical strips of brown 
packing tape of approximately 6cm in length and 0.5-0.8cm in width were wrapped 
around the hairless part of the forepaws of the animal. Care was taken in order to 
apply the tape with equal pressure and the order of the application (i.e., left or right 
paw first) was reversed for each consecutive trial. The time to removal from each 
paw was measured and each trial lasted a maximum of 180 seconds. Tests were not 
considered or repeated if the animal was unable to remove the tape from both the 
affected and the unaffected paw. Similarly, if the tape was not removed from one 
paw, the test was assigned the maximum value of 180 seconds for that paw. Two 
trials were performed and averaged per timepoint, starting at three days and up to one 
month after stroke.
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6. 2 . 6.2 Foot-fault test
The foot-fault test was used to assess the animal’s motor-coordination deficit 
over time. To this end, a homebuilt frame of 40cm in width, lm  in length and 30cm 
in height was used. The frame was covered with a 7-cm-whole mesh wire and the 
animals were placed at one end and encouraged to walk on this surface. The total 
number of steps and the correct or incorrect placement of the left affected forelimb 
(contralateral to the infarction) were recorded. Precise grip and placement of the 
limbs is required to successfully complete the test (Hernandez & Schallert, 1988). 
Each trial lasted 60 seconds and, as for the bilateral asymmetry test, two trials per 
timepoint were averaged. The test was discarded and not repeated if the animal took 
less than 10 steps.
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6.3 Results
6.3.1 Effect of HSP expression on lesion size
Figure 6.2 shows the centre slice of a multislice T2 -weighted-spin echo image 
dataset obtained 24 hours, 1 week and 3 weeks after transient MCA occlusion. The 
three groups of six animals had been microinjected with HSV-HSP27, HSV-HSP70 
or HSV-LacZ as a control 30 minutes after suture retraction and tissue reperfusion. 
Averaged total lesion volumes measured from the images at all timepoints are 
presented in table 6.1, and figure 6.3 shows lesion volume per slice from front to 
back of the brain for all rats at all 6 timepoints.
A regression analysis was carried out to assess the evolution of the lesion 
over time, t tests on the individual regression slopes indicated a significant change in 
the mean lesion volume in HSP27 treated animals over time (-0.59 ± 0.2 mm3/day; p 
= 0.01) (figure 6.4). The regression slopes for the two other groups were -0.08 ± 0.2 
mm3/day for HSP70 and -0.07 ± 0.2 mm3/day for LacZ injected animals respectively 
and did not achieve statistical significance (pHsp7o= 0.72; pLacz= 0.75).
The mean absolute lesion volume estimates at 28 days were 48.5 ± 8.3mm3 
for HSP27 injected rats, 68.9 ± 8.3mm3 for HSP70 injected rats and 71.5 ± 8.3mm3 
for LacZ injected animals. The difference in mean lesion volume between HSP27 
treated and LacZ injected controls was statistically significant (difference = 23 ± 
11.8mm ; p = 0.05), whereas no significant difference was found between HSP70 
treated animals and controls (difference = 2.6 ± 11.8mm ; p = 0.8).
A regional analysis was performed on the multislice data by grouping frontal 
slices (1, 2), mid MCA territory slices (3, 4, 5, 6) and posterior slices (7, 8, 9) (figure 
6.5). Results indicated that the three groups differed in their regional dependence in 
lesion volume (p = 0.02). The regional population mean volume estimates at 28 days 
suggested that HSP27 treatment was more effective in the posterior region than in the 
frontal and mid regions (table 6.2). In fact, the differences in mean absolute lesion 
volumes in regions 1 and 2 between HSP27 treated rats and controls were 1.8 ±
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4.4mm (p = 0.4) and 5.05 ± 4.4mm (p = 0.2), while region 3 presented a significant
' i
16.1 ± 4.4mm difference in lesion volume (p = 0.0003). No differences were found 
when comparing mean absolute lesion volume estimates over time in regions 1, 2 
and 3 in HSP70 treated rats and controls (differenceregioni= 2.6 ± 4.4mm3, p = 0.6; 
differenceregion2 = 2.3 ± 4.4mm3, p = 0.6; differenceregion3 = 2.9 ± 4.4mm3, p = 0.5).
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Figure 6.2. Representative centre slices of multislice T2-weighted spin echo 
datasets. The scans show the lesion area (bright) in HSP27, HSP70 and LacZ 
injected rats at 24 hours, 1 week and 3 weeks after MCA occlusion.
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Timepoint Lesion Size (m m 3)
HSV-HSP27 HSV-HSP70 HSV-LocZ
24 hours 60 ± 12.4 68.6 ± 7 7}.5 ± 7.5
72 hours 60 ± 8.5 69.9 ± 5.2 73.3 ± 4.6
1 w e e k 59.6 ± 9.9 65.2 ±4.1 73.3 ± 4.9
2 w eek s 44.5 ± 9.2 71.4 ± 3 .6 74.7 ± 6
3 w eek s 44.8 ± 10.7 57.5 ± 4.4 69.6 ± 4.4
4 w eek s 41.4 ± 10.4 64.9 ±5.1 71.9 ± 3 .8
Table 6.1. Mean lesion size at each timepoint for HSP-treated and LacZ 
injected control animals (n = 6). Values represent absolute lesion volume 
(mm3) determined on multislice T2 -weighted spin echo scans ± s.e.m.
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Figure 6.3. Mean lesion size calculated from multislice T2 -weighted spin echo 
images for HSP27, HSP70 and LacZ injected animals at 6 different timepoints (n = 
6). Bars represent absolute lesion volume (mm3) in 9 slices from front to back of the 
brain ± s.e.m.
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Figure 6.4. Population mean estimates of the absolute lesion volume evolution 
over time in HSP treated and LacZ injected controls (n = 6).
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Figure 6.5. Regional analysis of mean absolute lesion volume estimates in frontal (1, 
2), mid (3, 4, 5, 6), and posterior (7, 8, 9) slices calculated form multislice T2 - 
weighted spin echo images at 6 different timepoints in HSP treated and control 
animals.
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Region Lesion Size (m m 3)
HSV-HSP27 HSV-HSP70 HSV-LacZ
1 0.68 ±3.1 3.69 ±3.1 1.1 ±3.1
2 33.8 ±3.1 36.5 ±3.1 38.9 ±3.1
3 15.4 ± 3.1 28.7 ±3.1 31.6 ±3.1
Table 6.2. Four weeks difference in lesion size estimates for each region in 
HSP treated and LacZ injected control animals. Values represent population 
mean absolute lesion volumes (mm3) ± s.e.m.
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6.3.2 CBF
Cerebral blood flow (CBF) was measured at 24 hours, 72 hours, 1 week, 2, 
weeks, 3 weeks, and 4 weeks after occlusion-reperfusion. Values in the ischaemic 
hemisphere for treated and control animals are presented in table 6.3, expressed as a 
percentage of flow in the contralateral hemisphere. Complete recovery of CBF was 
not achieved acutely but all values were above the ischaemic threshold (Kohno et al.,
1995). Statistical analysis showed no significant differences between the groups 
(Controls vs. HSV-HSP27 [F(2;15) = 1.9, p > 0.2]; Controls vs. HSV-HSP70 (p > 
0.9) at all timepoints after reperfusion.
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Timepoint % CBFipsi/contra
HSV-HSP27 HSV-HSP70 HSV-LocZ
24 hours 85.5 ± 5 90.6 ± 8.7 76.1 ± 7 .8
72 hours 85.9 ± 2.8 86.6 ± 5 .6 84.3 ±5.1
1 w e e k 96.3 ± 3 .4 90.25 ± 1.5 93.1 ± 4 .5
2 weeks 97.51 ± 4 .5 92.8 ± 1.7 89.7 ± 4.4
3 weeks 89.9 ± 2.5 88.5 ± 4.2 86.7 ± 3.5
4 weeks 96.8 ± 2.3 87 ± 4.8 87.5 ±4.1
Table 6.3. CBF measurements obtained at 6 timepoints after 30 minutes of 
MCA occlusion in HSV-HSP27, HSV-HSP70 and control animals (n = 6). 
Values represent averaged CBF in the ipsilateral hemisphere as a percentage of 
the contralateral flow values (% CBF ipSi/Contra) ± s.e.m.
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6.3.3 Effect of gene therapy on functional recovery
6.3.3.1 Bilateral asymmetry test
The sensorimotor asymmetry test showed that all animals subjected to 
transient MCA occlusion preferentially removed the tape from the forelimb 
ipsilateral to the ischaemic hemisphere first. The time to removal of the tape from 
left (affected) and right (unaffected) paws was recorded at 5 different timepoints: 72 
hours, 1 week, 2 weeks, 3 weeks, 4 weeks. All animals performed the task twice per 
timepoint and the average of the two trials was used to calculate the mean removal 
time per paw for each group presented in table 6.4 below. The values demonstrate a 
marked difference in removal time from the left and right paw for all three groups 
and such sensory neglect persisted throughout the period tested. Figure 6.6 shows the 
plots for removal time with the affected and the unaffected paw for all three groups.
A significant difference was found in the difference between left and right 
paw removal times in HSP27 and LacZ controls at all post-ischaemic timepoints 
[F(2;10) = 4.656, p < 0.05], while no differences were found between HSP70 and 
controls (p < 1.00) (figure 6.7).
The total removal time from left and right paws was not different across 
groups at most timepoints. However, a significant improvement was observed in 
HSP27 treated animals at 3 (p < 0.03) and 4 weeks (p < 0.02). Interestingly, HSP70 
treated animals took slightly longer than controls to remove the sticky tape from the 
left paw at most timepoints although this difference did not reach statistical 
significance (table 6.4; figure 6.8).
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Timepoint Removal time (secs)
HSV-HSP27 HSV-HSP70 HSV-LacZ
Left Right Left Right Left Right
72 hours 146.6 ± 26 .5 42.2 ± 6.2 171.5 ± 6.7 72.9 ± 12.4 154 ± 20 .3 71.2 ±23.7
1 w eek s 124.3 ±21 .6 47 ± 11.2 180 ± 0 .0 52.6 ± 6.8 167.1 ± 3 .5 42.1 ±7 .4
2 w eeks 114.2 ±24 .2 55.7 ± 25.8 159.3 ± 15.5 60.2 ± 22.2 114.6 ±22 .9 47.6 ± 10.9
3 w eeks 72.6 ± 20.5 32 ± 8.9 122.6 ± 16.8 67.7 ± 18.8 100.5 ±23 .7 44.7 ± 13.4
4 w eek s 83.7 ±21 .8 43.7 ± 14.6 131.7 ±25 .3 61.3 ±26.1 133.9 ±16.6 56.9 ± 17.3
Table 6.4. Bilateral asymmetry test. Mean removal times from affected (left) and unaffected (right) forelimbs 
at 72 hours, 1 week, 2 weeks, 3 weeks and 4 weeks after MCA occlusion for HSP treated and LacZ injected 
controls.
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Figure 6.6. Total removal time o f the sticky tape from left and right forepaws in 
HSP27, HSP70 and LacZ injected animals over time.
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Figure 6.7. Difference in the mean time to removal o f the sticky tape from the 
affected paw (left) in HSP treated and controls animals up to 1 month after stroke.
Total removal time (L+R)
—• — H SP27LacZ H SP70
300
250
—F -200
r  150
100 -
72  hours 1 w eek 2 w eek s 3 w eek s 4  w eek s
Figure 6.8. Total removal time from left and right paws in HSP27, HSP70 and LacZ 
injected rats over time. Values represent the addition o f removal times for both paws 
(L+R) in seconds.
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6. 3. 3.2 Foot-fault test
At 72 hours after occlusion animals were placed in an elevated mesh wire grid 
for 1 minute and the total number of paired steps was counted together with the 
number of foot-fault or errors in which the animal misplaced the left forelimb such 
that it fell through the grid (figure 6.9). The total number of errors for the affected 
forelimb was recorded. The total number of steps and the percentage of correct steps 
for all animals at all timepoints tested are presented in table 6.5. The total number of 
left steps was not significantly different between either HSP27 treated or HSP70 
treated animals and controls at all timepoints tested [F(2;75) = 3.520, p < n.s.]. 
Similarly, there were no significant differences in the number of right steps between 
the three groups over time [F(2;75) = 4.637, p < n.s.]. All animals showed some 
degree of impairment in this task on the first few weeks after MCA occlusion (figure 
6.10). HSP27 treated animals, however, showed a higher percentage of correct steps 
compared to controls [F(2;15) = 29.878, p < 0.0001]. HSP70 treated animals, on the 
other hand, performed worse than controls in this task but this difference did not 
reach statistical significance (p < 0.062).
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Timepoint HSV-HSP27 HSV-HSP70 HSV-LacZ
Total % correct L Total % correct L Total % correct L
72 hours 32.5 73.4 26.7 53.5 27.33 57.2
1 weeks 24.7 74.4 23.5 45.1 25.08 51.5
2 weeks 25 87.3 19.8 48.4 26.83 60.5
3 weeks 29.5 85 21.5 50.1 22.5 59.7
4 weeks 22.4 82.8 20.3 53.1 22.59 68.8
Table 6.5. Total mean number of steps and percentage of correct steps with the 
affected paw (L, left) in HSV-HSP27, HSV-HSP70 and HSV-LacZ injected rats at 
all timepoints.
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Figure 6.9. Foot-fault test. The picture illustrates a foot-fault with the left forepaw in 
a rat performing the grid walking test.
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Figure 6.10. Foot-fault test in HSP27, HSP70 and LacZ control animals. The 
percentage of correct left steps was calculated from the total mean number of left 
steps at 5 different timepoints after MCA occlusion in treated and untreated rats.
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6.4 Discussion
The aim of the study was to investigate neuroprotection in vivo after post- 
ischaemic delivery of an HSV-based vector expressing HSP27 or HSP70 in a rat 
focal model of transient cerebral ischaemia. Longitudinal MRI measurements 
enabled the assessment of the effect of HSP27 and HSP70 treatment on lesion size at 
1, 3, 7, 14, 21 and 28 days after stroke. Behavioural tests were performed at the same 
scanning timepoints in order to get an indication of sensorimotor impairment and 
recovery over time. The model of stroke chosen for this in vivo study has been 
previously reported to produce a reproducible lesion encompassing the right cortex 
and basal ganglia. Similarly, direct intrastriatal microinjection of viral vectors was 
previously observed to yield high levels of protein expression in the ipsilateral 
hemisphere of HSP treated and LacZ injected control animals (chapters 4 and 5). 
Multislice T2 -weighted scans provide an indirect measure of the area of vasogenic 
oedema in the cortex and basal ganglia, and were used to determine lesion size 
(figure 6.2). These images demonstrated a marked reduction in lesion volume in 
HSV-HSP27 treated animals compared to HSV-LacZ controls. In contrast, HSV- 
HSP70 treatment had no effect on lesion size. Moreover, regional analysis of lesion 
volume showed that HSP27 treatment was most effective on posterior slices 
compared to controls. All CBF values obtained 24 hours and up to 4 weeks after 
occlusion-reperfusion were above the ischaemic threshold and similar in the three 
groups. Behavioural studies indicate that the sensorimotor skills of HSV-HSP27 
injected animals are less impaired immediately after stroke and show improvement 
over time.
6.4.1 MRI findings: lesion size and CBF
The changes in lesion volume over time were different among the three groups 
tested here. Multislice T2 -weighted images acquired at 24, 72 hours, and weekly for 
one month after transient occlusion of the MCA indicate that overall lesion volume at 
4 weeks was 25% smaller in HSP27 treated animals while LacZ injected controls
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showed no reduction over time. HSP70 treatment caused a 3% reduction in lesion 
size at 4 weeks and the lesion volume values were not significantly different from 
those obtained for LacZ controls at the same timepoint. MRI techniques also 
confirmed that the tissue was highly although not fully reperfused in all three groups 
and that CBF levels were above ischaemic levels at all timepoints measured. This 
rules out the possibility that the changes in lesion size were caused by incomplete 
tissue reperfusion over time. These results are in line with findings described in 
chapter 5, where pre-ischaemic microinjections of HSV-HSP27 and not HSV-HSP70 
caused a significant 44% reduction in lesion size. Contrary to the present 
experiments, the only other post-ischaemic study to date using an HSV viral vector 
to deliver HSP70 to the ischaemic brain showed protection (Hoehn et al., 2001). 
Gene therapy applied at 0.5 and 2 hours but not 5 hours after transient MCA 
occlusion improved survival of striatal neurones but had no effect on lesion size. 
This discrepancy could be due to differences between the two studies, such as the 
animal model, the delivery method chosen, the HSP expression levels and the lesion 
size assessment and time. Hoehn and colleagues induced 60 minutes of MCA 
occlusion followed by reperfusion (as opposed to 30 minutes in this study), used an 
amplicon HSV vector and gave two injections in the ipsilateral and contralateral 
striatum respectively, assessed damage at 48 hours only and used a semiquantitative 
histological scale to determine lesion size. Such differences in study design and 
methodology have been thought to underlie the variable results obtained for HSP70 
transgenic mouse models of stroke and also the rat studies using viral vectors to 
deliver HSP70 before and after stroke. This has been reviewed in detail in section 
5.4.3.
The fact that the two in vivo studies presented here are consistent indicates that, 
at least in this model, HSP27 has an obvious neuroprotective effect and HSP70 does 
not. This in turn might reflect a difference in the mechanisms of action of HSP27 and 
HSP70 after an ischaemic insult. The roles of these two chaperones in cerebral 
ischaemia have been detailed in chapter 1: they are both potentially involved in 
improving cell survival by refolding denatured proteins and/or interfering with 
apoptotic pathways (Melhen et al., 1996; Garrido et al., 1997; Garrido et al., 1999; 
Pandey et al., 2000; Bruey et al., 2000; Saleh et al., 2000; Mosser et al., 2000; 
Creagh et al., 2000; Beere et al., 2000; Paul et al., 2002; Benn et al., 2002; Akbar et
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al., 2003; Garrido & Solari, 2003; Rashmi et al., 2003; Tsuchiya et al., 2003; 
Takayama e/ al., 2003; Steel e/ al., 2004; Latchman, 2004; Zourlidou e/1 al., 2004; 
Whitlock e/ a/., 2005). However, there is currently not enough evidence to 
distinguish specific functions that might make one chaperone more suitable than the 
other. Section 5.4 has, however, attempted to enumerate a series of “advantages” that 
HSP27 might have over HSP70 in an ischaemic environment, ATP dependence 
being the most salient one (Rogalla et al., 1999; Garrido et al., 2002; Riordan et al., 
2005). Moreover, this chaperone has been implicated in antioxidant mechanisms by 
causing a decrease in intracellular ROS and thus protecting against cell death due to 
oxidative stress (Melhen et al., 1996, 1997; Orrenius et al., 1998). Cytoskeletal 
stabilization by capping and decapping of actin filaments could protect such 
microfilaments from degradation and depolymerization due to stress (Guay et al.,
1997). In vitro experiments in astroglia have shown that HSP27 interacts with GFAP 
and vimentin and prevents stress-induced aggregation of these proteins, thus 
promoting cell stabilization and survival (Perng et al., 1999). Moreover, as 
previously suggested (section 5.4.3), the protective effect of increasing the levels of 
HSP70 could be limited by the low levels of ATP at early timepoints after ischaemia 
onset (Mallouk et al., 1999). Alternatively, the inefficacy of HSP70 could be 
explained by the pro-apoptotic role of this chaperone observed in the presence of 
TNF, which could be triggered by the viral microinjection (Ran et al., 2004).
6.4.2 Lesion size and behaviour
Regional analysis suggests that posterior slices are more protected against 
stroke progression in HSP27 treated animals only. In fact, the lesion seems to be 
larger in the posterior brain region in untreated MCA occluded controls. Moreover, 
this progression becomes more obvious at 2, 3 and 4 weeks after stroke induction 
(figure 6.5).
The peri-infarct region or penumbra corresponds to moderately ischaemic 
tissue peripheral to the core of the infarct. Viable neurones can be found in this 
region and it is thought that suitable therapeutic intervention can salvage this tissue
154
(Astrup et al., 1981; Hossman, 1994). This region is, however, metabolically 
demanding and if the energetic requirement is not met due to hypoperfusion, the 
lesion can expand into the penumbral zone (reviewed in van der Weerd et al., 2004). 
Post-ischaemic neuroprotective strategies attempt to prevent such compromised 
tissue to progress to infarction. The posterior region (slices 7, 8, 9), could correspond 
to a penumbral zone that proceeds to infarction over time without intervention as 
seen in HSV-LacZ injected controls.
It is interesting to note that differences in lesion size in the posterior region 
became more apparent at 2 weeks after MCA occlusion in HSP27 treated animals. 
Differences in behavioural improvement between treated and untreated animals were 
more obvious at this timepoint in the total removal time (figure 6.8) and in the 
percentage of correct steps (figure 6.10) in particular, and this correlates to other 
experimental evidence. Stroke patients exhibit functional recovery over time and this 
has been associated with functional reorganization and plasticity in the brain. Animal 
studies using MRI to investigate functional activation after stroke in combination 
with behavioural tests have shown correlations between contralateral limb 
impairment and activation impairment in the lesioned cortex (Dijkhuizen et al., 
2001). An increase in activation in the contralateral hemisphere was observed at 3 
days after stroke but was significantly reduced at 14 days after stroke, and this was 
accompanied by an increase in activation of the ipsilateral cortex. This and other 
studies support the idea that the activation shifts correspond to the contralateral 
hemisphere compensating for the sensorimotor deficit at early timepoints after 
stroke. The activation balance is then restored once the ipsilateral hemisphere 
recovers and reorganizes. Furthermore, a different study by the same group later 
established that the degree of injury determines the extent of activation shift to the 
contralateral hemisphere at early timepoints and that the extent of functional 
recovery over time is related to the preservation or restoration of activation in the 
lesioned hemisphere (Dijkhuizen et al., 2003). In this context, the reduction in lesion 
size found in HSP27 treated animals in the present study could be associated with an 
increased preservation of function in the ipsilateral hemisphere and explain why 
these animals exhibit a behavioural improvement compared to untreated controls.
155
The mechanisms by which HSP27 could prevent cellular damage and 
therefore lesion size from expanding have been described in the previous section. 
However, certain experiments investigating the role of endogenous HSP27 highlight 
its involvement in plasticity. Astroglial expression of HSP27 has been observed in 
the immature and mature rat brain in vivo after different insults including ischaemia, 
excitotoxicity, axonal degeneration and photothrombotic injury, suggesting that this 
is a common defence mechanism in the brain (reviewed in Acarin et al., 2002). 
Moreover, there is evidence supporting the role of HSP27 in protecting not only the 
cells where it is expressed (i.e. astroglia), but also the surrounding damaged tissue. 
Acarin and colleagues found HSP27 expression in the subthalamic nuclei secondarily 
damaged after excitotoxic cortical injury. This and other studies looking at HSP27 in 
epilepsy rat models, suggest there is a relationship between HSP27 expression and 
areas undergoing anatomical reorganization and axonal sprouting (Kato et al., 1999). 
Such evidence, in conjunction with a reduction in lesion size, could explain the 
behavioural improvement observed in this study in HSP27 treated animals compared 
to untreated controls.
6.4.3 Behavioural studies
Physical and cognitive impairments ranging from mobility to communication 
deficits have been described in stroke patients (reviewed in Rose et al., 1994; Hunter 
et al., 1998). Hemineglect has been extensively investigated, as it is one of the most 
commonly reported sensorimotor impairments resulting from MCA occlusion in rats 
and humans (Andersen et al., 1991; Markgraf et al., 1992, 1994; Nudo et al., 1999). 
Patients can in fact present tactile extinction and partial or total hemiparesis on the 
contralateral side of stroke. This impairment was detected by simultaneously 
stimulating both sides of the body and showing that the brain can process 
information from the ipsilateral side more efficiently (Heilman et al., 1985; Rose et 
al., 1994).
The bilateral asymmetry or “sticky label” test in rats detects the delay in 
removing the tape from the contralateral forepaw due to stroke-induced damage and
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can be useful in relating experimental and clinical findings after MCA occlusion. 
This test was used together with the foot-fault test, which measures motor 
coordination, in order to evaluate the effects of HSP treatment on functional outcome 
up to one month after transient focal ischaemia. The results of the bilateral 
asymmetry test show that HSP27 treated animals become faster at removing the 
sticky tape from their left paw over time than LacZ injected controls, while HSP70 
treated animals behave similarly to controls (figures 6.6, 6.7). Since the initial deficit 
was similar for all groups, this suggests that the HSP27 treated animals are able to 
change the tape removal strategy over time in order to solve the test more effectively. 
The foot-fault test indicates that HSP27 treated animals present a higher number of 
correct steps than controls at all timepoints assessed. In this case, the initial deficit 
was already reduced in HSP27 treated animals compared to HSP70 treated and LacZ 
injected controls (figure 6.10).
Several studies have found strong correlations between infarct size and 
neurobehaviour. Menzies and colleagues showed that neurological score scales could 
be reliably used to predict lesion size (Menzies et al., 1992). Other studies found a 
linear relationship between the severity of the lesion with varying occlusion times 
and the degree of functional impairment in the foot-fault test (Rogers et al., 1997). 
Neuroprotective experiments using a variety of drugs have further supported the 
correlation between reduction in lesion volume and improved sensorimotor function 
(Belayev et al., 1995; Mackay et al., 1996; Minematsu & Fisher, 1993). The 
behavioural work presented in this chapter is in agreement with the literature since 
improvements in sensorimotor tasks were accompanied by reduction in lesion size in 
HSP27 treated animals. Conversely, no improvement in deficit recovery or 
significant reduction in lesion size was observed control animals.
As mentioned in the introduction, some neuroprotection studies have 
suggested that behavioural outcome is not necessarily related to a decrease in lesion 
volume (Wahl et al., 1992; Aronowski et al., 1996; van der Staay et al., 1996a). In 
this context, the lack of effect on lesion size observed in HSP70 treated animals did 
not rule out the possibility that the therapeutic intervention could have some effect on 
sensorimotor deficit recovery. HSP70 injected rats, however, presented similar
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behaviour to LacZ injected controls, suggesting that this chaperone has no beneficial 
effect in this animal model of stroke.
6.4.6 Conclusion
In spite of the many experimental studies on the MCA occlusion model, 
efficient therapy for stroke is still lacking. Moreover, the increasing number of 
therapies attempting repair and regeneration has enhanced the need for investigation 
of functional outcome in clinical and experimental stroke. The study presented here 
addresses both these issues by evaluating the effects of HSP treatment on stroke on 
the basis of longitudinal non-invasive MRI measurements of lesion size and long 
term sensorimotor testing.
Consistent to the pre-ischaemic findings described in chapter 5, post- 
ischaemic viral delivery of HSP27 causes a reduction in lesion size that persists up to 
one month after transient focal cerebral ischaemia. Moreover, the foot-fault and 
bilateral asymmetry tests demonstrated that these animals present an increased ability 
to integrate sensory and motor responses over time compared to controls. No 
reduction in lesion size was observed in HSP70 treated animals and their 
performance on the behavioural tests over time was similar to that of untreated MCA 
occluded controls.
These results are in agreement with most of the literature on neurobehaviour 
and further support a correlation between reductions in functional impairment and in 
lesion size. The mechanisms underlying the protective effect of HSP27 in vivo have 
not been elucidated yet. A possible explanation is that the tissue that was salvaged by 
early therapeutic intervention with HSP27 undergoes some degree of functional 
reorganization that is absent in controls. The improvement in behavioural deficit 
observed might therefore reflect an enhancement in remodelling or connectivity in 
HSP27 treated animals compared to MCA occluded controls.
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The work presented in this thesis investigates the hypothesis that gene 
therapy with heat shock proteins is protective in an experimental model of transient 
focal cerebral ischaemia. Moreover, it evaluates the relevance of combining MRI 
techniques, histology and behavioural tests to assess the effect of therapy in vivo.
The experiments described in chapter 4 deal with the spatio-temporal 
expression profile of the disabled HSV viral vector used. Expression of the LacZ 
transgene after intrastriatal microinjection was assessed in intact rats at six different 
timepoints ranging from 3 days to 1 month. The results confirmed that the virus was 
able to infect neurones in vivo and that it was expressed at high levels in the basal 
ganglia at all timepoints tested. Previous work had shown that the viral construct 
carrying HSP27 was able to express the protein in vivo after direct microinjection to 
the brain (Kalwy et al., 2003). HSP70 expression was not tested and was assumed to 
be similar since the same backbone and promoter were used.
Chapter 5 details the effect of pre-ischaemic viral gene delivery in a transient 
middle cerebral artery occlusion model of stroke. While the neuroprotective effect of 
pre-ischaemic HSP70 expression had previously been investigated (Yenari et al.,
1998), the study here described was the first to report a significant reduction in lesion 
size after HSP27 treatment using MRI techniques. A four-fold increase in HSP27 and 
HSP70 expression was detected via histology in the ipsilateral hemisphere. However, 
in the present study, HSP70 treatment appeared to have no effect on lesion size as 
assessed by MRI at 24 hours. One previous study had found HSP27 to enhance 
hippocampal neurone survival in a kainic acid model of epilepsy in rats (Kalwy et 
al., 2003) and one later experiment found HSP27 transgenic animals to be protected 
from permanent middle cerebral artery occlusion (van der Weerd, personal 
communication).
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The effects of post-ischaemic HSP gene therapy in the same MCAO animal 
model were described in chapter 6. Once more, MRI images demonstrated that viral 
delivery of HSP27 at 30 minutes after reperfusion caused a reduction in lesion size, 
and that this persisted up to 1 month after stroke induction. The implication of such 
reduction was further evaluated via behavioural studies which confirmed that the 
degree of functional deficit in HSP27 treated animals was significantly less than in 
LacZ injected and MCA occluded controls. HSP70 treatment appeared to have no 
positive effect on lesion size or on sensorimotor tests.
It is biologically feasible that the number of denatured proteins upon stress 
exceeds the ability or rate at which the cell can repair such damage, thus leading to 
the formation of protein aggregates (Cohen et al., 1999). Aggregates have been 
found to be associated with a number of conditions and attempts to use chaperones 
for the treatment of protein aggregation and misfolding have been made in 
neurodegenerative diseases, cancer and ischaemia (Hu et al., 2000, 2001; Bonini et 
al., 2002; Scott & Frydman 2003). The studies described in this thesis are consistent 
with previous in vivo work supporting HSP27 as a strong candidate for therapy in the 
rat brain (Kalwy et al., 2003; van der Weerd et al., personal communication).
Heat shock proteins act as inducible molecular chaperones, preventing changes in 
protein conformation, facilitating cell repair and mediating the delivery of proteins to 
their appropriate intracellular domain. Both of the HSPs used in this study have been 
extensively investigated in vitro and to a lesser extent in vivo in the brain and have 
been shown to be involved in a variety of protective mechanisms such as:
• mitochondrial membrane stabilization
• inhibition of apoptosis
• reduction of protein aggregation
• protein refolding
• alteration of protein kinase activity
• maintenance of normal cellular homeostasis
• cytoskeletal repair and reorganization
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Chapter 1 has given a detailed account of the literature that has described 
these functions. Overall, experiments have focussed on either the upregulation of 
endogenous HSPs as a mechanism of cell defence after an insult, or on pre-insult 
expression of exogenous HSPs conferring protection against a subsequent insult. 
Consistent with the previous work, the purpose of the present study was to exploit 
and enhance an endogenous mechanism of cell survival upon ischaemic stress. The 
results are partially in agreement with the literature described, although current 
knowledge is insufficient to explain the differential protective effects observed.
HSP27 has been shown to have a potent anti-apoptotic effect in vitro and to 
significantly reduce cell death in stroke and epilepsy animal models in vivo. 
Similarly, the protective role of HSP70 has been long established in neuronal cell 
lines in vitro and to some extent in transgenics and virally transfected neurones in 
vivo. However, the results for HSP70 in the rat brain in vivo show more variability on 
the extent of protection, mostly improving neuronal morphology and/ or survival but 
only sometimes causing reductions in lesion size.
Although HSP27 has been associated with tissue remodelling more than 
HSP70 (Kato et al., 1999; Acarin et al., 2002), most of the functions listed above are 
shared by both chaperones. The most salient difference that could be relevant to this 
animal model is the dependence on ATP to exert chaperoning functions. As 
mentioned in previous chapters, ATP binds to the N terminus of HSP70 and induces 
a conformational change, locking the unfolded proteins. It is only through ATP 
hydrolysis that bound proteins can be released after being refolded. HSP27, on the 
other hand, does not require ATP to perform its chaperoning functions. The HSP70 
refolding complex also recruits other co-chaperones, like HSP40, that help increase 
and stabilize the ATPase activity of HSP70. It is therefore plausible that 
overexpressing HSP70 on its own is not sufficient to enhance its protective function 
while other co-factors are not simultaneously available at the same levels, and this 
could explain the lack of protection observed in this study. However, previous 
experiments carried out in vitro in this laboratory have attempted co-transfection 
with viruses expressing HSP40 and HSP70 and did not observe an increase in 
protection in ND7 and B 130/2 BHK cell lines subjected to a range of stresses such as
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ischaemia and serum removal (Zourlidou et al. 2004, 2005). Moreover, the fact that 
some studies have identified the pro-apoptotic role of HSP70 suggest that this 
chaperone can have a detrimental role in the presence of specific molecules such as 
TNF (Ran et al., 2004).
The importance and novelty of the work here described relies not only on the 
results of the individual studies but also on the experimental design. In fact, each of 
the individual techniques described has been previously used and it is the 
combinatorial approach taken that makes these findings more interesting.
MRI has been extensively used to investigate stroke both in research and 
clinical settings. MRI techniques can identify physiological and pathological changes 
in the brain that are reflected by alterations in the physical micro-environment of 
water in tissue (Knight et al., 1991; Gadian, 1995; Hoehn-Berlage et al., 1995; van 
der Weerd et al., 2004). Thus, MRI can detect changes occurring in the brain after 
ischaemia and evaluate the effect of therapeutic agents on structure and on metabolic 
and haemodynamic responses (chapter 2). Moreover, histological determination of 
lesion size by either tetrazolium chloride (TTC) or cresyl violet stains has been 
extensively correlated to imaging findings, implying that MRI techniques can be 
reliably used to determine lesion size non-invasively. Similarly, behavioural tests 
have been correlated to lesion size and widely used to evaluate recovery after stroke 
and the effect of neuroprotective drugs (see section 6.1.4).
The bimodal approach described in chapter 5, combining non-invasive MRI 
with histology, is certainly beneficial in the investigation of the pathophysiology and 
evolution of the ischaemic lesion after therapy. However, there is a limitation in 
trying to fully capture the complexity of damaging and repairing the brain by 
delineating a lesion area on a tissue section or scan, or by quantifying the number of 
necrotic neurones. This is why it is increasingly important to complement 
histological or MRI analysis with behavioural assessment in order to predict outcome 
or to evaluate the effect of stroke therapies. Impairment of behaviour detected by 
sensorimotor tests might reflect changes at a subcellular level, not only in 
morphology but also in synaptic function or electrophysiology of neurones.
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This issue was directly addressed by the work described in chapter 6, where 
longitudinal MRI measurements of lesion size were related to functional recovery to 
evaluate the effects of post-ischaemic therapy. Many parameters had to be 
considered in these set of experiments, such as the model of stroke used, the route of 
delivery and dose of therapeutic agent applied, the sensitivity of the tests and 
methods used to evaluate the effect of therapy, and the timing of such assessment. 
This and other studies have highlighted the importance of choosing a battery of tests 
and scoring systems that can detect specific damage and be sensitive to differences 
according to the duration and areas affected by the stroke (see section 6.1.2). It has 
been suggested that long periods of ischaemia can damage the brain to such an extent 
that treatment appears ineffective, and this could explain why other studies with 
shorter times of occlusion find the same treatment to be protective (Aronowski et al., 
1994). Moreover, the timepoints of post-ischaemic assessment are also crucial since 
some reflexes and motor deficits have been shown to recover spontaneously. Some 
studies, for example, have observed recovery in the asymmetry test at 3 or 4 weeks 
after stroke, suggesting that the initial impairment might be related to the extent of 
cerebral oedema and that oedema reduction over time underlies the sensorimotor 
improvement detected (Aronowski et al., 1996; Corbett & Nurse, 1998; Szentirmai 
& Carter, 2004).
The relevance of using gene therapy in experimental ischaemia is that it 
relates better to clinical scenarios. Other in vivo experiments in HSP27 and HSP70 
transgenic animals have shown neuroprotection, but the therapeutic proteins were 
expressed before and after the insult and the possibility of a preconditioning 
phenomenon cannot be ruled out. The advantage of using gene therapy in this study 
is that it allowed to separately test whether pre-ischaemic and post-ischaemic HSP 
delivery had an effect on lesion size. Moreover, the work reported in this thesis 
benefits from the use of non-invasive neuroimaging techniques to determine cerebral 
blood flow and lesion size in vivo. This approach yields multiparametric data while 
significantly reducing the number of animals required if histological measurements 
were performed instead. This becomes more obvious when the data is acquired at 
several timepoints as described in chapter 6. Furthermore, the correlation with 
repeated neurological assessment on the same animals over time would have been 
technically demanding without non-invasive lesion size determination. Finally, a
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further strength of the present study is the evaluation of behavioural deficits after 
stroke and therapy, an approach that is becoming increasingly important in relating 
pre-clinical and clinical neuroprotection studies.
Overall, these results significantly contribute to the ongoing stroke research 
by providing further support to the role of HSP27 as a major protective protein in the 
rat brain. However, this also highlights the need for further investigation of the 
mechanisms underlying such neuroprotection. Since the contribution of endogenous 
and exogenous HSP27 cannot be determined with current antibodies, it would be 
useful to engineer the viral vector further by inserting a marker gene such as LacZ in 
the same cassette as HSP27 in order to determine exact expression site. If the 
expression was more glial than neuronal it would in turn clarify the supportive role 
that is increasingly attributed to glial cells. Similarly, it would be interesting to 
investigate the lack of neuroprotection observed after HSP70 treatment. Following 
the line of research that identified the pro-apoptotic role of this chaperone, 
immunohistochemistry with apoptotic markers could be performed and compared to 
both HSP27 treated animals and controls. Moreover, only one post-ischaemic 
timepoint has been attempted in this study with encouraging results. A therapeutic 
window could be investigated by viral delivery of HSP genes at intermediate (2 
hours) and long (5 hours) timepoints after ischaemia onset in order to establish the 
feasibility of this therapeutic approach in the clinical setting. Finally, once this 
window was defined, other strategies should be devised to circumvent the limitations 
of this therapeutic approach, mainly the duration of HSP overexpression and the 
route of administration.
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